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Abstract 
Gaucher  disease  (GD),  a  recessive  disorder  characterised  by  hepatosplenomegaly, 
pancytopenia  and  skeletal  complications,  is  caused  by  deficiency  of  the  enzyme 
glucocerebrosidase  (GC).  GD  leads  to  the  accumulation  of  glucocerebrosides  within 
macrophages, particularly in the liver and spleen. Current treatment is limited to enzyme 
replacement  therapy  (ERT)  which  is  effective  for  most  symptoms  however  skeletal 
problems are slow to respond. Treatment also has significant cost and impact on quality 
of life as infusions must be administered every two weeks. GD is a candidate for gene 
therapy as bone marrow transplantation has been shown to be curative which serves as a 
proof-of-concept  that  correction  of  haematopoietic  stem  cells  (HSCs)  can  alleviate 
disease. This project produced lentiviral vectors carrying a range of constructs. GC was 
modified to contain a protein transduction domain (PTD) which could facilitate cross-
correction  of  untreated  cells  in  vivo.  Recombinant  vectors  carrying  PTD-GBA  cDNA 
corrected  the  metabolic  defect  in  patient-derived  fibroblasts  with  levels  of  enzyme 
activity restored to within the healthy range. Transduced cells secreted active protein, 
uptake of which by untransduced cells was mediated by fusion of a PTD to the C- but not 
the N-terminus of the enzyme. The skeletal complications of GD are likely to be caused by 
enzyme  deficiency  in  the  osteoclast,  a  cell  of  haematopoietic  origin.  Therefore  it  is 
possible that by transducing HSCs we will be able to alleviate skeletal symptoms. To this 
end  it  is  shown  that  modification  of  HSCs  does  not  affect  their  ability  to  generate 
osteoclasts.  It  is  also  demonstrated  that  osteoclasts  derived  in  vitro  from  the 
neuronopathic GD mouse model have increased activity and this could be a useful model 
for osteoclast correction when treating GD. In conclusion, this project generated lentiviral 
vectors for use in treating Gaucher disease. Further work should include correction of the 
osteoclast phenotype and further investigation of the potential for cross-correction in 
vivo.    7 
 
Table of Contents 
1  Introduction ................................................................................................................ 15 
1.1  Gaucher disease .................................................................................................. 15 
1.1.1  Discovery ..................................................................................................... 15 
1.1.2  Lysosomal biology ....................................................................................... 18 
1.1.3  Genetics ...................................................................................................... 20 
1.1.4  Pathophysiology .......................................................................................... 23 
1.1.5  Bone disease ............................................................................................... 28 
1.1.6  Current treatment  ....................................................................................... 31 
1.1.7  Animal models ............................................................................................ 37 
1.2  Gene therapy ...................................................................................................... 40 
1.2.1  History ......................................................................................................... 40 
1.2.2  Clinical trials ................................................................................................ 42 
1.2.3  Vectors ........................................................................................................ 47 
1.2.4  Lentiviruses ................................................................................................. 53 
1.2.5  Protein transduction domains .................................................................... 63 
1.3  Gene therapy for Gaucher disease ..................................................................... 66 
1.4  Summary and Aims ............................................................................................. 70 
2  Materials and Methods  ............................................................................................... 71 
2.1  Materials ............................................................................................................. 71 
2.1.1  Cloning ........................................................................................................ 71 
2.1.2  Plasmid preparation .................................................................................... 71 
2.1.3  Virus production ......................................................................................... 71 
2.1.4  Virus titration .............................................................................................. 72 
2.1.5  Cell culture .................................................................................................. 72 
2.1.6  Assays .......................................................................................................... 72 
2.1.7  Western blotting ......................................................................................... 73 8 
 
2.1.8  Immunocytochemistry ................................................................................ 73 
2.1.9  Antibodies ................................................................................................... 74 
2.1.10  Solutions ..................................................................................................... 75 
2.2  Methods .............................................................................................................. 76 
2.2.1  PCR amplification ........................................................................................ 76 
2.2.2  Restriction digests ....................................................................................... 76 
2.2.3  Klenow polymerase treatment (filling 5’-protruding ends) ........................ 76 
2.2.4  Ligation  ........................................................................................................ 76 
2.2.5  TOPO cloning  ............................................................................................... 77 
2.2.6  Transformation ........................................................................................... 77 
2.2.7  Gel electrophoresis ..................................................................................... 77 
2.2.8  Plasmid preparation .................................................................................... 77 
2.2.9  Propagation of mammalian cell lines  .......................................................... 78 
2.2.10  Virus production ......................................................................................... 79 
2.2.11  Virus titration .............................................................................................. 79 
2.2.12  Osteoclast culture ....................................................................................... 81 
2.2.13  Bone marrow cultures ................................................................................ 82 
2.2.14  Assays .......................................................................................................... 83 
2.2.15  Western blotting ......................................................................................... 84 
2.2.16  Immunocytochemistry ................................................................................ 85 
2.2.17  Software ...................................................................................................... 86 
3  Vector production and characterisation ..................................................................... 87 
3.1  Aims .................................................................................................................... 87 
3.2  Introduction ........................................................................................................ 87 
3.3  Results ................................................................................................................. 89 
3.3.1  Patient interest in gene therapy for type I Gaucher disease ...................... 89 
3.3.2  Vector production ....................................................................................... 91 
3.3.3  Glucocerebrosidase activity can be determined with fluorometric assays 95 9 
 
3.3.4  Vector constructs produce functional glucocerebrosidase protein ........... 97 
3.3.5  Enzyme activity levels peak at day 3 post transduction ........................... 100 
3.3.6  Integrated vector can restore enzyme activity in patient fibroblasts ...... 104 
3.3.7  Chitotriosidase activity cannot be measured in fibroblasts in vitro ......... 106 
3.4  Summary ........................................................................................................... 109 
4  Secreted glucocerebrosidase for the cross-correction of untransduced cells ......... 111 
4.1  Aims .................................................................................................................. 111 
4.2  Introduction ...................................................................................................... 111 
4.3  Results ............................................................................................................... 114 
4.3.1  Developing assay for secreted protein ..................................................... 114 
4.3.2  Cloning vectors  .......................................................................................... 120 
4.3.3  pHR-SFFV-GBA-WT TAT ............................................................................. 120 
4.3.4  The addition of the protein transduction domain does not affect 
expression or activity of GC ...................................................................................... 126 
4.3.5  Transduced cells secrete GC protein via an endogenous secretion signal128 
4.3.6  Uptake of GC can be mediated by protein transduction domains ........... 132 
4.4  Summary ........................................................................................................... 134 
5  Investigating gene therapy as a potential treatment for the osteoclast .................. 135 
5.1  Aims .................................................................................................................. 135 
5.2  Introduction ...................................................................................................... 135 
5.3  Results ............................................................................................................... 138 
5.3.1  Comparison of osteoclast number in BL6 and CD1 mice .......................... 138 
5.3.2  Osteoclasts can be derived from transduced bone marrow .................... 140 
5.3.3  Osteoclast numbers in healthy vs GD mice .............................................. 145 
5.3.4  Viral transduction of osteoclast cultures .................................................. 147 
5.3.5  CFU-assay in transduced bone marrow .................................................... 149 
5.4  Summary ........................................................................................................... 151 
6  Discussion ................................................................................................................. 153 10 
 
7  Appendix ................................................................................................................... 168 
7.1  Papers presented .............................................................................................. 168 
7.2  Sequence alignment of GBA including mTAT or WT TAT fusion ....................... 169 
7.3  Gene therapy factsheet sent to Gaucher patients ........................................... 172 
7.4  Results of survey to Gaucher patients .............................................................. 177 
7.5  Free text answers to Q5 .................................................................................... 181 
8  References ................................................................................................................ 183 
   11 
 
Table of Figures 
Figure 1.1 Lysosomal storage disorders  .............................................................................. 17 
Figure 1.2 Schematic showing the GBA gene, cDNA, mRNA and amino acid sequences ... 22 
Figure 1.3 Graph showing the number of results from a PubMed search for the term 
"gene therapy" plotted against year .................................................................................. 41 
Figure 1.4 The number of gene therapy trials reported by two sources from 1989-2013. 46 
Figure 1.5 Structure of the Gag and Gag-Pol polyproteins of HIV-1  ................................... 55 
Figure 1.6 Development of first and second generation lentiviral vectors from the HIV-1 
provirus ............................................................................................................................... 62 
Figure 1.7 Cells of the haematopoietic lineage showing differentiation of the macrophage 
and osteoclast from the HSC. ............................................................................................. 69 
Figure 3.1 Patient response to gene therapy for GD questionnaire  ................................... 90 
Figure 3.2 Removal of IRES-eGFP to give the pHR-GBA plasmid ........................................ 93 
Figure 3.3 Fluorescence assays for the detection of glucocerebrosidase activity.............. 96 
Figure 3.4 Glucocerebrosidase expression and activity in HEK293T cells .......................... 99 
Figure 3.5 Glucocerebrosidase expression and viability over time in transduced cells. .. 102 
Figure 3.6 Expression and activity of glucocerebrosidase is restored in patient fibroblasts 
after transduction with LNT-GBA ...................................................................................... 105 
Figure 3.7 Chitotriosidase cannot be measured in cultured fibroblasts. ......................... 108 
Figure 4.1 Comparison of the levels of autofluorescence produced by different 
preparations of FDGlu substrate in medium .................................................................... 115 
Figure 4.2 Autofluorescence of fluorescein-β-D-glucopyranoside in media with and 
without conduritol-β-epoxide........................................................................................... 116 
Figure 4.3 Detection of velaglucerase alfa by enzymatic assay and western blot ........... 118 
Figure 4.4 Cloning strategies to generate fusion constructs ............................................ 122 
Figure 4.5 Schematic showing vectors produced ............................................................. 124 
Figure 4.6 Addition of the mTAT PTD does not affect GC expression or activity ............. 127 
Figure 4.7 Secretion of GC from transduced cells ............................................................ 130 
Figure 4.8 A 14-day time course showing GC activity within the supernatant of transduced 
cells revelas secretion of enzyme ..................................................................................... 131 
Figure 4.9 Cross-correction of GBA
-/- LCLs by protein secreted from transduced HEK293T 
cells ................................................................................................................................... 133 
Figure 5.1 Surveyed type I patients find skeletal problems a significant aspect of living 
with Gaucher disease ........................................................................................................ 137 
Figure 5.2 in vitro osteoclast differentiation differs in mice of different strains ............. 139 
Figure 5.3 Osteoclasts can be derived from a genetically modified, autologous bone 
marrow transplant ............................................................................................................ 142 
Figure 5.4 in vivo osteoclasts from mice transplanted with eGFP transduced bone 
marrow.............................................................................................................................. 144 
Figure 5.5 in vitro osteoclast generation in GBA
-/- mice and healthy controls ................. 146 
Figure 5.6 in vitro transduction is most effective when performed at day 3 of 
osteoclastogenesis. ........................................................................................................... 148 
Figure 5.7 Colony forming assay with transduced GBA
-/- bone marrow .......................... 150 12 
 
Table of Tables 
Table 1.1 Subtypes of GD with associated symptoms ........................................................ 27 
Table 1.2 Altered cytokine production by activated macrophages and the effect on 
osteoclasts/osteoblasts ...................................................................................................... 30 
Table 1.3 Viral types used as gene therapy vectors adapted from (256) ........................... 52 
 
   13 
 
Abbreviations 
4-MUG  4-methylumbelliferryl-β-D-glucopyranoside 
BM  bone marrow 
BSA  bovine serum albumin 
CBE  conduritol-β-epoxide 
ChT  chitotriosidase 
CMV  cytomegalovirus 
cPPT  central polypurine tract 
DAPI  4'-6-diamidino-2-phenylindole 
DMEM  Dulbecco’s modified essential medium 
DMSO  dimethyl sulfoxide 
DNA  deoxyribonucleic acid 
dNTP  deoxyribonucleotide triphosphate 
ECL  enhanced chemiluminescence 
eGFP  enhanced green fluorescent protein 
Env  Envelope protein 
ERT  enzyme replacement therapy 
FDGlu  fluorescein di-β-D-glucopyranoside 
GAPDH  glyceraldehyde 3-phosphate dehydrogenase 
GBA  glucocerebrosidase gene 
GC  glucocerebrosidase protein 
GD  Gaucher disease 
GDI  Gaucher disease type I 
GlcCer  glucocerebroside 
HEK293T  human embryonic kidney cell line 
HIV-1  human immunodeficiency virus 1 
HRP  horseradish peroxidase 
HSC  haematopoietic stem cell 14 
 
HSCT  haematopoietic stem cell transplant 
IN  integrase  
IRES  internal ribosome entry site 
LB  Luria-Bertani 
LCL  lymphoblastic cell line 
LSD  lysosomal storage disorder 
LT  Life Technologies 
LTR  long terminal repeat 
MA  matrix 
M-CSF  macrophage colony stimulating factor 
MEM  minimum essential medium 
MGT  Marker Gene Technologies 
MOI  multiplicity of infection 
mTAT  modified trans-activator of transcription 
NaT  sodium taurocholate 
PBS  phosphate buffered saline 
PCR  polymerase chain reaction 
PGE2  prostaglandin E2 
SFFV  spleen focus-forming virus  
PTD  protein transduction domain 
PVDF  polyvinylidene fluoride 
RANK-L  receptor activator of nuclear factor kappa-B ligand 
RPMI  Roswell Park Memorial Institute medium 
RRE  Rev response element 
SRT   substrate reduction therapy 
TAT  trans-activator of transcription 
WPRE  woodchuck hepatitis virus posttranscriptional regulatory 
element 15 
 
1  Introduction 
1.1  Gaucher disease 
1.1.1  Discovery 
Gaucher disease (GD) is one of the most prevalent lysosomal storage disorders; a family 
of syndromes which cause accumulation of metabolic substrates within the lysosome of 
cells. It was first described in 1882 by a French medical student who reported a female 
patient with a greatly enlarged spleen which he thought to be cancerous. At post-mortem 
it was discovered that the spleen contained a large number of enlarged cells with a 
distinctive appearance (1). Subsequent to the publication of this report, further patients 
were  identified  and  the  swollen  cells,  identified  as  macrophages,  were  found  to  be 
symptomatic of GD and so came to be known as ‘Gaucher cells’ (2).  
Further  investigations  revealed  GD  to  be  caused  by  a  deficiency  of  the  enzyme 
glucocerebrosidase (GC) (3) the gene for which localises to chromosome 1q21 (4). It is 
now  known  that  GD  is  an  autosomal  recessive  disorder  affecting  approximately  1  in 
100,000 births in Europe (5) although this figure is significantly higher in the Ashkenazi 
Jewish population which has a carrier frequency of approximately 1 in 17 (6).  
Gaucher disease is one syndrome in a family of over 50 metabolic disorders known as 
lysosomal storage disorders (LSDs). It is thought that, collectively, LSDs affect around 1 in 
7,000 live births although it is difficult to accurately assess prevalence due to a high 
number of asymptomatic individuals and a lack of coherence in the literature (7).  
Metabolism is an incredibly intricate process performed by a network of enzymes which 
sequentially degrade a macromolecule into its component parts. This is an important 
process as the released monomers are then available for use elsewhere in the cell or are 16 
 
made available throughout the body. Mutations in any one of the metabolic enzymes can 
lead to accumulation of a substrate and when this accumulation occurs in the lysosome, 
the syndrome is classified as an LSD.  
Figure 1.1 shows part of the lipid metabolism pathway which occurs within the lysosome; 
the key enzymes are labelled, along with their associated LSD. Although this work is 
concerned primarily with the development of gene therapy for the treatment of GD, the 
same principles could be used to treat other LSDs because, in many cases, storage is seen 
primarily in cells of the haematopoietic system, as in GD (8).  
Despite being closely related in aetiology, LSDs tend to be clinically distinct and share 
only a limited number of pathological features. Although not all of these are associated 
with every LSD, common symptoms include: hepatosplenomegaly (swelling of the liver 
and spleen), dysmorphic facial features, cardiac complications, neurological involvement 
and skeletal abnormalities. The severity of any individual LSD is also hard to estimate 
because disease exists on a spectrum, from patients who are so mildly affected that they 
go undiagnosed, to levels which are incompatible with life (9, 10).  17 
 
 
Figure 1.1 Lysosomal storage disorders 
Metabolism of ingested lipids in the lysosome is performed by a network of enzymes (rounded boxes) acting sequentially to degrade molecules into 
products for reuse within the body. Mutations which prevent the activity of any enzyme in the network can severely affect the activity of the affected cell 
leading to disease (square boxes). GA: ganglioside, GM: monosialic ganglioside, GM2A: GM2 ganglioside activator, MLD: metachromatic leukodystrophy. 18 
 
The characteristic feature shared by all LSDs is the accumulation of a substrate within the 
lysosome of cells which allows for classification based on the substrate accumulated (8): 
  Mucopolysaccharidoses (I-VII) 
  Sphingolipidoses  
  Oligosaccharidoses  
  Glycogen storage disease type II (Pompe disease) 
  Lipidoses 
There  are  additional  classes  of  LSD  which  include  disease  caused  by  non-enzymatic 
defects but the categories above contain the most common disorders (8). 
GD is classified as a sphingolipidosis because affected cells accumulate glucocerebrosides 
(GlcCer) which are a class of lipid with a backbone of sphingoid bases and a glucose head. 
In  unaffected  individuals  the  glucose  head  is  removed  from  glucocerebrosides  in  a 
reaction catalysed by glucocerebrosidase (11). This allows for recycling of the glucose and 
further  digestion  of  the  sphingolipid  to  provide  monomers  that  can  re-enter  the 
sphingolipid biosynthesis pathway (11, 12). In GD, patients have genetic mutations which 
result  in  the  absence  of  functional  GC  leading  to  accumulation  of  glucocerebrosides 
within the lysosome (4, 13, 14). 
1.1.2  Lysosomal biology 
The lysosome is the final compartment of the endocytic pathway and is responsible for 
the degradation of macromolecules resulting from endocytosis or the autophagocytosis 
of subcellular components. Lysosomes were first identified by Christian de Duve in 1955 
while  he  was  investigating  the  subcellular  location  of  glucose-6-phosphatase  by 
differential centrifugation of cellular compartments. He discovered a membrane-bound 19 
 
organelle, characterised by the presence of enzymes with a lytic action (15, 16), which he 
named the lysosome and which won him the 1974 Nobel Prize in Medicine or Physiology. 
Within  a  cell  there  are  two  routes  for  degrading  proteins:  the  ubiquitin-proteasome 
system which is mostly involved in the processing of small, short-lived cellular proteins; 
and the endosomal-lysosomal network. The lysosome receives molecules being trafficked 
into the cell as well as intracellular moieties intended for degradation, which first pass 
through the autophagosome (17, 18). Although it was first identified as containing the 
enzyme acid phosphatase, it is now known that the lysosome contains over 60 hydrolytic 
enzymes which combine to digest macromolecules present within the cell (19).  
Lysosomal hydrolases are manufactured in the endoplasmic reticulum and transported 
through the Golgi network where the majority acquire a mannose-6-phosphate (M6P) 
group, which enables sorting to pre-lysosomal compartments through the M6P receptor 
(20, 21).  
Although this is the usual route of delivery to the lysosome, there are other methods of 
transport. In I-cell disease (mucolipidosis type II) patients are deficient in the enzyme N-
acetylglucosaminyl phosphotransferase meaning that the formation of the M6P signal 
does  not  occur.  This  leads  to  the  majority  of  hydrolases  being  secreted  rather  than 
delivered  to  the  lysosome.  However,  some  enzymes,  including  GC,  still  reach  their 
intended cellular location (22). This is because GC does not acquire an M6P tag during 
synthesis and instead binds to lysosomal integral membrane protein type 2 (LIMP2) in the 
endoplasmic reticulum. LIMP2 is responsible for the trafficking of GC through the Golgi 
network  and  into  the  lysosome  through  a  direct  association  which  occurs  in  the 
endoplasmic reticulum (23, 24). The association between GC and LIMP-2 is maintained 
through the Golgi body where exit and entrance to the lysosome is co-ordinated by two 20 
 
phosphatidylinositol  4-kinases  (25).  Dissociation  of  the  two  proteins  in  the  lysosome 
occurs as a result of the low lumenal pH. 
1.1.3  Genetics 
The gene for glucocerebrosidase (GBA) was cloned and mapped to chromosome 1q21 in 
the mid-1980s (4, 26). Further investigation showed the gene to span 7.8kb and to consist 
of  11  exons  (Figure  1.2)  (27).  Interestingly  there  is  also  a  GBA  pseudogene  located 
downstream of the functional copy which appears to have arisen as a result of a tandem 
duplication but which has large deletions from exons two, four, six, seven and nine (27). 
Synthesis  of  GC  can  be  initiated  from  one  of  two  ATG  codons  within  the  sequence. 
Transcription seems to occur predominantly from the upstream initiator codon although 
deletion of either ATG does not affect the overall expression level in vitro. The initiator 
codon used for transcription alters the length of the leader sequence at the N-terminus 
of the protein which is 39 or 19 amino acids long depending on the codon used. However 
this sequence is cleaved from the mature enzyme and therefore it is unlikely that there is 
any effect on enzyme activity (28). It has also been shown that there are two promoters 
which can be used to initiate GBA transcription. The second, upstream promoter has an 
associated CpG island which is a common feature of housekeeping genes and may explain 
the ubiquitous expression of GC (29). 
Translation  of  the  GBA  gene  yields  a  60kDa  protein  which  has  a  modular  structure 
consisting  of  three  domains  which  were  identified  when  the  X-ray  structure  of  the 
enzyme was published in 2003 (30). The catalytic activity of the protein is associated with 
domain III which is formed from amino acid residues 76-381 and 416-430.  
The  first  pathogenic  mutations  in  GBA  (L444P  (13)  and  N370S  (14))  were  described 
shortly after the gene was identified. To date, over 200 different mutations have been 21 
 
reported,  but  the  N370S  and  L444P  mutations  are  the  most  prevalent  (31).  Certain 
populations have a higher than average incidence of a particular subclass of GD (for 
example, type I in Ashkenazi Jews (6) and type III in the Norrbotten region of Sweden 
(32)), but even when alleles are considered independently of patient origin, N370S and 
L444P are the most commonly found mutations (31, 33). Mutations reported to date 
include:  203  missense,  18  nonsense,  36  indels,  14  splice  junction  variants,  and  13 
complex alleles (containing multiple mutations), in addition to recombination events (31). 
Many of the mutations described in GBA, including N370S, have structural effects on the 
protein  and  disrupt  the  protein  folding  which  leads  to  retention  in  the  endoplasmic 
reticulum and degradation of a catalytically active protein (34, 35). The N370S mutation 
occurs in the active site of the enzyme but in a loop outside the catalytic domain causing 
a structural change to the protein which makes it less flexible (36). The L444P mutation 
also causes a structural change, this time within the hydrophobic core of the protein (30) 
and which appears to affect the interaction of the protein with the activator  protein 
saposin C (37). Another common mutation is the insertion of a second guanine base at 
residue 84 giving the 84GG allele which results in premature termination of transcription 
and  is  predicted  to  severely  compromise  the  enzyme  as  it  has  never  been  seen  in 
homozygosity (33, 38). The locations of the three mutations are shown in Figure 1.2. 22 
 
 
Figure  1.2  Schematic  showing  the  GBA  gene,  cDNA,  mRNA  and  amino  acid 
sequences 
 
Although many mutations have been described and GBA is well characterised, there is 
still  only  a  limited  understanding  of  genotype-phenotype  correlation  and  the  same 
mutations can be implicated across a spectrum of disease (39). There is even discordance 
found within twin studies (40, 41). One of the few examples of correlation that has been 
found is the N370S mutation (c.1226A>G) with non-neuronopathic or type I disease (42). 
However,  even  N370S  homozygotes  display  a  wide  range  of  symptoms  from 
asymptomatic to severe organomegaly with bone involvement (42, 43).  
Similarly, the L444P (c.1448C>T) allele, which usually indicates neuronopathic disease, 
has  been  shown  to  exist  on  a  continuum  of  symptoms  ranging  from  moderate 
neurological and systemic symptoms to seizures and severe developmental delay (44).  
Some studies have reported data which points to a dosage effect of individual alleles 
which results in the spectrum of disease seen in patients. For example; homozygosity for 23 
 
the  N370S  allele  results  in  milder  symptoms  and  later  onset  than  in  heterozygous 
patients (33, 42). 
A degree of phenotypic variability may be due to the effect of other genes which act as 
modifiers. Candidates include: SCARB2 (the gene encoding the LIMP2 protein (45)), CLN8 
(46) and PSAP (47). PSAP encodes a polyprotein called prosaposin which is cleaved into 
four distinct saposins. Of these saposin C is a known activator of GC and mutations have 
been shown to cause GD (46). The CLN8 gene was identified as a potential modifier of GD 
by  a  genome-wide  screen  and  has  been  shown  to  be  resident  in  the  endoplasmic 
reticulum and to have a stimulatory effect on glucosylceramide synthase (48). 
1.1.4  Pathophysiology 
The symptoms of Gaucher disease are complex as it is a multisystem disorder which can 
cause significant haematological (49), skeletal (50) and neurological complications (51). 
The exact symptoms that a patient displays can be used to classify their disease based 
primarily on the presence or absence of neurological involvement, but also the age at 
which symptoms present (summarised in Table 1.1) (52).  
The distinctive, swollen cells which were found in the spleen of the original GD patient 
are today known as Gaucher cells and are considered to be a hallmark of GD (2); the 
presence of these cells in a bone marrow biopsy is one of the main indicators used for 
diagnosis  (53).  Gaucher  cells  are  macrophages  which  have  a  ‘crumpled  tissue  paper’ 
appearance due to the accumulation of the substrate, glucocerebroside (GlcCer), within 
the  lysosome  (11).  GlcCer  is  released  from  the  breakdown  of  cell  membranes  and 
therefore phagocytic cells such as the macrophage and the Kupffer cells of the liver are 
particularly affected and store large quantities of the substrate (54). 24 
 
The mildest form of GD is type I in which patients predominantly experience visceral 
pathology including hepatosplennomegaly (with a spleen size of up to 20 times that of 
unaffected  individuals  (55)),  anaemia  and  skeletal  problems.  This  form  is  the  most 
common and can be diagnosed at any age but is most commonly identified in adulthood. 
Symptoms can be effectively managed with treatment and patients have a normal life 
expectancy (53, 56). 
Until recently, type I GD was defined as non-neuronopathic as patients did not display 
any neurological impairment. However, within the last decade a link has been established 
between type I GD and parkinsonism (56, 57). There have been anecdotal reports of 
Gaucher patients developing parkinsonian symptoms as far back as 1942 ((58) reviewed 
in (59)) but it was not until recently that a definitive link has been shown between type I 
GD and the development of early onset parkinsonism (59, 60). Subsequently it has been 
found that there is a high prevalence of GBA mutations amongst non-GD Parkinson’s 
disease patients, making heterozygosity for GD mutations a risk factor for parkinsonism 
(61). The mechanism behind this association is still under investigation, but it has been 
suggested that it may be due to impaired mitochondrial function (62) or accumulation of 
mutant GC in Lewy bodies (63). However, parkinsonism in GD patients does not appear to 
be due to elevated levels of α-synuclein, which is associated with classical Parkinson’s 
disease (64). 
GD in patients with neurological disease can be classified as either type II or type III. Of 
these, type II is the most severe with symptoms arising in the first six months of life and 
deteriorating very rapidly leading to death at around 2 years of age (51). Type III is a 
milder  form  with  less  severe  neurological  symptoms  and  a  later  age  of  onset.  The 
condition deteriorates over time but at a slower rate than in type II and is usually fatal in 
early adulthood (65). 25 
 
The  molecular  basis  for  neurological  disease  in  GD  remains  unclear,  although 
degeneration appears to be due to neuronal loss and astrogliosis (66, 67). This may be 
caused  by  the  accumulation  of  GlcCer  within  neurones  (68)  or  by  impaired 
autophagocytosis (69). 
In  addition  to  the  three  classical  types  of  GD  (I,  II,  III),  further  subtypes  have  been 
described in efforts to more accurately discriminate between groups of patients.  
A subtype of type II which is often viewed as a distinct class of disease is named perinatal-
lethal GD because affected individuals usually die within hours of birth, if not in utero. 
Symptoms  indicative  of  this  class  of  GD  include  hydrops  fetalis,  congenital  icthyosis, 
hepatosplenomegaly and arthrogryposis in combination with very low GC activity (<7% 
normal value) (70).  
The delineation of type III GD has been subject to significant debate with three subclasses 
being suggested based on the severity of neurological symptoms (65). According to these 
subdivisions type IIIa patients would have milder visceral symptoms but early onset of 
neurological disease with seizures and horizontal supranuclear gaze palsy. In comparison, 
type IIIb is associated with significant hepatosplenomegaly as well as kyphoscoliosis and a 
barrelled  chest,  but  later  appearance  of  seizures.  Although  type  IIIb  is  generally 
considered to be the class of GD seen at high frequency in the Norrbotten region of 
Sweden (known as the Norrbottnian type), the distinction between IIIa and IIIb is hard to 
make clinically and therefore these subdivisions are rarely used (71).  
A  subclass  of  type  III  GD  used  more  frequently  is  type  IIIc  which  is  associated  with 
calcification of the cardiac valves (atrial and mitral) and corneal opacity. Other visceral 
and neurological symptoms appear to be mild in these patients other than oculomotor 26 
 
apraxia. Unusually for GD, type IIIc is very clearly associated with a specific mutation – 
the D409H substitution which strongly correlates with valvular calcification (72, 73). 27 
 
Classification  Age of onset  Life expectancy  Neurological symptoms  Visceral symptoms 
Type I (non-
neuronopathic) 
(53, 56, 74) 
Any  Relatively unaffected  None (Parkinsonism)  Hepatosplenomegaly, skeletal involvement 
(bone crises, osteonecrosis, osteomyelitis), 
anaemia, thrombocytopenia  
Type II (acute 
neuronopathic) 
(51) 
<9 months  1-2 years  Strabismus, oculomotor apraxia, 
extrapyramidal symptoms, 
seizures, neck hyperextension, 
apnoea hypertonia 
Pulmonary involvement, idiopathic fever, 
haemorrhage, splenomegaly 
Type III (chronic 
neuronopathic) 
(65) 
Childhood  Childhood  Oculomotor apraxia, myoclonic 
epilepsy, dementia, ataxia, 
spasticity 
Hepatosplenomegaly, thrombocytopenia, 
anaemia, skeletal involvement, pulmonary 
involvement, oesophageal varices 
Type IIIc  
(73, 75, 76) 
0-20 years  20 years  Oculomotor apraxia  Mitral/aortic valve calcification, corneal 
opacity 
Perinatal lethal 
(51, 70)  Birth/in utero   <3 months  Hypokinesia   Non-immune hydrops fetalis congenital 
icthyosis, facial dysmorphia, splenomegaly 
Table 1.1 Subtypes of GD with associated symptoms 28 
 
1.1.5  Bone disease 
For type I GD patients, and to some extent type III, a significant pathology is bone disease 
which occurs in approximately 75% of patients (77).  
Clinically skeletal involvement can include: restricted growth, osteopenia, osteonecrosis, 
lytic bone lesions and a specific class of bone malformation known as Erlenmeyer flask 
deformities (50, 78). Many patients also experience bone crises – periods of severe bone 
pain  which  can  be  very  disabling.  These  crises,  as  with  all  GD  symptoms,  differ  in 
frequency  and  intensity  from  patient  to  patient.  The  primary  manifestations of  bone 
disease are often a starting point for the development of secondary problems such as 
osteomyelitis, fractures, and osteoarthritis which cause further disability to the patient 
(50, 79). 
The primary reason for the development of skeletal complications appears to be the 
infiltration of Gaucher cells into the bone marrow. This leads to an expansion of red 
marrow which alters the vascularity of the bone marrow compartment and allows the 
occurrence of infarction and thrombosis (50).  
While infarction and thrombosis are both serious complications of GD, bone maintenance 
is a delicate balance between the two types of osteological cell – the osteoclast and the 
osteoblast – and so it is likely that there is also a cellular explanation for bone disease 
(80). Osteoblasts are mesenchymal cells which are involved in the formation of bone by 
laying down the matrix and differentiating into osteocytes (reviewed in (81)). Conversely 
the osteoclast, a haematological cell, is responsible for degrading and remodelling bone 
by breaking down the matrix (82). Both cell types can influence the behaviour of the 
other (83) and it is the balance between the activity of the two which ultimately results in 
a healthy skeleton (84). 29 
 
As with all cells, the functions of osteoclasts and osteoblasts are influenced by cytokines, 
and  so  it  is  likely  that  altered  cytokine  production  by  macrophages  within  the  bone 
marrow which have been activated by the accumulation of GlcCer has a role in bone 
disease ((85), summarised in Table 1.2).  
The exact impact of GD on the cells of the skeletal system remains unclear although 
recently  evidence  has  emerged  that  there  is  increased  stimulus  leading  to  the 
differentiation of osteoclasts in the GD setting (80, 86, 87). Evidence for the involvement 
of osteoblasts is less promising with a recent in vitro model showing that inhibiting GC 
had no effect on osteoblast activity (88), while another paper showed that there may be 
an uncoupling of osteoblast-osteoclast interactions in GD (86) and a recent GBA
-/- mouse 
model suggested that the osteoblasts was the most severely affected  bone cell (89). 
Taken together, these studies suggest that a treatment strategy which directly targets the 
osteoclast may prove beneficial for the skeletal complications of GD.   30 
 
Cytokine  Change in GD  Effect on 
osteoclasts 
Effect on 
osteoblasts 
Interleukin-1β 
(90)  Increased  Stimulatory  - 
Interleukin-6
 (90, 91)  Increased  Stimulatory  - 
Interleukin-8 
(85, 92, 93)  Increased  Stimulatory  - 
Interleukin-10
 (91)  Increased  -  Inhibitory 
Macrophage-colony 
stimulating factor 
(85) 
Increased  Stimulatory  - 
Tumour necrosis factor-
alpha
 (94) 
Increased  Stimulatory   - 
Prostaglandin E2
 (93)  Increased  Stimulatory   - 
Table 1.2 Altered cytokine production by activated macrophages and the effect 
on osteoclasts/osteoblasts   31 
 
1.1.6  Current treatment  
Originally, treatment for Gaucher disease was on a purely symptomatic basis. The most 
common measures were blood transfusions to treat anaemia and other cytopenias, with 
splenectomy when splenomegaly became too pronounced (95). However, splenectomy 
leaves patients at an increased risk of bacterial infections and is no longer used except 
when patients who fail to respond to treatment exhibit pronounced thrombocytopenia 
(96, 97).  
Hematopoietic stem cell transplant (HSCT) has also been used for patients with severe 
disease and successful engraftment has been found to improve blood counts and reduce 
hepatomegaly in addition to correcting the underlying metabolic defect (98) It has also 
been  shown  that  in  some  cases  HSCT  can  stabilise  bone  disease  (99,  100)  and 
neurological condition in some type III patients (71, 101). Despite promising evidence of a 
curative  effect,  the  mortality  rate  among  HSCT  recipients  is  around 10-25% and  it  is 
therefore not used as a routine treatment option (98, 102). However as HSCT has never 
been used with any degree of regularity and the majority of data is from the 20
th century 
it is difficult to assess the true potential of the treatment. Given recent advances in 
technology, such as high-resolution human leukocyte antigen typing allowing for more 
accurate donor-recipient matching (103, 104) and improved stem cell mobilisation and 
collection regimens (105), some groups are now calling for re-evaluation of HSCT as a 
treatment option (106, 107). 
1.1.6.1  Enzyme Replacement Therapy 
The  possibility  of  treating  lysosomal  disorders  with  replacement  therapy  was  first 
suggested 50 years ago when it was observed that any substance taken up by endocytosis 
was likely to end up in the lysosome (15) (reviewed in (108)) but it was not until 1991 that 
this possibility was realised for GD (109).  32 
 
Once  the  enzyme  deficient  in  GD  was  identified  (11),  and  a  method  for  large-scale 
purification of the enzyme from human placenta was established (110, 111); researchers 
began experiments treating patients with infusions of enzyme. The first three studies 
used  either  unaltered  enzyme  ((112)  reviewed  in  (113)),  or  enzyme  encapsulated  in 
either red blood cell membrane (114) or liposomes (115), but none were particularly 
successful in ameliorating disease.  
An explanation for this failure came from a study performed in rats which showed that 
native GC enzyme administered intravenously localises predominantly to hepatocytes; 
cells which do not store GlcCer (116) and is therefore unlikely to alleviate disease. Rapid 
uptake of lysosomal enzymes by hepatocytes is a mechanism that has been seen in a 
number of studies (117-119) suggesting it to be a common mechanism of uptake for 
lysosomal proteins. Further investigations of the placental enzyme revealed it to contain 
a  high  percentage  of  galactose-terminated  oligosaccharide  side  chains  which  interact 
strongly with a lectin expressed on hepatocyte cell membranes (120). The discovery that 
macrophages bear a receptor (macrophage mannose receptor; MMR) which interacts 
with mannose-terminal side chains provided a mechanism for targeting purified GC to its 
site of action (119, 121). The side chains of GC can be modified to target the enzyme to 
macrophages by the sequential removal of monosaccharide residues using the enzymes 
neuraminidase, β-galactosidase and β-N-acetylglucosaminidase (109, 121). 
The  first  study  of  mannose-terminated  placental  glucocerebrosidase  used  a  dose  of 
60U/kg  administered  once  a  fortnight  which  reduced  organomegaly  and  improved 
haematological parameters with no serious adverse events (109). On the back of this trial 
the  preparation  was  approved  by  the  Food  and  Drug  Administration  (122)  and  was 
marketed  by  Genzyme  as  alglucerase  (Ceredase®)  but  at  considerable  cost  and  with 
incredibly  limited  supply.  In  1994  a  second  form  of  ERT,  imiglucerase  (Cerezyme®, 33 
 
Genzyme), a recombinant form of protein produced in Chinese hamster ovary cells, was 
approved and became the primary treatment for GD (123, 124). 
Since  the  approval  of  imiglucerase  two  other  forms  of  ERT  have  been  developed: 
velaglucerase alfa (VPRIV®, Shire Pharmaceuticals), a gene activated form of GC produced 
in human fibroblast cells (125, 126); and taliglucerase alfa (Elelyso®, Protalix/Pfizer) (127). 
Velaglucerase  alfa  is  known  as  ‘gene  activated’  as  it  is  generated  by  the  targeted 
recombination of the endogenous GBA gene with a promoter that would produce high 
levels of expression within fibroblasts (128). Adding kifunesine, a mannosidase I inhibitor, 
to the culture medium results in a protein with a high percentage of mannose-terminated 
side  chains  without  the  need  for  in  vitro  processing  (129,  130).  Taliglucerase  alfa  is 
produced in carrot cells and in 2012 became the first drug made in plant cells to win FDA 
approval (131, 132). Producing the enzyme in plant cells eliminates the need for post-
translational  modification to expose  the  mannose  residues  as more than  90% of  the 
native side chains are mannose terminated (133). 
A nine month randomised control study comparing imiglucerase and velaglucerase alfa in 
treatment  naïve  patients  found  no  difference  in  the  effectiveness  of  the  two  drugs, 
although  there  was  a  slightly  increased  risk  of  adverse  events  when  treating  with 
velaglucerase alfa (134). In addition, it has been shown that patients who switched from 
imiglucerase to velaglucerase alfa had no significant decline in the main GD parameters 
and  that  the  change  was  well  tolerated  (135-137).  Taliglucerase  alfa  has  only  been 
available to patients for a short space of time so there is less clinical data available but 
initial  reports  are  promising  with  reduction  of  organomegaly  and  improvement  in 
haematological parameters (127) and increase of bone marrow fat fraction (138) and 
stability in patients switching from imiglucerase (131). The results of a phase III clinical 
trial  assessing  the  efficiency  and  safety  of  taliglucerase  alfa  in  adult  and  paediatric 34 
 
patients previously treated with imiglucerase showed the change to be well tolerated 
with maintenance of haemoglobin and platelet concentration as well as liver and spleen 
volume (139). Taliglucerase alfa was approved by the FDA for use in paediatric patients in 
August  2014  and  importantly  for  many  patients,  is  the  only  one  of  the  four  drugs 
available to be deemed kosher by the US Orthodox Union (140, 141). 
The approval of these two variants of ERT was driven in part by viral contamination 
(Vesivirus 2117) at the Genzyme manufacturing plant in 2009 which caused a worldwide 
shortage and left many patients without treatment (142, 143). In addition to pushing 
velaglucerase  alfa  through  the  regulation  process,  a  second  effect  of  the  Cerezyme 
shortage has been beneficial for this project as it has left patients less willing to rely on a 
treatment  where  supply  could  be  interrupted at  any  time  and,  therefore,  potentially 
more willing to consider trying genetic therapies and permanent correction to disease 
(Tanya Collin-Histead: personal communication). 
It is also worth noting that ERT is an expensive treatment option costing around £100,000 
per  patient,  per  year  in  the  UK  (144,  145)  and  it  is  not  curative  meaning  that  any 
interruption to supply can lead to the recurrence of symptoms (146, 147). While the cost 
is not a major problem for patients in the UK, those in less developed countries such as 
India (148) and Pakistan (149) may have limited or no access to ERT because the cost is 
too  high  (146,  150).  Some  of  these  patients  are  supported  by  compassionate  access 
programs  such  as  those  run  by  Genzyme  (Massachusetts,  USA)  and  the  European 
Gaucher Association but such schemes are limited and a one-time, curative treatment 
may represent a more accessible option for these patients. 
1.1.6.2  Response of bone disease to treatment 
While ERT has been shown to be effective in treating the majority of visceral symptoms, 
evidence for the treatment of skeletal symptoms is less easy to interpret. In general, the 35 
 
frequency and intensity of bone crises appears to decrease rapidly in response to ERT 
(151,  152)  but  some  patients  continue  to  experience  crises  and  in  some  cases 
osteonecrosis  can  continue  to  develop  asymptomatically  (153).  Another  measure  of 
skeletal disease in GD is bone mineral density (BMD) which is highest among adolescents 
and then gradually declines with age (154). In keeping with this pattern, an analysis of 
patient data from the International Collaborative Gaucher Group registry showed that 
osteopenia  was  evident  in  children  as  young  as  five  years  and  most  pronounced  in 
adolescents  (155).  It  is  therefore  unsurprising  that  younger  patients  respond  to  ERT 
better with the most significant increase in BMD and reduction in both bone pain and 
bone crises (155, 156). Rosenthal et al. (1995) showed that bone density takes an average 
of 3.5 years treatment with ERT to return to normal values. The same study also showed 
that it takes a similar length of time for the marrow fat fraction to normalise in treated 
patients (157). 
1.1.6.3  Substrate Reduction Therapy 
Around 15% of patients display hypersensitivity to alglucerase/imiglucerase (158) and 
although this can be managed, there is another option – substrate reduction therapy 
(SRT).  Patients  are  treated  with  an  inhibitor  of  glucosylceramide  synthase  (miglustat, 
marketed  as  Zavesca®,  Actelion)  which  limits  the  formation  of  GlcCer  and  has  been 
shown  to  be  effective  in  treating  GD  (159).  The  active  ingredient  in  miglustat  is  N-
butyldeoxynojirimycin  (NB-DNJ),  an  iminosugar  which  was  originally  identified  as  an 
inhibitor  of  HIV  infectivity  (160,  161).  Subsequent  investigation  showed  it  to  be  an 
analogue of D-glucose and a competitive inhibitor of glucosylceramide synthase which is 
the first enzyme in the glycolipid synthesis pathway (159). SRT has been shown to be 
effective in treating GD, particularly in reducing organomegaly (162) and with promising 
results emerging for the treatment of bone disease (163). However, utility is limited due 
to gastrointestinal disturbances including osmotic diarrhoea and weight loss (164). These 36 
 
side effects are caused by the inhibition of intestinal disaccharidase enzymes by NB-DNJ 
which affects the digestion of carbohydrates (164). Although they can be controlled by 
dietary alterations, miglustat is a less preferable treatment option and therefore SRT is 
only offered to patients who do not respond to, or who display sensitivity to ERT (162). 
1.1.6.4  Pharmacological chaperone therapy 
An  emerging  treatment  area  for  GD  is  the  use  of  chaperone  proteins  which  can  be 
employed to augment the activity of mutant protein. Pharmacological chaperone therapy 
(PCT) is a potential treatment strategy as many mutations which cause GD are missense 
mutations  which  either  prevent  the  protein  folding  into  the  correct  conformation  or 
which prevent its trafficking to the lysosome.  
PCT was first hypothesised after the observation that β-galactosidase inhibitors could in 
fact restore enzymatic activity in fibroblasts derived from patients with GM1-gangliosidosis 
(β-galactosidase  deficiency,  Figure  1.1)  (165,  166).  Enzyme  inhibitors  have  also  been 
shown to act as chaperones in Fabry disease (167), Pompe disease (168, 169) and GM2-
gangliosidosis (170, 171). It has taken many years to elucidate the mechanism of PCT but 
it appears that chaperones can stabilise the substrate-enzyme complex thereby enable 
the misfolded protein to be targeted to the lysosome (167, 171, 172). 
Two compounds have been identified which act as chaperones for mutant GC in cells – 
isofagomine  (IFG)  (173,  174)  and  ambroxol  (ABX)  (175).  Incubation  of  GD-derived 
fibroblasts with either compound results in increased levels of enzyme activity, lysosomal 
localisation of the enzyme and clearance of stored GlcCer.  
A pilot study which treated 12 GD type I patients with ABX over a 6 month period showed 
the drug to be safe for use in people with GD (it has already been approved for use in 
patients with lung disease). Although the study only produced limited clinical effects this 37 
 
is likely to be due to the low dose used, and further trials with higher doses are planned 
for  the  future  (176).  IFG  has  been  shown  to  increase  survival  and  reduce  substrate 
storage in mouse models of neuronopathic GD (177, 178) suggesting that it may be of use 
in the treatment of patients. 
1.1.6.5  Treatment monitoring 
Whether or not patients are receiving treatment, they require monitoring by clinicians on 
a regular basis. This monitoring includes the use of CT scans to assess organomegaly and 
MRI scans or X-rays to check for skeletal deterioration. Patients also undergo regular 
blood  tests  to  monitor  haemoglobin  and  platelet  levels  as  well  as  the  plasma 
concentration of chitotriosidase (ChT), a known biomarker of GD. ChT was first identified 
as a GD biomarker in 1994 when Hollak et al. showed it to be highly elevated in patient 
plasma  samples  compared  to  unaffected  individuals  and  that  levels  decreased  in 
response to treatment with ERT (179). The exact function of ChT remains unclear but it is 
known to be highly expressed in the lymph node, lung and bone marrow (180) with the 
majority of protein expressed by macrophages and monocytic cells (181). 
1.1.7  Animal models 
In order to study disease it is useful to have animal models which mimic the phenotype 
seen in humans. To date research into GD has been hampered by a lack of viable models. 
Two  independent  groups  attempted  to  produce  a  mouse  model  of  GD  by  targeted 
disruption of exons 9-11 of the GBA gene (182, 183). Although both models resulted in 
mice with high levels of Gaucher cell infiltration in the liver, spleen and, in one case, the 
brain; the affected animals all died within 24 hours of birth meaning both models are of 
very limited use. The affected animals in both studies died of dehydration due to the 
incorrect  formation  of  skin  architecture,  not  unlike  the  congenital  icthyosis  seen  in 
perinatal-lethal GD.  38 
 
A subsequent model produced by a Swedish group yielded mice which had a cassette 
inserted into intron 8 of the GBA gene (184). This cassette was flanked by loxP sites 
enabling excision by Cre recombinase. Mice carrying this insertion were crossed with 
mice carrying Cre recombinase under the control of a keratinocyte specific promoter 
(K14). This scheme allows for expression of functional GC which is confined to the skin 
and is sufficient for rescue of the fatal skin phenotype seen in a ubiquitous knock-out 
animal. The mice produced in this study developed normally for the first ten days of life 
and then experienced rapid neurological deterioration leading to continuous seizures and 
paralysis by two weeks of age. Post-mortem analysis showed widespread neuronal loss 
and microglial activation (184). This mouse represents a close model of GD type 2 with 
little visceral pathology; however the absence of GC expression in all tissues means it has 
utility in investigating the correction of the metabolic defect in type I GD and therefore it 
has been of use to this project. 
Other successful models have used a similar strategy for example Sinclair et al. (2007) 
produced  a  conditional  knock-out  in  which  GBA  disruption  was  confined  to  cells  of 
endothelial and haematopoietic lineages. This model exhibits splenomegaly with Gaucher 
cells present in the liver and spleen and lives beyond one year of age (185). Models have 
also been generated carrying specific mutations which correlate with human disease. 
These  include:  a  mouse  homozygous  for  the  L444P  mutation  which  has  very  limited 
pathology  (186),  mice  homozygous  for  N370S  which  died  at  birth  (187)  and  mice 
homozygous for the mutations V349L, D409H and D409V all of which showed extensive 
GlcCer accumulation in visceral tissues but no accumulation in the CNS (187).  
A further model which has been produced recently recapitulates the type I GD phenotype 
(89).  It  was  created  by  the  targeted  knock-out  of  GBA  in  haematopoietic  and 
mesenchymal  stem  cells  at  day  two  after  birth.  Mice  show  significant 39 
 
hepatosplenomegaly with Gaucher cells present in the liver, spleen, bone marrow and 
thymus. They also display a skeletal phenotype including osteonecrosis and osteopenia 
which appears to be due to a defect in osteoblastogenesis as no defect was found in the 
formation of osteoclasts (89). This represents a very promising model of GD for future 
experimentation.    40 
 
1.2  Gene therapy 
Gene  therapy  is  an  emerging  branch  of  medicine  which  aims  to  treat  disease  by 
introducing genetic material which will correct the underlying defect. Gene therapy has 
benefited greatly from significant advances in knowledge of genetics and recombinant 
technology over the last 100 years; this chapter will describe those advances and the way 
in which they have led to the advent of gene therapy. 
1.2.1  History 
In the first half of the 20
th century it was observed that injecting a dead, virulent, (S) 
strain of Pneumococcus bacteria into mice in conjunction with an avirulent, living strain 
(R)  led  to  a  fatal  bacteraemia  caused  by  the  transformation  of  the  R  type  by  some 
unknown method (188). In 1944, Avery and colleagues determined that the mechanism 
of transformation was the exchange of DNA between the two bacterial strains (189). This 
discovery, that DNA from one cell can be used to alter phenotypic characteristics of 
another, allowed researchers to hypothesise a new method of treating genetic disease – 
the correction of a genetic defect by supplying a healthy copy of the aberrant gene. This 
hypothesis  gained  weight  from  demonstrations  that  mammalian  cells  could  also 
incorporate and retain DNA from exogenous sources (190, 191).  
However, the majority of early experiments relied on exposing recipient cells to naked, 
genomic  DNA  from  the  donor  source  and  this  only  gave  inefficient,  transient 
transformation (191-193).  
The discovery that malignancies induced by infection with polyoma virus or simian virus 
40 (SV40) occur because of the incorporation of viral DNA into the host cell genome (194, 
195) suggested the use of viruses as an efficient method of transforming cells. It was at 41 
 
this  time  that  the  first  references  to  ‘gene  therapy’  can  be  found  within  academic 
literature (196) (Figure 1.3). 
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Figure 1.3 Graph showing the number of results from a PubMed search for the 
term "gene therapy" plotted against year 
However, these developments in gene delivery arose before the advent of recombinant 
genetic technology so researchers were unable to engineer viruses that would deliver 
specific  genes  into  cells.  This  changed  in  1978  when  Tom  Maniatis  and  colleagues 
announced that they had successfully cloned the gene for β-globin from three eukaryotic 
species (197). The isolated rabbit gene was subsequently cloned into the viral genome of 
SV40 and used to infect cells where it was shown to be transcribed into a hybrid virus-
mammal mRNA which could be used to produce full-length rabbit β-globin protein (198). 
Improved recombinant DNA techniques coupled with increased understanding of viral life 
cycles allowed several groups to produce replication-deficient retroviral constructs. 
When  transfected  into  a  cell  which  was  subsequently  infected  with  a  replication-
competent ‘helper’ virus, these constructs yielded replication-incompetent vectors as the 42 
 
engineered genome was incorporated into the viral particle in place of the wild type 
genome (199-201). 
To refine the technology it was necessary to eliminate the requirement for a helper virus. 
This was achieved by splitting the genes necessary for virus production away from the 
rest  of  the  viral  genome.  Concurrent  transfection  of  these  genes  together  with  a 
construct containing the gene of interest and a minimal amount of viral DNA (including a 
packaging  signal)  allowed  for  the  formation  of  infectious  viral  particles  which  were 
capable of transmitting the gene of interest but were replication deficient (202-204). This 
development will be covered in more detail later in this chapter. 
1.2.2  Clinical trials 
Some of the first demonstrations of gene therapy in vitro used cells derived from patients 
with  Lesch-Nyhan  syndrome  (hypoxanthine-guanine  phosphoribosyltransferase  (HPRT) 
deficiency). Two papers in the early 1980s from a group in California showed that it was 
possible to correct  HPRT
-/- fibroblasts (205) and lymphoblasts (206) using a retroviral 
vector.  In  the  lymphoblast,  which  is  the  more  disease  relevant  cell,  physiological 
correction was shown as purine accumulation fell and ATP/GTP ratio normalised (206). 
The following years saw the publication of papers reporting the genetic correction of 
patient  material  from  a  number  of  diseases  including:  adenosine-deaminase  linked 
severe  combined  immunodeficiency  (ADA-SCID)  (207),  alpha-1  anti-trypsin  deficiency 
(208), Gaucher disease (209) and leukocyte adhesion deficiency (210). As well as different 
diseases, researchers targeted a variety of cell types including connective tissue (211, 
212), renal cells (213), and haematopoietic cells (214, 215). 
However, developments faced a setback in the early 1980s when researchers at UCLA 
conducted  an  unsanctioned  experiment  in  humans  (216).  Following  their  published 
papers in which they had successfully inserted the genes for thymidine kinase (217) and 43 
 
dihydrofolate reductase (214) into the bone marrow of mice, the Cline group conducted a 
trial on two β-thalassemia patients. Bone marrow cells from patients were transduced 
with recombinant plasmids containing both the β-globin gene and thymidine kinase (a 
selectable  marker)  and  transfused  the  cells  back  into  the  patients.  Neither  patient 
showed any clinical benefit or significant side effects despite being subjected to high level 
irradiation  prior  to  reinfusion  (216).  However  the  work  was  heavily  criticised  on 
administrative and ethical grounds as the construct used had not been tested before the 
study and it emerged that the research had not been approved by UCLA, where Cline was 
based, and also that the protocol had been modified from the version approved by the 
participating institutions in Italy and Israel.  As a result, Cline lost his UCLA chair and 
funding from the NIH (218, 219). It is worth noting however that since no harm came to 
either of the patients treated in this study, it can be viewed as the first time recombinant 
DNA was shown to be safe in people which lent strength to the concept of gene therapy 
as a treatment option. 
Despite this setback, gene therapy development continued and in 1992 the first official 
clinical trial began in the USA. Dr W. French Anderson used gene corrected autologous T-
cells to treat a four-year old patient with ADA-SCID (220).  
T-cells were harvested by apheresis, transduced with a retrovirus carrying the ADA gene 
and reinfused to the patient. This was repeated five times over the course of six months. 
A second patient with a milder disease phenotype was also enrolled in the same trial and 
at four years post-treatment both patients showed healthy levels of lymphoblastic ADA 
expression  and  good  clinical  outcome  even  when  enzyme  replacement  therapy  was 
reduced (220). A second trial began in the European Union in 1992 and treated two 
patients with genetically modified haematopoietic stem cells (HSCs) and peripheral blood 
lymphocytes. Both patients showed short-term immune reconstitution with expression of 44 
 
ADA (221). However in both of these studies patients were kept on enzyme replacement 
therapy and therefore they do not constitute definitive proof of the success of gene 
therapy. However they did provide more data on the safety of the approach. 
Since these first studies, a number of other trials for ADA-SCID therapy have been run 
which included amendments to try and increase the success rate. These modifications 
include the refinement of the cytokine cocktail used to culture the stem cells during 
transduction (222), the use of fibronectin to increase transduction efficiency (223) and 
the addition of a conditioning regimen to improve engraftment ((224) reviewed in (225)). 
The most recent set of clinical trials using these adjustments have been run at centres in 
Italy, the UK and the US and have treated more than 40 patients. Of these, 29 (72.5%) are 
no longer on ERT and there have been no reported adverse events, making ADA-SCID one 
of the first diseases to be successfully treated with gene therapy (226-229). 
The same technology was adapted to develop a treatment for X-linked severe combined 
immunodeficiency (X1-SCID), caused by mutations in the IL2RG gene which encodes the 
γ-chain of interleukin receptors including that of IL2 (230). Trials were run at the Hôpital 
Necker, Paris and Great Ormond Street Hospital, London treating twenty patients with 
autologous HSCs transduced by a γ-retrovirus carrying the IL2RG gene. Results showed 
efficacy in the majority of patients including full immune reconstitution, normal thymic 
development and clearance of pre-existing infections (231-233). Unfortunately a number 
of these patients developed T cell leukaemia several months after gene therapy. One 
patient died as a result but the rest responded to chemotherapy and went into remission 
(234). Genetic analysis determined that the reason for the uncontrolled expansion of T 
cells  was  an  insertion  of  the  viral  genome  close  to  genomic  loci  containing  proto-
oncogenes, usually the LMO2 locus but also CCND2 and BMI1. The strong viral enhancer 
element  in  the  viral  backbone  upregulated  expression  of  genes  at  these  loci  which 45 
 
resulted in increased proliferation and survival of cells containing these insertions (234-
236).  
Clonal expansions were also observed in gene therapy trials for chronic granulomatous 
disease (leading to the death of one participant) (237, 238) and β-thalassemia (239) using 
γ-retroviruses although in these cases the expansions were found to have therapeutic 
benefit.  
In 1999, the gene therapy field suffered a major stumbling block when researchers at 
Pennsylvania State University working on ornithine transcarbamylase) deficiency treated 
an eighteen-year old boy named Jesse Gelsinger as part of their phase I clinical trial (240). 
The previous seven patients had been treated with escalating doses of intravenously 
administered virus and had experienced minor side effects (transient thrombocytopenia, 
myalgia,  fever)  but  no  serious  reactions  that  might  suggest  a  danger  to  future 
participants (241). However 18 hours after treatment Jesse Gelsinger began to exhibit 
signs of liver failure and 35 hours post-administration, he fell into a coma from which he 
never recovered, dying 98 hours after treatment despite the best efforts of the research 
and other medical teams (240). Subsequent investigations revealed a number of issues 
with the study which has led to revised policy on the reporting of adverse events in pre-
clinical studies as well as the involvement of trial staff with financing organisations (242, 
243). 
Despite the many challenges faced during the development of gene therapy, researchers 
have persevered. Figure 1.4 shows the number of clinical trial records in the PubMed 
database  (http://www.ncbi.nlm.nih.gov/pubmed)  returned  by  a  search  for  the  term 
“gene therapy” over time. This graph shows clearly the effect that the death of Jesse 
Gelsinger had on the gene therapy community, with the number of reports filed falling 
from forty in 1999 to twenty-four in 2002. This drop reflects the public loss of trust in 46 
 
clinical research after the widespread reporting of his death, as well as restrictions placed 
on a number of organisations while investigations were being conducted. The graph also 
shows a second fall in the number of clinical trials being conducted which corresponds 
with the reporting of T-ALL development in participants of the X1-SCID trial in 2003. 
Nevertheless, gene therapy continued to persevere with 25 records deposited in the 
PubMed database in 2013 and 120 trials in progress according to the Journal of Gene 
Medicine. The Journal of Gene Medicine collates the number of gene therapy trials and 
this data shows the same trend as the PubMed search with a steady increase in the 
number of records despite a drop in the number of records around 1999 and 2003. 
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Figure 1.4 The number of gene therapy trials reported by two sources from 
1989-2013 
Pubmed search for the term "gene therapy" restricted to records labelled as "clinical 
trials" (solid line) and the number of trials approved worldwide according to the Journal 
of Gene Medicine (dashed line). 
 
It is worth noting at this point that although the development of gene therapy has faced a 
number of setbacks, the development of a new treatment is rarely smooth. For example, 47 
 
an early review of bone marrow transplantation as a treatment strategy showed that 152 
of 203 patients had died after the therapy leading to widespread discontinuation of the 
practice  (244)  before  going  on  to  become  the  standard  of  care  for  a  number  of 
conditions. 
 
1.2.3  Vectors 
A  number  of  different  virus  types  have  been  developed  as  vectors  for  gene  therapy 
including: retroviruses (and lentiviruses), adenoviruses (Adv), adeno-associated viruses 
(AAV) and herpes viruses. Table 1.3 summarises the vector types available.  
A  variety  of  virus  genera  have  been  developed  as  vectors  because  of  the  differing 
requirements for treating the large variety of diseases targeted by gene therapy and the 
following pages will explain some of the differences between the vector types and their 
advantages and disadvantages in a clinical setting. 
One of the first considerations when choosing a vector type is the amount of genetic 
material which can be incorporated into the virion. AAV is the smallest gene therapy 
vector and has a capacity of 5kb which must include the transgene in addition to any 
other genetic components such as promoter or enhancer elements as well as any viral 
structures and therefore limits the utility of the vector as it cannot be used to transport 
large genes (245).  
An example of how the size of insert can affect vector choice comes from research into 
gene therapy for muscular dystrophy (MD). The gene responsible for causing both Becker 
and Duchenne muscular dystrophy is the dystrophin gene which has a cDNA of 11kb and 
this has hindered gene therapy for MD (246). 48 
 
Another  feature  which  must  be  considered  when  choosing  a  vector  system  is  the 
outcome of cellular transduction. Some vector systems such as retroviruses and AAV are 
able to integrate their genetic material into the host chromosome enabling maintenance 
and replication of the transgene within the cellular genome. This is important for the 
treatment of many conditions as it allows for the permanent correction of a genetic 
defect. It is of particular use when treating stem cells as it ensures that the therapeutic 
effect  will  not  be  lost  as  cells  divide  and  differentiate.  However  there  is  a  risk  that 
integration can lead to insertional mutagenesis which can have an oncogenic effect as 
has been seen in a number of clinical trials (234-238). 
Some vector types including adenovirus, herpes virus and non-viral vectors are unable to 
mediate this integrative effect and the transgene remains outside the  genome as an 
episome. Although episomal DNA will be lost if a cell divides, non-integrating vectors are 
of use when treating post-mitotic cells such as skin or neurones as the lack of integration 
removes the risk of insertional mutagenesis and the transgene will persist for the life of 
the cell which is often of sufficient length to provide relief from the disease. 
A number of viral vectors that have been developed to date have been derived from 
known  human  pathogens.  In  addition  to  the  possibility  that  these  vectors  could  be 
pathogenic themselves, this also introduces the risk that patients will have pre-existing 
immunity to the vector. This is a particular problem with Adv and herpes virus vectors as 
well as some AAV serotypes (247). Pre-existing immunity to a vector can result in its 
eradication from the body by the immune system before a clinical effect can be produced 
but it can also result in severe complications for the patient as seen in the case of Jesse 
Gelsinger (240). Vectors which have an immunogenic effect are also of limited use to 
researchers as they can only be used once for each patient and so the option of a repeat 
treatment is not available (although this can be overcome to a certain extent by changing 49 
 
the serotype of virus when using AAV or Adv). Additionally, the issue of immunity is only 
a problem when vectors are administered directly to the patient; in therapies where 
patient cells are treated ex vivo, as is often the case when treating haematopoietic stem 
cells, the virus is removed from the cells prior to their reinfusion to the patient reducing 
the likelihood of the virus and the host immune system coming into contact with one 
another. 
 
With these considerations in mind, a range of vector types have been developed. This 
project uses a subset of retroviral vectors known as the lentiviruses which will be covered 
in detail but a brief overview of the other vector types will be given here. 
Adenoviruses are a family of over 50 serotypes which commonly cause respiratory and 
intestinal tract infections. They are double-stranded DNA viruses which have an insert 
capacity  of  up  to  36kb  (serotype  dependent).  Adenovirus  predominantly  targets 
epithelium but the native receptor is expressed in almost every tissue. Expression of the 
receptor  is  greatly  upregulated  on  malignant  cells  making  Adv  ideal  for  cancer  gene 
therapy (248). However this significant benefit for Adv vectors is countered to a certain 
extent by the significant immunogenicity of the virus type. This is due to both the vector 
capsid  and  the  residual  viral  genes  which  are  expressed,  albeit  at  low  levels,  in 
transduced cells (249). Not only does this high immunogenicity reduce the potential for 
repeating a treatment, it also limits the duration of transgene expression which can be 
useful where only short-term expression is required or the target cells are post-mitotic 
but is of little use where the goal is permanent correction. Pre-existing immunity also 
limits  the  initial  dose  that  can  be  administered  as  lower  doses  reduce  the  risk  of 
stimulating an immune response. 50 
 
The smallest viral vector to be developed is derived from the adeno-associated viruses 
(AAV); non-pathogenic,  single-stranded DNA viruses  with a maximum capacity of 5kb 
(245). This small size in addition to relatively high immunogenicity and high levels of pre-
existing immunity can limit utility in gene therapy to a certain extent (250) but it remains 
a  popular  virus  type  for  a  number  of  reasons.  There  are  at  least  eleven  different 
serotypes of AAV which all have distinct antigenic profiles. This array of serotypes of AAV 
gives  a  wide  range  of  tropisms  allowing  vectors  to  be  designed  on  the  basis  of  the 
intended  target.  For  example  AAV8  has  a  strong tropism  for  liver  transduction  (251) 
whereas both AAV8 and AAV1 show a preference for muscle targeting (252). Additionally, 
it  is  possible  for  researchers  to  ‘pseudotype’  AAV  vectors,  using  the  genome  of  one 
serotype in combination with the capsid of another to alter the tropism of the vector 
(253). This strategy can also be used to overcome the problem of repeat administration 
of a vector which has significant immunogenicity as changing the capsid protein would 
provide resistance to neutralising antibodies produced after the first administration.  
One of the most significant  discoveries in AAV gene therapy was the revelation that 
AAV9, or virus pseudotyped with the AAV9 capsid, is able to cross the blood-brain barrier 
and can mediate wide-spread nervous system transduction (254, 255). This is of great 
benefit to gene therapy researchers as it is  currently the only vector system able to 
transduce neuronal tissue without the need for intracranial delivery. 
Herpes simplex virus (HSV) type 1 has a 152kb, single-stranded DNA genome resulting in 
vectors which can incorporate very large genes. It is also a highly infectious virus type 
with a broad host range (despite the wild type virus being predominantly neurotropic) 
and is able to infect dividing and non-dividing cell types. All of which makes HSV-based 
vectors a very promising area of gene therapy research. 51 
 
Not all gene delivery methods rely on viral vectors, particularly when integration is not 
required and the target tissue is easily accessible. Non-viral vectors often consist of a 
positively charged polymer (for example: polylysine or polyethylenimine) or lipid (such as 
lipofectamine) which condenses around the DNA and is able to fuse with the plasma 
membrane  enabling  delivery  of  the  genetic  material.  Although  naked  DNA  can  be 
delivered to cells using methods such as electroporation or the gene gun, encapsulation 
within a polymer increases the stability of the material allowing for more widespread 
distribution. Non-viral vectors have some significant advantages over viral agents as they 
have unlimited capacity so are able to transport very large genetic elements. They also 
have a very low immunogenic profile so that the risk of pre-existing immunity or inducing 
an immune response is greatly reduced compared to a viral vector and re-administration 
of a treatment is usually permissible. However the efficiency of non-viral methods is quite 
low compared to viruses, especially in vivo which has limited their use.   52 
 
  γ-retrovirus  Lentivirus   Adenovirus   Adeno-associated 
virus  
Herpesvirus   Non-viral 
Packaging capacity  9kb  10kb  30kb  5kb  100kb  Unlimited 
Transduction of non-
dividing cells 
No  Yes  Yes  Yes  Yes  Yes 
Integration into host 
genome 
Yes  Yes  No   Yes  No  No 
Duration of 
expression 
Long   Long   Short   Long   Short   Short  
Pre-existing immunity  No  No  Yes  Some serotypes  Yes   No 
Table 1.3 Viral types used as gene therapy vectors adapted from (256) 
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1.2.4  Lentiviruses  
Many of the earliest gene therapy experiments used vectors developed from the Retroviridae; a 
family which is characterised by a single-stranded RNA genome which is reverse transcribed into 
DNA  within  the  host  cell  and  subsequently  integrated  into  the  host  genome  (257-259).  The 
Retroviridae  is  a  large  family  consisting  of  seven  genera  including  the  alpharetroviruses, 
gammaretroviruses, lentiviruses and spumaviruses most of which have been developed as gene 
therapy vectors. The earliest clinical trials focused on the use of the gammaretroviruses but in recent 
years the focus has shifted towards lentiviruses such as the vectors used in this report. 
One of the principal reasons the Retroviridae were chosen as vectors is the integration of the viral 
genome after transduction of target cells. Once DNA is integrated into the host genome, it will 
replicate with the cell and so the delivered gene will be maintained throughout cell division and 
differentiation  (259,  260).  In  this  way  correction  of  cells  can  be  seen  as  permanent.  This  is  of 
significant benefit to gene therapy researchers treating progenitor cells as it means that a treatment 
may only need to be performed once. 
However,  factors  including  the  association  of  retroviral  transduction  with  the  development  of 
leukaemia seen in some trials (234-236) led researchers to look for alternative viral vectors. One 
such alternative was found in the lentivirus family, a subset of retroviruses which include the human 
immunodeficiency virus 1 (HIV-1) which preferentially integrate within actively transcribed genes 
(261) unlike γ-retroviruses, which have a preference for integrating close to transcription start sites 
(261-263). There is also evidence that γ-retroviruses but not lentiviruses have integration hotspots 
within the region of proto-oncogenes which increases their potential for insertional mutagenesis 
(264).  
1.2.4.1  HIV  
This section will give some general background to wild type HIV biology and explain the changes 
required to develop gene therapy vectors. 54 
 
Genome 
The wild type HIV-1 genome can be split into two types of sequence: coding and non-coding. Coding 
sequences include the three major HIV-1 genes – env, gag and pol – in addition to genes encoding 
accessory  and  regulatory proteins.  The  non-coding sequences consist  primarily  of the 3’  and  5’ 
untranslated  regions  (U3  and  U5  respectively)  together  with  primer  binding  sites  for  reverse 
transcription, and a packaging signal (265). 
The genome is transcribed by the host cell RNA polymerase II (PolII) which is recruited to the TATA 
box within the 5’ long terminal repeat (LTR; Figure 1.6) (265) by the viral TAT protein and the host 
cell  protein P-TEFb  (266, 267)  and results  in multiple  mRNAs.  Translation  of  the  unspliced viral 
mRNAs occurs at host ribosomes and results in a number of polyproteins which require further 
processing to yield the functional viral proteins (268-270).  
Env  
The HIV envelope protein (Env) consists of two parts – surface and transmembrane units (271, 272) 
which associate to form the structure which is responsible for mediating cellular entry (273, 274). 
The Env complex is only weakly associated with the virion which has allowed for pseudotyping of 
lentiviral  vectors  with  alternative  proteins.  Pseudotyping  has  allowed  the  creation  of  lentiviral 
vectors carrying the envelope proteins of the vesicular stomatitis virus, murine leukaemia virus and 
herpes simplex virus among many others (275). 
Gag-Pol 
The major structural proteins of a lentiviral virion are encoded by the gag and pol genes which 
overlap by 205 or 241 nucleotides (268, 276). Transcription of the gag and pol genes yields two 
polyproteins, Gag (55kDa) and Gag-Pol (160kDa), due to ribosomal slippage which allows the host 
ribosomes to read through the stop codon between the two genes (Figure 1.5) (268, 269). It appears 55 
 
that ribosomal slippage occurs infrequently as the ratio of Gag to Gag-Pol production in an infected 
cell is approximately 20:1, analogous to the ratio of the same proteins in other retroviruses. This 
20:1 ratio appears to be important for maintaining the infectivity of viruses (277). 
 
 
Figure 1.5 Structure of the Gag and Gag-Pol polyproteins of HIV-1 
Schematic showing the two polyproteins translated from the gag and pol genes of HIV-1. A) Gag 
polyprotein B) Gag-Pol polyprotein p17: matrix (MA), p24: capsid (CA), p2/p1/p6: spacer proteins, 
p9; nucleocapsid (NC), PR: protease, RT: reverse transcriptase, IN: integrase 
 
The cleavage of the polyproteins is an essential step in the production of a mature virion as without 
it, the viral core cannot form (278) and the RNA is not adequately stabilised (279) resulting in non-
infectious particles (280). Cleavage is performed by the HIV-1 protease which is released from the 
Gag-Pol polyprotein by autoproteolysis and goes on to cleave the rest of the protein (281). 
The components of the Gag polyprotein (Figure 1.5A) are structural proteins which are important 
during viral assembly including the three main proteins – capsid (CA), nucleocapsid (NC) and matrix 
(MA). All three are essential proteins due to their role in forming the virion; NC and CA are involved 
in encapsulating the genome (282-287) while MA targets the complex to the plasma membrane 
where the full molecule is formed (288, 289). 
In addition to CA, NC and MA, the full length Gag-Pol polyprotein (Figure 1.5B) yields two other 
enzymes which are essential for viral function: reverse transcriptase and integrase. 
p1  p17  p2  p9  p24  p6 
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Reverse transcriptase 
The first of these, reverse transcriptase (RT), is responsible for the conversion of the RNA genome to 
double  stranded  DNA  which  can  be  processed  by  the  host  cell.  The  occurrence  of  the  reverse 
transcriptase event was hypothesised by Howard Temin in 1964 (290) and was found to be due to 
the action of a viral protein in 1970 by two separate groups (257, 258). The protein itself functions as 
a heterodimer composing of a 66kDa subunit and a smaller, 15kDa subunit (291) which are both 
products of Gag-Pol cleavage. The complete enzyme has both polymerase and RNase activities both 
of which are essential for reverse transcription to occur (292). The process of reverse transcription 
itself has taken several years to elucidate but is now relatively well understood. 
The HIV-1 genome is plus-stranded meaning that both strands of DNA are synthesised from the 
same molecule of RNA using a host cell tRNA (Lys3) as a primer (293, 294). The polymerase activity 
of RT uses nucleotides present in the host cell, and the RNA template to extend the primer and begin 
synthesis of the DNA strand. After polymerase extension, the RNase H activity of RT degrades the 
RNA portion of the RNA-DNA complex produced (295). Production of the second DNA strand is 
mediated by a short section of the RNA genome known as the central polypurine tract (cPPT) which 
is resistant to RNase degradation and so is able to act as a primer for second strand synthesis (296).  
The final product, called a provirus, is larger than the original RNA genome as each end contains 
both U3 and U5 regions in a combination known as a long terminal repeat (LTR) (297).  
Each  viral  particle  produces  one  provirus (297)  and  reverse  transcription  products  peak  around 
twelve hours post-transduction with integrated DNA being detected by  twenty four hours after 
infection (298).  
Integrase 
RT is responsible for the production of the DNA provirus but it is the integrase (IN) protein, a 32kDa 
protein found at the N-terminus of the Gag-Pol polyprotein, which catalyses the integration of the 57 
 
provirus into the host cell genome (259). Within the cell IN localises to the nucleus as it contains a 
nuclear localisation signal (NLS) (299) and it binds to DNA through the C-terminus (300).  
To begin the process of integration a tetramer of IN proteins binds to both LTRs of the newly 
synthesised viral DNA (301) and associating with other cellular factors including LEDGF/p75 and 
Ku70 to form the pre-integration complex (PIC). The PIC mediates nuclear entry by a mechanism 
which  remains  unclear  but  which  is  likely  to  involve  proteins  at  the  nuclear  envelope  such  as 
importin-α (302), nucleoporin 153 (303) and ADAM10 (304). 
Once nuclear entry has been achieved, IN cuts the host chromosome leaving a 5bp overhang and 
simultaneously joins the 3’ end of the viral DNA to the 5’ phosphate group of the host genome (305). 
Host cell enzymes then repair the cut DNA and fill in the overhangs caused by IN (306, 307) 
Accessory proteins 
In addition to the major proteins transcribed from the env, gag and pol genes, HIV-1 requires two 
other proteins – regulator of expression of virion proteins (Rev) and transactivator of transcription 
(TAT) both of which are involved in the regulation of HIV gene expression. 
Rev  acts  post-transcriptionally  by  controlling  nuclear  export  of  the  viral  mRNA  allowing  for 
translation of viral proteins (308). It is able to mediate this effect as the Rev protein binds to a motif 
within the RNA known as the Rev response element (RRE) and is exported from the nucleus by virtue 
of a nuclear export signal within the protein itself (309, 310). 
TAT functions to increase transcription of the viral genome. It binds to a site in the RNA known as 
the  transactivation-responsive  region  (TAR)  (311)  which  enhances  elongation  of  the  transcribed 
mRNA (312). The TAT protein is secreted from, and taken up by, infected cells in an autocrine 
fashion  (313,  314)  through  a  protein  transduction  domain  which  can  be  used  to  engineer  the 
transduction of other proteins into a cell (315-317). 58 
 
In addition to the essential proteins described above, the HIV-1 genome encodes a number of other 
accessory  proteins  which  have  a  variety  of  functions  but  no  intrinsic  enzymatic  activity.  These 
include nef, vif, vpr and vpu all of which can be deleted from the genome without any significant 
effect on the ability of the virus to act as a vector (318, 319).  
Viral structure and assembly 
A mature viral particle contains two copies of the RNA genome as well as the host cell tRNA Lys3 
required  for  reverse  transcription  and  the  viral  IN,  RT,  PR  and  Gag  proteins  transcribed  in  the 
producer cell. The virion is encapsulated by a coat of the cell’s plasma membrane which contains 
molecules of the assembled Env protein. Some of the accessory proteins and some cellular factors 
are also packaged into the virion but in much lower quantities (320). 
The first step in viral assembly is dimerization of the RNA genome which is driven by the NC protein 
(282, 284), which recognises the viral packaging signal (Ψ) (321). The full length Gag polyprotein also 
associates with the RNA genome through the integral NC sequence as well as the uncleaved CA C-
terminal domain (322). The MA portion of Gag is then able to bind to PIP2 in the plasma membrane 
and this facilitates the localisation of the Gag-RNA complex to the cell membrane (323).  
The  mechanism  of  Env  incorporation  into  the  virion  remains  unclear.  It  is  known  that  the 
cytoplasmic  domain  of  gp41  interacts with MA  (324,  325)  but the  nature  and  necessity  of this 
interaction remains unclear (326). 
Once the viral components are assembled at the membrane, the virion is produced by ‘budding’ off 
the  cell,  a  process  which  may  involve  the  host  cell  ‘endosomal  sorting  complexes  required  for 
transport’ pathway (327, 328). 
Once budding has occurred, or possibly concurrently, the Gag and Gag-Pol polyproteins which have 
been  incorporated  undergo  cleavage  by  the  viral  PR  and  the  virion  takes  on  the  characteristic 
structure of a retrovirus. NC condenses around the genome, CA forms the ‘Fullerene cone’ structure 59 
 
which  encapsulates  the  RNA,  RT  and  IN  molecules  (329,  330)  whereas  MA  appears  to  remain 
associated with the lipid envelope (331, 332). This process is called maturation and it is the final step 
in viral production. 
1.2.4.2  Lentiviral Vectors 
Several important steps had to be taken in order to develop lentiviral vectors suitable for use in gene 
therapy from wild type HIV. 
One of these steps was the development of so-called ‘self-inactivating’ viruses by the deletion of 
promoter/enhancer sequences within the LTR so that vectors can be regulated by external elements. 
The endogenous retroviral promoter and enhancer elements are contained within the U3 region of 
the virus and function only after reverse transcription when they have been translocated to the 5’ 
LTR (333). Yu et al. (1986) introduced a 299bp deletion within U3 which removed both the enhancer 
and  the  promoter  elements  and  replaced  them  with  an  internal  promoter  to  drive  transgene 
expression (334). This has proved a hugely important development as deletion of the endogenous 
promoter has allowed researchers to control transgene expression by choosing a relevant internal 
promoter. For example, a gene or tissue specific promoter could be used to restrict expression to a 
particular cell lineage (225) or tissue (335, 336). Additionally, recombinant promoter elements such 
as ubiquitously acting chromatin opening element (337, 338) or the β-globin locus (225) can be used 
to give sustainable, high levels of gene expression. Many early experiments used viral promoters 
such as the spleen-focus forming virus (SFFV) promoter (237) or the endogenous retroviral LTR 
promoter (220) as these are expressed in a wide number of cell types and usually at high levels. 
Using a strong promoter allows for high levels of protein expression even when transduction and 
rate of genome integration is low. However viral promoters fell out of favour as it they are prone to 
methylation by the host cell which leads to gene silencing (339, 340) and because many contain 
enhancer elements which increase the risk of insertional mutagenesis (235, 237).  60 
 
A further development came about because many viral proteins are present in the viral particle itself 
and do not require transcribing in the host cell. Therefore the genes encoding these proteins can be 
removed from the viral genome and supplied in trans in a packaging cell. Supplying genes in trans 
has two advantages: first it reduces the size of the viral cassette, allowing for the packaging of larger 
therapeutic nucleic acids; secondly, minimising the viral genome reduces the possibility that the 
vector will recombine with any viral sequences present within the host genome and produce a 
pathogenic or replication competent virus (341).  
Figure  1.6  shows  the  development  of  lentiviral  vectors  from  the  wild  type  HIV-1  genome  by 
sequentially splitting the genome into separate plasmids. The first generation vectors are described 
in Naldini et al. (1996) and carry the majority of the viral genome on three plasmids (342).  
The  main  packaging  construct  contains  the  gag  and  pol  genes  which  encode  all  the  necessary 
enzymes and regulatory sequences including Vif and Vpr. It also contains a defective version of the 
env and vpu genes and a 5’ UTR from which the packaging signal has been deleted but the splice 
donor preserved. The 3’ LTR has been replaced by a polyA signal which eliminated the sequences 
required for packaging, reverse transcription and integration of the plasmid (342).  
The second plasmid contains the gene encoding the envelope protein under the control of the CMV 
promoter.  Changing  the  envelope  gene  included  in  the  plasmid  provides  an  opportunity  to 
pseudotype the vectors (342, 343); altering the protein coat in order to direct the tropism of the 
virus. In the original paper, as in many subsequent studies (including this project), the envelope gene 
used encodes the vesicular stomatitis virus glycoprotein (VSV-G) which increases the stability of virus 
particles as well as providing a wide tropism (344).  
The transfer plasmid (pHR’)contains the gene to be transferred to the target cells, as well as 350bp 
of the gag gene which, in combination with a part of the env gene spanning the RRE sequence, 
increases packaging efficiency and limits transcription to occuring only in the presence of TAT (as the 61 
 
TAT binding sequence is in the LTR) and Rev proteins generated by the packaging construct. The gag 
sequence also contains the packaging signal allowing for incorporation into viral particles. This third 
plasmid also has a full length 3’ LTR allowing for reverse transcription and integration (342). 
In order to generate new vectors containing even less of the original viral genome, researchers 
performed deletion studies on the packaging plasmid which showed that the accessory genes, vif, 
vpr, vpu and nef as well as the entire env gene can be deleted from the plasmid without adverse 
effects on titre or viral infectivity (318, 319). Vectors produced from this reduced packaging cassette 
are known as second-generation lentiviral vectors (Figure 1.6). 
Further efforts to improve the biosafety of lentiviral vectors have yielded a third generation of 
vectors in which the rev gene has been separated onto a fourth plasmid and deletion of the TAT 
gene was made possible through the use of a strong, constitutive promoter within the chimeric 5’ 
LTR used on the third generation transfer plasmid (345).    62 
 
 
Figure 1.6 Development of first and second generation lentiviral vectors from the HIV-1 
provirus 
LTR:  long  terminal  repeat;  GAG:  polygene  encoding  virion  structural  parts;  PRO  POL:  polygene 
encoding viral enzymes; VIF, VPR, VPU, NEF are viral accessory proteins; ENV: viral envelope gene; 
TAT, REV are regulatory sequences; CMV: cytomegalovirus promoter; polyA: polyadenylation signal, 
VSV-G: vesicular stomatitis virus glycoprotein, GA: attenuated GAG sequence; prom: promoter ; 
cDNA: complementary DNA sequence (transgene); Ψ: packaging signal. For 1
st and 2
nd generation 
vectors, plasmids 1 and 2 are supplied in trans in the packaging cell line and only plasmid 3 is 
incorporated into the virion.  
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1.2.5  Protein transduction domains  
Many conditions which are a target of gene therapy are restricted to a particular cell type or lineage 
and therefore it is sufficient to modify only this tissue. While this is likely to be the case for GD as 
demonstrated by the fact that macrophage targeted ERT is able to relieve the majority of symptoms; 
it  may  also  be  beneficial  if  there  is  more  widespread  delivery  of  GC.  This  is  because  GBA  is  a 
housekeeping  gene  and  as  such  is  expressed  ubiquitously  albeit  at  low  levels.  There  are  two 
methods to achieving systemic or widespread protein distribution, one of which is to administer 
vector systemically allowing it to target all tissues. However this method risks stimulating an immune 
response within the recipient as well as requiring higher vector doses and giving reduced control of 
the actual tissues modified. 
An alternative method of achieving widespread correction is to focus on increasing the extent of 
protein rather than gene, distribution. One way is to fuse the protein, which has an endogenous 
secretion signal, to a protein transduction domain (PTD) which would allow any secreted protein to 
penetrate unmodified cells in the environment. PTDs often function through receptor-independent 
mechanisms making them less specific and allowing them to target a wide variety of cell types which 
is ideal in this scenario.  
One of the best characterised PTDs is that of the HIV-1 transactivator of transcription (TAT) protein 
domain. The PTD from the TAT protein has been shown to work by stimulating protein uptake by 
lipid  raft-mediated  endocytosis  when  the  fusion  protein  is  greater  than  30kDa  (346,  347).  This 
method of protein transduction is ideal for lysosomal proteins such as GC because once the protein 
has been endocytosed it becomes trapped in the endosome which progresses through the cell and 
fuses with vesicles which contain lysosomal proteins and have low pH. This becomes the mature 
lysosome which is the site of action of GC (4, 13, 14).  
A previous study demonstrated that in an ERT setting, addition of the TAT PTD to the C-terminus of 
GC  results  in  a  significant  increase  in  the  amount of  protein  taken  up  by  fibroblasts  in  culture 64 
 
compared to both imiglucerase and wild type GC (315). The same paper showed that fusion of the 
PTD  to  the  N-terminus  of  the  protein  abolished  protein  expression.  A  subsequent  study 
demonstrated the presence of two furin cleavage sites within the PTD which presents a possible 
explanation for the lack of expression from the N-terminal fusion (316). The authors were able to 
show  that  changing  the  amino  acid  sequence  could  remove  the  furin  cleavage  sites  while 
maintaining the cell penetrating properties of the domain. This modified version of the PTD (mTAT) 
is used in this project in addition to the WT version (WT TAT) to compare the effect of PTD fusion to 
GC.  
The TAT PTD was the first entity to be described as a mediator of protein transduction (314, 348, 
349) but since those early studies, many other domains have been described. These include: Antp, 
from the Drosophila Antennapedia protein (350); VP22, found in Herpes Simplex virus (351); and 
polyarginine (352) or polylysine domains (353, 354). One of the most important factors that make 
for  a  successful  PTD  is  a  positive  charge  so  that  the  domain  can  interact  with  the  anionic  cell 
membrane  allowing  for  the  uptake  of  the  associated  protein  (347).  For  this  reason  most  PTDs 
contain a high proportion of the basic amino acids arginine and lysine. 
Studies comparing the different forms of PTD have repeatedly shown the polylysine and polyarginine 
domains to be very effective at enabling protein transduction but it has also been suggested that 
they may be more toxic than other sequences with Antp being at the opposite end of both spectra 
(354-356). This study used the TAT PTD because of previous work which has shown it to be capable 
of mediating the transduction of GC and other lysosomal proteins into various cell types (315, 317, 
357, 358) but it would be worth investigating other domains particularly those which have higher 
efficiency such as Antp. 
One potential limitation of PTDs which must be considered is the need for the protein to escape the 
endosome  after  internalisation.  However  this  is  not  relevant  for  GC  as  its  site  of  action  is  the 65 
 
lysosome which is the ultimate location of endocytosed molecules and it is in fact of great benefit 
that the protein is delivered to the lysosome without the requirement for extra adaptations.   66 
 
1.3  Gene therapy for Gaucher disease 
As discussed above, gene therapy has been used to treat a number of monogenic disorders and this 
project aims to develop gene therapy for Gaucher disease. 
There are a number of reasons that GD is being considered as a candidate for gene therapy. Firstly, it 
is a monogenic disorder and the gene responsible has been well characterised so that researchers 
have a good idea of the tissues which need to be targeted and the level of expression necessary to 
correct the disease (studies have shown 11-15% enzyme expression to be sufficient for correction in 
vitro (54) and 1-10% engraftment of WT HSCs in vivo (359)). Secondly, correction of the disease has 
been  seen  following  allogeneic  haematopoietic  stem  cell  transplantation  (HSCT)  with  patients 
showing reversion of skeletal manifestations (360) and neurological stabilisation of type III disease if 
performed sufficiently early in life (100, 101, 361). However, these observations are based on very 
limited clinical  data  as  HSCT  has  never  been  used as  a  routine  treatment option  and  very  few 
patients have undergone transplantation since the advent of ERT (106). 
The fact that HSCT can be a curative treatment for Gaucher disease serves as proof of the principle 
that gene therapy is a suitable option for treating GD. Ex vivo gene therapy would involve treating 
the  patient  with  a  genetically  corrected  autologous  haematopoietic  stem  cell  graft  which  is 
potentially safer than HSCT from an allogeneic donor because there is reduced risk of rejection or 
graft  versus  host  disease  (GVHD).  GVHD  occurs  when  transplanted  T  cells  mount  an  immune 
response against the recipient tissues and is a major complication of HSCT with symptoms including 
skin rashes, gastrointestinal disturbances and liver failure (362). This risk should be eliminated by 
using autologous HSCs. 
Before the development of ERT, there was significant interest in gene therapy as an option for GD 
because of the limitations of HSCT and the shortage of suitable donors. This interest began to wane 
after ERT became a licensed treatment in the early 1990s and was proved to be effective and 67 
 
popular with patients, with the result that there have been relatively few gene therapy studies 
published in the last 20 years. 
The  studies  published  in  the  pre-ERT  era,  used  a  range  of  vector  types,  predominantly 
gammaretroviruses (209, 363-365) although there are occasional reports using lentiviruses (366, 
367) or adeno-associated virus (368, 369). In addition to using different vector types, papers also 
focussed  on  a  number  of  different  cell  types  including:  fibroblasts  (370),  lymphoblasts  (370), 
myoblasts (371) and, most relevantly for gene therapy, haematopoietic stem cells (209, 363-366). 
Two papers, Correll et al., (1992) and Ohashi et al., (1992), both showed that when murine HSCs 
were transduced with a γ-retrovirus carrying the GBA cDNA and transplanted into recipient mice, 
supranormal levels of enzyme activity could be found in macrophages of the BM and spleen up to 
seven or eight months post-transplantation (363, 372). This study showed that transduction of HSCs 
with GBA can give rise to corrected macrophages in vivo but used an early vector-promoter system 
which is less clinically relevant than a lentivirus and also was not a disease model as in both cases, 
the donor and recipient mouse strains were GBA
+/+. A similar study which also used WT mice as both 
donor and recipient showed that lentiviral vectors could also mediate long-term reconstitution up to 
6 months post-HSCT and even after a secondary transplant (366). 
In 1998, an American group initiated a clinical trial for gene therapy using ex vivo transduction of 
CD34+ cells with a retroviral vector in three patients (373). This study showed very low gene transfer 
into the target cells and one day after reinfusion, the cDNA sequence could not be detected in any of 
the patients. Some gene marking was seen in one patient three months post-infusion indicating 
short-term survival and expansion of the transduced cells, but the level of cDNA detected was low 
and was lost six months after treatment. None of the patients had any significant increase in GC 
expression or activity at any point during the study (373). It is worth noting that the study protocol 
did  not  include  a  conditioning  step  before  the  administration  of  transduced  cells.  Conditioning 
involves  the  administration  of  chemotherapeutic  agents  to  suppress  or  destroy  the  recipient 68 
 
haematopoietic system. The lack of a conditioning step in the previous study protocol could mean 
that if the corrected cells have no competitive advantage in the bone marrow environment, it is 
likely  that  they  were  outcompeted  by  the  unmanipulated  HSCs  and  were  therefore  lost.  It  is 
probable that any future gene therapy trial for GD would need to contain a conditioning step and 
that  that  conditioning  would  probably  need  to  be  complete  (Adrian  Thrasher:  personal 
communication). This study also highlights the need for higher levels of transduction than were 
achieved in this paper. 
One of our reasons for investigating gene therapy as a potential treatment for GD is the skeletal 
disease which remains the main cause of morbidity in type I patients on ERT. In many cases bone 
disease is refractory to ERT (153, 157) whereas HSCT has been shown to be curative for a number of 
skeletal complications (99, 100). It is likely that the ability of HSCT to ameliorate skeletal disease to a 
greater  degree  than  ERT  is  due  to  direct  correction  of  the  osteoclast,  a  member  of  the 
haematopoietic lineage (Figure 1.7) (374). There has been very little research into the use of gene 
therapy within the context of the osteoclast and what work there is has tended to focus on the 
transduction  of  preosteoclasts,  rather  than  true  stem  cells  (375).  There  is  one  recent  report, 
however,  which  showed  that  by  targeting  HSCs  as  opposed  to  more  committed  cells,  levels  of 
transduction are greatly improved (376) which is a very promising result for the potential of gene 
therapy to treat skeletal disease. There have also been equally promising results from studies which 
have been developing treatments for the gene therapy of another osteoclast disorder, osteopetrosis 
(377). 69 
 
 
Figure 1.7 Cells of the haematopoietic lineage showing differentiation of the macrophage and osteoclast from the HSC. 
Both of the major cell types involved in GD, the macrophage and the osteoclast, differentiate from HSCs meaning that a gene therapy strategy targeting the 
HSC could be successful in treating both cell types directly. 70 
 
1.4  Summary and Aims 
We hypothesise that lentiviral vectors will provide a suitable method of mediating ex vivo 
gene therapy for GD.  
In chapter 3 of this study we aim to develop vectors which are capable of correcting the 
genetic defect seen and which will be tested using patient-derived cell lines as well as 
tissue harvested from a GBA
-/- mouse model (184). 
The majority of GD patients are currently treated with an enzyme replacement therapy 
which directly targets the macrophage (109) but as GBA is a housekeeping gene with 
some expression in almost all tissues of the body (378-380); it may be preferable to 
develop a therapy which is capable of restoring expression to tissues other than the 
haematopoietic system. To achieve this, chapter 4 shows the fusion of the GBA gene to a 
protein  transduction  domain  to  investigate  the  potential  for  the  cross-correction  of 
untransduced cells by secreted GC protein. 
The major morbidity found in type I GD, even among treated patients, is bone disease 
which we believe can be ameliorated by gene therapy of the HSC. To investigate this, in 
chapter 5 we will firstly establish whether genetic modification of HSC can lead to the 
differentiation of modified osteoclasts in vitro and in vivo and secondly investigate the 
occurrence of an osteoclast phenotype within the GBA
-/- mouse model (184).    71 
 
2  Materials and Methods 
2.1  Materials 
Unless otherwise stated all reagents were supplied by Sigma-Aldrich, enzymes for cloning 
by Promega and cell culture reagents by Life Technologies. 
2.1.1  Cloning 
1kb Plus DNA ladder  Life Technologies 
Q5 High-fidelity polymerase  New England Biolabs 
Deoxynucleotides  Promega 
XL-gold chemically competent E. coli  Agilent Technologies 
QIAquick gel extraction kit  QIAgen 
Glycerol  ACROS Organics 
2.1.2  Plasmid preparation 
QIAprep Spin Miniprep kit  QIAgen 
QIAquick Maxiprep kit  QIAgen 
2.1.3  Virus production 
Centrifuge tubes  Beckman Coulter 72 
 
2.1.4  Virus titration 
DNAreleasy  Anachem 
DNeasy blood & tissue kit  QIAgen 
Platinum® Quantitative PCR SuperMix-UDG 
with ROX 
Life Technologies 
2.1.5  Cell culture  
MethoCult GF M3434  StemCell Technologies 
Prostaglandin E2  VWR International 
Macrophage colony stimulating factor (M-CSF)  R&D Systems 
Receptor activator of nuclear factor kappa-B 
ligand (RANK-L) 
R&D Systems 
Dentine  Dr Derralynn Hughes (Royal 
Free Hospital, London) 
TRAP staining kit  Sigma-Aldrich 
Transwell inserts (diameter 12mm, pore size 
0.4μm) 
Fisher Scientific 
2.1.6  Assays 
Velaglucerase alfa (VPRIV)  Shire Human Gene 
Therapeutics 73 
 
FDGlu  Life Technologies 
Citric acid  VWR International 
Disodium hydrogen orthophosphate  VWR International 
2.1.7  Western blotting  
NP40  Calbiochem 
Leupeptin  AppliChem 
Aprotinin  AppliChem 
NuPage gels  Life Technologies 
MES buffer  Life Technologies 
PVDF membrane  Millipore 
Transfer buffer  Life Technologies 
SeeBlue Plus2 pre-stained standard  Life Technologies 
Pierce enhanced chemiluminescence western 
blotting substrate 
Thermo Scientific 
2.1.8  Immunocytochemistry 
BSA  Promega 
Rat serum  Dessi Malinova (Institute of 
Child Health) 74 
 
PFA  Alfa Aesar 
Mounting medium   Life Technologies 
DAPI  Life Technologies 
Phalloidin  Life Technologies 
Slides  Thermo Scientific 
 
2.1.9  Antibodies 
Antibody  Manufacturer (catalogue number) 
Mouse monoclonal to GC  Abcam (ab55080) 
Mouse monoclonal to GAPDH  Santa Cruz Biotechnologies (sc-32233) 
Rabbit polyclonal to GFP(FL)  Santa Cruz Biotechnology (sc-8334) 
Rabbit polyclonal to BSA  Life Technologies (A11133) 
Anti-mouse CD51-PE  eBioscience (12-0512) 
Sheep anti-mouse, HRP conjugated  GE Healthcare (NXA931) 
Donkey anti-rabbit, HRP conjugated  GE Healthcare (NA934V) 
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2.1.10   Solutions 
Western blot lysis buffer  1% NP40, 10mM TRIS pH 8.0, 130mM NaCl, 1mM 
PMSF, 10mM NaF, 1mM DTT, 100mM Na3VO4 1% 
aprotinin, 200mM leupeptin 
Western blot stripping buffer  15g glycine, 1g SDS, 10ml Tween20 in 1L water, 
pH 2.2 
TAE (50x)  242g TRIS Base, 57.1ml glacial acetic acid, 100ml 
0.5M EDTA pH 8.0 in 1L distilled water 
DNA loading dye  10% glycerol, 0.1% Orange G 
Stopping solution   1M glycine in water, pH 10.4 with NaOH. Diluted 
to 0.25M in water for working solution 
McIlvaine citrate-phosphate 
buffer (MV 5.4) 
0.1M  citric  acid,  0.2M  disodium  hydrogen 
orthophosphate. pH 5.2 
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2.2  Methods 
2.2.1  PCR amplification 
100ng template DNA was combined with 1μM of each primer, 200μM each dNTP, 1.25U 
Pfu polymerase, and 1X Pfu polymerase buffer and made up to a total volume of 50μl 
with sterile water. Initial denaturation was performed at 95°C for 2 minutes and followed 
by  30  amplification  cycles  consisting  of  denaturation  at  95°C  for  30  seconds,  primer 
annealing at 58°C for 30 seconds (adjusted for each primer melting temperature) and 
extension at 72°C for 1 minute/kb, followed by a final extension step of 5 minutes at 
72°C. 
2.2.2  Restriction digests 
1μg plasmid DNA was digested by 1U enzyme in 1x reaction buffer made up to a final 
volume  of  20μl  with  sterile  water.  Digestion  was  performed  at  37°C  for  2  hours.  If 
required, inactivation of the restriction enzyme was performed by heating the reaction 
mixture to the temperature and for the time given in the specification sheet. 
2.2.3   Klenow polymerase treatment (filling 5’-protruding ends) 
Digested DNA was incubated with 1U Klenow per microgram DNA in reaction mixture 
containing 50mM Tris-HCl, 10mMMgSO4, 0.1mM DTT, 40μM each dNTP and 20μg/ml 
acetylated BSA for 10 minutes at room temperature. The reaction was terminated by 
heating to 75°C for 10 minutes. 
2.2.4   Ligation 
Insert DNA was ligated into 100ng digested pHR’ plasmid backbone in a 3:1 or 5:1 ratio 
using  3U  T4  DNA  ligase  in  1x  reaction  buffer  overnight  at  room  temperature 77 
 
(approximately 22°C). The resulting ligated plasmid DNA was transformed into chemically 
competent XL-Gold E. coli and grown in the presence of ampicillin. 
2.2.5  TOPO cloning 
Digestion products were blunted with Klenow and ligated into the pCR- Blunt II-TOPO® 
subcloning vector using the Zero Blunt TOPO PCR cloning kit (Life Technologies) according 
to the manufacturer’s instructions. Cultures were grown with kanamycin. 
2.2.6   Transformation 
2-4μl ligation mixture was gently mixed with 50μl chemically competent E. coli in a pre-
cooled 14ml tube and incubated on ice for 30 minutes. Cells were heat-shocked at 42°C 
for 45 seconds and returned to ice for 2 minutes. 250μl SOC medium was added to the 
tube and incubated with shaking at 37°C for 1 hour and then plated on an LB-agar plate 
containing the relevant antibiotic (ampicillin for lentiviral plasmids, kanamycin for TOPO 
plasmids) at 50μg/ml. Plates were incubated at 37°C overnight. 
2.2.7   Gel electrophoresis 
DNA samples were added to 1x loading dye and applied to a 1% (w/v) agarose gel in TAE 
buffer alongside 10μl 1kb Plus DNA ladder and separated by electrophoresis at 80-120V 
in  1X  TAE.  DNA  fragments  were  visualised  by  exposure  to  ultraviolet  light  using  the 
UviDoc system. 
2.2.8  Plasmid preparation 
Bacterial  clones  were  grown  in  5ml  (Miniprep  yield  =  approximately  6μg)  or  500ml 
(Maxiprep yield = approximately 500μg) LB broth with the relevant antibiotic at 50μg/ml 
overnight  at  37°C  with  shaking.  The  following  day  cultures  were  pelleted  by 78 
 
centrifugation  and  plasmid  DNA was extracted  using  QIAgen  plasmid  purification kits 
according to manufacturer’s instructions. 
2.2.9  Propagation of mammalian cell lines 
All cells were incubated at 37°C with 5% CO2. For long-term storage 1-5x10
6 cells were 
pelleted and resuspended in 1ml freezing medium (90% FCS, 10% DMSO), transferred to 
cryovials  and  slowly  cooled  to  -80°C  in  an  isopropanol  freezing  box  before  being 
transferred to liquid nitrogen for long-term storage. 
Human embryonic kidney 293T (HEK293T) 
HEK293T cells were maintained in Dulbecco’s Modified Eagle’s Medium (DMEM) with 
10% foetal calf serum (FCS) and 1% streptomycin/amphotericin (complete DMEM) until 
confluent and passaged using 1x trypsin-EDTA to remove cells from flask and diluted into 
new flasks. 
Fibroblasts 
Gaucher patient fibroblasts were obtained from Coriell Cell Repositories (GM00852) and 
cultured  in  Modified  Eagle’s  Medium  (MEM)  with  10%  FCS,  1% 
streptomycin/amphotericin and 2mM L-Glutamine. Passaging was performed using 1X 
trypsin-EDTA to remove cells which were seeded according to the cell data sheet. 
Lymphoblastic cell lines (LCL) 
Lymphoblastic cell lines (LCL) are suspension cell lines and were maintained in RPMI 1640 
medium with 10 FCS and 1% penicillin/streptomycin. 79 
 
2.2.10   Virus production 
HEK293T cells were seeded at 1.5x10
7cells/175cm
2 flask and allowed to reach 80-90% 
confluency. For each flask, 40µg vector construct, 10µg pMD.G2 and 30µg pCMV-ΔR8.74 
plasmids  were  added  to  5ml  OptiMEM  and  filtered  through  0.22μm  filter.  10mM 
polyethylenimine  was  added  to  5ml  OptiMEM  for  each  flask  and  passed  through  a 
0.22μm  filter.  The  two  mixtures  were  combined  and  allowed  to  complex  at  room 
temperature for 20 minutes. Seeded cells were washed in OptiMEM to remove residual 
serum and 10ml transfection mixture was added to each flask and left at 37°C for 5 hours. 
After this time the medium was exchanged for 15ml DMEM and the flasks were returned 
to  the  incubator.  Supernatant  was  harvested  at  48  and  72  hours  post-transfection, 
passed  through  0.22µm  filters  and  centrifuged  at  98,000g  for  2  hours.  Pellets  were 
resuspended in 150µl PBS and incubated on ice for 1 hour. The suspension was removed 
and centrifuged at 1,500g for 10 minutes and stored in 30µl aliquots at -80°C.  
2.2.11   Virus titration 
HEK293T cells were seeded in a 12 well plate at a density of 5x10
4 cells/well and left to 
adhere for 4 hours. Serial dilutions of virus in 1ml DMEM replaced the medium on the 
adhered cells which were incubated at 37°C for 72 hours. After this period, cells were 
harvested  and  titre  was  determined  using  two  methods.  For  viruses  containing  a 
fluorescent protein (GFP), titre was calculated using flow cytometry performed on live 
cells.  The  titre  of  viruses  without  a  fluorescent  marker  had  to  be  performed  using 
quantitative PCR as described below. 
2.2.11.1 Flow cytometry 
Cells were harvested with trypsin-EDTA and transferred to polystyrene flow cytometry 
tubes and pelleted by centrifugation at 1,500g for 5 minutes. Cells were washed twice in 80 
 
PBS  and  finally  resuspended  in  500μl  PBS  and  analysed  for  fluorescence  by  flow 
cytometry using the CyAn ADP cell analyser (Beckman Coulter, High Wycombe, UK). 
Titre was calculated using the following formula: 
∑
(% positive cells) × (dilution factor) × (number of cells transduced)
100
 
 
2.2.11.2 Quantitative Real-Time PCR (qPCR) 
72  hours  post-transduction  cells  were  washed,  pelleted  and  DNA  extraction  was 
performed  using  20μl  DNAreleasy  per  sample  according  to  the  manufacturer’s 
instructions.  Quantitative  PCR  (qPCR)  was  performed  using  100ng  genomic  DNA  as 
template. The reaction mixture contained 0.9mM each primer, 0.2mM fluorescent probe 
and  1X  qPCR  SuperMix-UDG  with  Rox  mastermix.  The  reaction  was  performed  in 
triplicate with 40 cycles of: 95°C for 15 seconds and 60°C for 1 minute with quantification 
using  an  ABI  Prism  7000  (Applied  Biosystems,  California,  USA).  Plasmid  standards 
containing  the  human  β-actin  and  HIV-1  WPRE  sequences  diluted  in  TE  were  kindly 
supplied by Dr Conrad Vink (UCL Institute of Child Health). 
β-actin sequences 
Forward primer: TGAGGATCTTCATGAGGTAGTCAG 
Reverse primer: TCACCCACACTGTCCCATCTACGA 
Probe: 5'FAM- ATGCCCTCCCCCATGCCATCCTGCGT-3'TAMRA 
WPRE sequences 
Forward primer: TGGATTCTGCGCGGGA 81 
 
Reverse primer: GAAGGAAGGTCCGCTGGATT 
Probe: 5’FAM-CTTCTGCTACGTCCCTTCGGCCCT-3’TAMRA 
Virus titre was obtained using the following calculation: 
∑(
Qty WPRE
Qty β − actin
) × dilution factor × number of cells transduced 
 
2.2.12   Osteoclast culture 
Culled mice were sterilised with 70% ethanol. Bone marrow was harvested by removing 
the tissue from the long bones of the limbs and flushing with PBS using a  25 gauge 
needle. Extracted bone marrow was collected in a 15ml Falcon tube and pelleted by 
centrifuging  at  1,500g  for  5  minutes  at  room temperature.  Samples  were  blinded  to 
prevent experimenter bias. Cells were resuspended in 15ml S1MEM (OptiMEM with 10% 
FCS, 1% streptomycin/amphotericin, 2mM L-glutamine, 10
-7 M PGE2 and 86μM M-CSF) 
and plated in a 75cm
2 flask and incubated at 37°C. 24 hours later 6mm dentine discs were 
sterilised by immersion in 100% ethanol, allowed to air-dry and soaked in OptiMEM + 
10% FCS for 1 hour. Non-adherent cells were collected from flasks and pelleted at 1,500g 
for  5  minutes.  Pellets  were  resuspended  in  S2MEM  (OptiMEM  with  10%  FCS,  1% 
streptomycin/amphotericin, 2mM L-glutamine, 10
-7 M PGE2, 38μM M-CSF and 157μM 
RANK-L)  at  a  concentration  of  5  x  10
6  cells/ml.  200μl  cell  suspension  was  added  to 
sterilised  6mm  dentine  discs  or  13mm  glass  coverslips  in  a  96-well  plate  (6-8 
discs/mouse) and incubated overnight at 37°C and 5% CO2. The following day discs were 
transferred to 6-well plates with 4 discs/well in 3ml S2MEM. A half media change was 
performed after 48 hours. On day 7, cultures were acidified by complete media change 
with  acidified  S2MEM  (82μl  concentrated  HCl  in  100ml  S2MEM).  Cultures  were 82 
 
terminated  48  hours  after  acidification;  discs  were  washed  in  PBS  and  fixed  in  2.5% 
citrate-acetate buffer for 30 seconds and washed in distilled water.  
2.2.12.1 Assessment of osteoclast activity by resorption 
Cells on dentine discs were removed using ProteoJet lysis solution (Fermentas). Discs 
were washed in distilled water and incubated in 1% toluidine blue for 30 seconds and 
washed in distilled water to remove residual dye. Areas of bone resorption were counted 
using a Nikon Eclipse 400 microscope. 
2.2.12.2 Identification of osteoclast-like cells by TRAP staining 
Cells  cultured  on  glass  coverslips  were  terminated  as  above  and  stained  for  tartrate 
resistant acid phosphatase (TRAP) using the leukocyte acid phosphatase detection kit 
from Sigma-Aldrich according to the manufacturer’s instructions. 
2.2.13   Bone marrow cultures 
Culled mice were sterilised with 70% ethanol. Bone marrow was harvested by removing 
the tissue from the long bones of the limbs and flushing with PBS using a  25 gauge 
needle. Marrow was collected in a 15ml Falcon tube and pelleted by centrifugation at 
1,500g  for  5  minutes  at  room  temperature.  Lineage  negative  cells  (representing  the 
murine haematopoietic stem cell component) were isolated using the MACS Lineage Cell 
Depletion Kit (Miltenyi Biotec) according to the manufacturer’s instructions. Isolated cells 
were seeded at a density of 10
6 cells/ml and transduced with lentivirus overnight. The 
following day cells were seeded in MethoCult medium (M3434, StemCell Technologies) 
for colony forming cell assays according to the manufacturer’s protocol. 83 
 
2.2.14   Assays 
2.2.14.1 Glucocerebrosidase 
Two assays were used to establish glucocerebrosidase activity levels. Both used non-
fluorescent substrates but followed different protocols. 
2.2.14.1.1 FDGlu assay 
Cells were diluted to 10
5-10
6 cells/ml and 100μl added to each of two FACS tubes. 10μl 
10mM conduritol-β-epoxide (CBE) was added to one tube and 10μl DMEM to the other. 
Cells  were  incubated  at  room  temperature  for  1  hour.  100μl  2mM  fluorescein-β-D-
glucopyranoside (FDGlu) was added to each tube and mixed gently then incubated at 
37°C for 1 minute. 790μl DMEM was added to both tubes and incubated in the dark at 
room temperature for 45 minutes. Cells were centrifuged at 1,500g for 5 minutes and 
resuspended in PBS twice. Cells were analysed using flow cytometry using the CyAn ADP 
cell analyser with fluorescence read at excitation 490 nm, emission 515 nm. 
2.2.14.1.2 4MUG 
Cell pellets were resuspended in 10μls distilled water and lysed by ultrasonication for 10 
seconds  at  amplitude  6  using  an  MSE  100W  sonicator.  Supernatant  samples  were 
centrifuged at 16,000 x g to pellet cell debris and transferred to new tubes. Samples were 
diluted to a protein concentration of 1mg/ml in distilled water. 10μg protein sample was 
added  to  25μl  MV  5.4  with  22.35mM  sodium  taurocholate  and  5mM  4-
methylumbelliferyl-β-D-glucopyranoside  was  added  to  each  tube  and  mixed.  Samples 
were incubated at 37°C for 1 hour then 1100μl stopping solution (0.25M glycine buffer 
pH 10.4) was added to terminate the reaction. Fluorescence was read at excitation 365 
nm,  emission  450  nm  using  the  Perkin  Elmer  LS  55  fluorometer  (Perkin  Elmer, 84 
 
Massachusetts,  USA).  1nmol  4-methylumbelliferone  was  used  as  a  standard.  Enzyme 
activity was calculated as nmol/hr/mg protein. 
2.2.14.2 Chitotriosidase  
Supernatants were harvested and centrifuged for 5 minutes at 16,000 x g to pellet cell 
debris. On ice 5μl supernatant was added to 21μM 4-methylumbelliferyl-β-D-N,N’,N’’-
triacetylchitotriose and mixed. Tubes were incubated for 60 minutes at  37°C then at 
timed intervals 1000μl of 0.25M glycine buffer (pH 10.4) was added to each tube to 
terminate the  reaction.  Fluorescence was  read  at  excitation  365nm,  emission  450nm 
using the Perkin Elmer LS 55 fluorometer. 16μM 4-methylumbelliferone was used as a 
standard. Activity was calculated as nmol/hr/ml supernatant. 
2.2.15   Western blotting 
2.2.15.1 Preparation of cell lysates 
10
6  cells  were  pelleted  by  centrifugation  and  resuspended  in  200μl  lysis  buffer  and 
incubated on ice for 5 minutes. Debris was pelleted by centrifugation at 16,000g for 15 
minutes at 4°C. 200μl Laemmli buffer was added to the supernatant and samples were 
heated to 85°C for 5 minutes. After this samples were kept at 4°C or stored at -20°C. 
2.2.15.2 Gel electrophoresis 
30μl sample was run on a NuPage gel in 1X MES SDS buffer at 150V for 1 hour alongside 
10μl SeeBlue Plus 2 prestained protein standard.  
2.2.15.3 Membrane transfer 
Protein bands were transferred to a PVDF membrane using 2X transfer buffer at 18V in a 
BioRad semi-dry transfer machine. After transfer membranes were blocked in 4% milk to 
minimise non-specific staining on the roller for 1 hour at room temperature. 85 
 
2.2.15.4 Staining and visualisation 
Primary  antibodies  were  added  at  a  dilution  of  1:250  or  1:500  in  3ml  4%  milk  and 
incubated overnight with rolling at room temperature. Antibody mixture was removed 
and blot washed with 3x3ml PBS with 0.0.5% Tween-20 (PBST) for 5 minutes. Secondary 
antibodies were added at a dilution of 1:1000 in 3ml 4% milk and incubated for 45-60 
minutes with rolling. Antibody mixture was removed and blot washed with 3x3ml PBST 
for 5 minutes before blots were developed with ECL. ECL reagents were mixed in a 1:1 
ratio  to  a  volume  of  1ml.  Mixture  was  applied  to  the  blot  and  incubated  at  room 
temperature for 5 minutes after which time excess ECL mixture was removed. Bands 
were then visualised using the UVIchemi chemiluminescence detection system (UVItec, 
Cambridge, UK).  
Where necessary, visualised blots were stripped of antibodies by incubation with two 
applications of 5ml stripping buffer, incubated for 10 minutes at room temperature with 
shaking,  followed  by  three  washes  in  3ml  PBST  for  10  minutes  to  remove  residual 
stripping buffer. Blocking and visualisation of alternative protein bands could then be 
performed as described above. 
2.2.16   Immunocytochemistry 
Cells were seeded on 13mm coverslips 4 hours before staining. Cells were washed in PBS 
and fixed in 4% paraformaldehyde for 20 minutes at room temperature, permeabilised in 
0.1-0.5% Triton and blocked in 2% rat serum. Primary antibodies were diluted in PBS with 
0.2% BSA and incubated with cells for 1 hour. Secondary antibodies and cell markers 
were also diluted in PBS with 0.2% BSA and were incubated with cells for 45 minutes to 
an hour in the dark. Coverslips were mounted using ProLong Gold and stored in the dark 
before imaging. Between each step coverslips were washed twice in PBS with 0.2% BSA. 86 
 
Confocal images were taken using a Zeiss LSM 710inverted confocal microscope (Leica, 
Milton Keynes, UK). 
2.2.17   Software 
Microscopy and electrophoresis gel images were processed with ImageJ (NIH, Bethesda, 
Maryland).  Statistical  testing  was  performed  using  GraphPad  Prism  5  (San  Diego, 
California).    87 
 
3  Vector production and characterisation 
3.1  Aims 
  To produce and characterise a lentiviral vector carrying the glucocerebrosidase 
gene 
  To show the vector produces full length, active glucocerebrosidase protein 
  To correct enzyme deficiency of patient derived cells using this vector 
  To investigate the biomarker chitotriosidase as a read out of correction efficiency 
of fibroblasts in vitro 
3.2  Introduction 
Gaucher  disease  (GD)  arises  from  mutations  in  the  glucocerebrosidase  (GBA)  gene 
leading  to  a  deficiency  in  the  enzyme  glucocerebrosidase  (GC)  (3).  The  majority  of 
affected cells are part of the haematopoietic system (primarily the macrophage) and it 
has  been  shown  that  allogeneic  haematopoietic  stem  cell  transplant  (HSCT)  from  a 
healthy donor can be curative (71, 98-101). However due to a shortage of suitable donors 
and the high risk of mortality associated with HSCT from an unrelated donor, it is not 
performed routinely for the treatment of GD (98, 102). 
Regardless of its current usage, the curative effect of HSCT indicates that correction of 
the haematopoietic system is sufficient to alleviate disease; a hypothesis which is further 
supported by the response of patients to the current, macrophage targeted,  enzyme 
replacement therapy (ERT) (109, 123, 124). It is this evidence that has given rise to the 
hypothesis that ex vivo gene therapy of HSCs could be used to treat, and potentially cure, 
type I GD. 88 
 
Gene therapy could be preferable to HSCT as it can use autologous stem cells which 
reduces the risk of graft versus host disease and other complications of unrelated donor 
HSCT (381). In addition, correcting stem cells at the genetic level potentially allows for a 
permanent curative effect as enzyme will be produced throughout the lifetime of the 
cells, dramatically reducing the dependence of patients on ERT as shown in the ADA-SCID 
clinical trial (226-228). 
Before  the  advent  of  ERT,  a  number  of  groups  were  investigating  the  possibility  of 
developing gene therapy for GD but the licensing of Ceredase® in 1991 (109) caused 
researchers to suspend this work. However, given the limited impact of ERT on skeletal 
symptoms (50, 153, 157) and the risk of symptom recurrence if supply is interrupted 
(146, 147) we believe that the time to reconsider gene therapy has come and so this 
project aims to produce and test lentiviral vectors which have the potential for use in 
treating GD. 
The following chapter will describe the design of the GBA vector produced in this project; 
it will also detail the efforts made to characterise the protein produced from integrated 
vector, and the ability of the virus to correct patient material.   89 
 
3.3  Results 
3.3.1  Patient interest in gene therapy for type I Gaucher disease 
Gene therapy for GD was first investigated in the late 20
th century but efforts to develop 
it were abandoned for several reasons. Firstly, serious adverse reactions were reported in 
a number of participants in gene therapy trials for immunodeficiencies which cast doubt 
on the suitability of the procedure and the vectors in use (234-236). At the same time, no 
response was found in a human trial of gene therapy for GD (373). These results coupled 
with the approval of the enzyme replacement therapy manufactured by Genzyme (109, 
124,  156)  contributed  to  the  discontinuation  of  the  majority  of  gene  therapy 
investigations. 
This has produced a lasting belief amongst clinicians that gene therapy is of no interest to 
the Gaucher community. To address this concern, a small survey of type I patients and 
their families was conducted with the assistance of the Gauchers Association to gauge 
the levels of patient interest. A factsheet (Appendix 7.3) explaining the rationale behind 
gene therapy and the procedure involved was provided to participants with a follow-up 
questionnaire to assess their response (Appendix 7.4). 
The results showed that 80% respondents would consider gene therapy as a viable option 
for GD and 50% might prefer a fully licenced gene therapy treatment to ERT (Figure 3.1B). 
Of those who answered not sure (20%) or no (30%) to question 6, the main comments 
were  concern  about  the  possible  side  effects  (especially  those  connected  with  the 
conditioning regimen) and patients with mild/stable disease expressing that they would 
be happier to continue with ERT (Appendix 7.5).    90 
 
 
Figure 3.1 Patient response to gene therapy for GD questionnaire 
A small group of type I GD patients were given a factsheet describing how gene therapy 
could  be  used to treat  GD  and  were  then asked  for  their  response  to  the  proposal. 
Answers to two of the questions are shown here and show that 50% of these patients 
would  welcome  gene  therapy  as  an  option  for  GD  with  another  20%  remaining 
undecided. Patients were able to select more than one response for each question.   
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3.3.2  Vector production 
The first aim of this project was to create a lentiviral vector carrying the GBA gene which 
could be used for gene therapy. 
The  lentiviral  backbone  consists  of  a  minimal  viral  genome  containing  the  central 
polypurine tract (cPPT), a packaging signal (Ψ) and the woodchuck post-transcriptional 
regulatory element (WPRE) flanked by long terminal repeats (LTR) of which the 3’ LTR is 
self-inactivating.  In  addition  to  these  elements,  the  backbone  used  in  this  project 
contains the spleen focus-forming virus promoter to drive expression of the transgene 
cassette.  
Previous  unpublished  work  by  Dr  Ahad  Rahim  (UCL  Institute  for  Women’s  Health) 
inserted the genes encoding glucocerebrosidase (GC) and enhanced green fluorescent 
protein (eGFP) separated by an internal ribosomal entry site (IRES) into the lentiviral 
backbone (Figure 3.2A). The IRES element allows two genes to be transcribed from the 
same mRNA independently of each other so that the result is not a fusion protein (382). 
Concurrent production of a marker protein such as eGFP is often used in order to confirm 
transduction of cells and that introduced DNA is being expressed. However there have 
been  recent  studies  which  suggest  that  eGFP  is  incorrectly  polyubiquitinated  and 
therefore may not be efficiently degraded by the cell. It has been suggested that the 
protein accumulates in the lysosome where it may interfere with enzymatic function 
(383). As GC is a lysosomal protein it was decided to remove the eGFP gene from the 
plasmid, kindly donated by Dr Rahim, to produce a lentiviral vector containing only the 
GBA  gene  (Figure  3.2B).  Additionally,  the  ultimate  goal  of  this  work  is  to  produce  a 
product which can be translated to the clinic and must therefore be free of any non-
human sequences, including eGFP. 92 
 
Removal of the eGFP sequence was achieved by simultaneously digesting the existing 
vector with the restriction enzymes XhoI and MluI to excise the IRES-eGFP fragment. The 
ends of the two resulting fragments were filled in using DNA polymerase I large fragment 
(Klenow)  and  the  larger  of  the  two  sequences,  which  corresponded  to  the  lentiviral 
backbone containing the SFFV promoter, GBA gene and WPRE sequence, was purified by 
agarose  gel  electrophoresis  and  religated  using  T4  DNA  ligase.  This  plasmid  was 
transformed  into  XL  Gold  chemically  competent  cells  and  grown  on  LB-agar  plates 
containing  ampicillin  in  order  to  identify  correct  clones.  Removal  of  the  IRES-eGFP 
sequence was confirmed by digestion with the restriction enzyme HindIII (Figure 3.2C) 
and by sequencing (Appendix 7.2).   93 
 
 
 
Figure 3.2 Removal of IRES-eGFP to give the pHR-GBA plasmid 
A) LNT-GBA-eGFP plasmid produced by Dr Ahad Rahim and donated for use in this study. 
Vertical  lines  show  recognition  sites  for  restriction  endonucleases.  B)  LNT  plasmid 
carrying only the GBA gene produced by digestion and relegation of the plasmid in A). 
LTR:  long  terminal  repeat,  Ψ:  packaging  signal,  cPPT:  central  polypurine  tract,  SFFV: 
spleen  focus  forming  virus  LTR/promoter,  GBA:  glucocerebrosidase,  IRES:  internal-
ribosomal  entry  site,  eGFP:  enhanced  green  fluorescent  protein,  WPRE:  woodchuck 
C) 94 
 
hepatitis  post-transcriptional  regulatory  element  ΔLTR:  self-inactivating  LTR.  C) 
electrophoresis gels showing the excision of the IRES-eGFP fragment (1342bp) from the 
pHR-GBA-IRES-eGFP plasmid. Subsequent blunting and ligation of the purified fragment 
(16871bp) gave the pHR-GBA plasmid. Excision of the IRES-eGFP fragment was confirmed 
by digestion with HindIII and sequencing.    95 
 
3.3.3  Glucocerebrosidase activity can be determined with 
fluorometric assays 
A common method of detecting enzyme activity is to use a substrate which emits a 
fluorescent signal after enzymatic cleavage. There are multiple substrates available for 
the detection of GC activity and two of them were tested in this project – fluorescein-β-
D-glucopyranoside (FDGlu) and 4-methylumbelliferryl-β-D-glucopyranoside (4MUG). The 
structures of both of these substrates are shown in Figure 3.3A, along with the sites of 
cleavage by GC (dashed lines). The protocol for both of these assays has been described 
elsewhere with the chief difference being that the FDGlu assay is performed on live cells 
and measured by flow cytometry (384) whereas the 4MUG assay uses cell lysates with 
fluorescence detected by spectrophotometry (385, 386). 
As readout is measured by flow cytometry, the FDGlu assay gives results as a percentage 
of cells expressing the enzyme but is unable to give information on the levels of actual 
enzyme  activity  within  cells.  This  makes  a  useful  tool  for  detecting  successful 
transduction of target cells but more information is required to determine the extent of 
enzyme activity and whether phenotypic correction has occurred. It is also worth noting 
that the FDGlu assay gives highly variable results as shown in Figure 3.3B where the assay 
was run on a single population of HEK293T cells at different time points.  
By  contrast  the  4MUG  assay  is  performed  on  lysed  cells  giving  readout  in  terms  of 
enzyme activity which is more informative as it allows for the detection of true molecular 
correction. The assay is also sensitive enough to distinguish the different activity levels in 
wild  type,  heterozygote  and  GBA  knockout  mice  (Figure  3.3C),  something  which  is 
otherwise only possible by sequencing. Because of the greater applicability of the 4MUG 
assay and the fact that its readout allows for a direct measurement of correction, it was 
decided  that  further  experiments  would  be  analysed  using  the  4MUG  assay  only. 96 
 
 
Figure 3.3 Fluorescence assays for the detection of glucocerebrosidase activity 
A)  Substrates  used  in  the  detection  of  GC  activity,  both  are  non-fluorescent  before 
cleavage by the GC enzyme. B) HEK293T cells assayed with the substrate FDGlu. Large 
error bars showing standard deviation indicate the high variability of results from this 
assay; each point indicates a replicate from the same population. C) Macerated livers of 
2-week old mice from the GBA
-/- colony were assayed using 4MUG and it was possible to 
determine phenotypic status (confirmed by genotyping performed by Dr Ahad Rahim). 
Each point represents an individual mouse.    
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3.3.4  Vector constructs produce functional glucocerebrosidase 
protein 
The vector produced here contains the full length GBA sequence with no mutations or 
frame-shifts as was confirmed by sequencing (Appendix 7.2).  
To test the functionality of the encoded protein, lentivirus made from the construct was 
used to transduce HEK293T cells at increasing multiplicity of infection (MOI). After a week 
in culture, cells were harvested and enzymatic assays and western blots were performed 
to check for an increase in the levels and activity of GC protein relative to untransduced 
cells.  
Below an MOI of 50 there was very minimal increase of protein expression or activity but 
at higher MOI, a significant increase in protein expression and enzyme activity was found 
(Figure 3.4). The western blot shown in Figure 3.4A shows that protein levels appear to 
double when MOI is increased from ten to 100, this is a smaller increase than might be 
expected with such a large increase of MOI and is also reflected in the modest increase of 
protein activity between the two viral concentrations (Figure 3.4B). Although the GAPDH 
band  for  MOI  10  sample  appears  to  be  smaller  than  that  for  the  other  two 
concentrations, it is likely that this is due to incomplete visualisation of the band rather 
than an error in sample loading. The limited increase in protein expression and activity 
between  MOI  10  and  100  could  be  due  to  high  levels  of  transduction  resulting  in 
significant  overexpression  of  the  protein  leading  to  secretion.  It  is  known  that  GBA 
contains a secretion signal and it is our hypothesis that accumulated protein would be 
secreted  using  this  endogenous  sequence.  This  hypothesis  will  be  addressed  in  the 
following chapter but would account for the small increase in intracellular GC between 
the two conditions especially as HEK293T cells are known to express sufficient GBA as is 
indicated by the GC activity levels in the MOI 0 condition. 98 
 
With the higher virus concentrations in the western blot shown in Figure 3.4A it appears 
that there are multiple bands being detected with the GC antibody (upper panel). This 
was unexpected as GC western blots should give only one band at a molecular weight of 
60kDa  however  it  was  also  found  on  other  western  blots  presented  in  this  thesis 
including a western blot performed on the velaglucerase alfa ERT preparation (Figure 4.6) 
and is most notable where there are high concentrations of GC. One possible explanation 
for  this  phenomenon  is  that  the  bands  of  lower  molecular  weight  correspond  to 
glycosylation variants of the enzyme, something which could be established using mass 
spectrometry. As part of this project we attempted to look at the glycosylation state of 
the enzyme produced by mass spectrometry but unfortunately the protein produced was 
not pure enough for the investigation to succeed and so no data is shown.   99 
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Figure 3.4 Glucocerebrosidase expression and activity in HEK293T cells 
HEK293T cells were transduced with increasing levels of GBA vector and harvested after 7 
days to assess levels of GC expression and activity. A) Western blot showing increase of 
GC protein in transduced cells. Lower bands correspond to GAPDH which is used as an 
internal control for protein loading. B) FDGlu assay showing that transduction of HEK293T 
cells results in increased GC activity within the live cells although significance was only 
achieved when an MOI of 100 was used. n=3, significance tested using one-way ANOVA 
with Dunnett’s post-hoc test. Error bars show standard deviation.    
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3.3.5  Enzyme activity levels peak at day 3 post transduction 
A time course experiment was run over 14 days  to investigate the effect of time on 
enzyme expression post-transduction. This data is important for optimisation of protocols 
as it will inform the choice of time points for subsequent experiments.  
HEK293T cells were transduced with virus carrying the GBA gene at an MOI of 50 and 
samples were harvested daily for 14 days. Cell viability was assessed at each time point to 
ensure that there was no toxicity of vector or protein. At the end of the time course cell 
pellets were lysed and investigated using a combination of western blotting to look for 
protein of the correct size and enzymatic assay to assess enzyme activity levels.  
After transduction, viability levels fell slightly as is expected when cells have to cope with 
a viral infection. Upon infection host cell machinery is used to transcribe and translate 
the viral genome which places a pressure on the cell which can lead to cell death and is 
one reason that levels of viral transduction have to be carefully controlled to prevent high 
levels of cell mortality. The drop in viability was not significant when compared to cells 
transduced with a control (eGFP) vector showing that the transgene in the experimental 
vector is no more toxic to transduced cells than the control protein. Viability levels had 
recovered by day 14 and remained above 80% throughout the experiment showing that 
the effect on cell survival is only transient (Figure 3.5A).  
On the second day post-transduction, enzyme activity levels exceeded the level deemed 
healthy for human fibroblasts which was an increase of 10-fold relative to levels on day 
zero. At their peak (day three) enzyme activity levels were 15 times greater than pre-
transduction. Activity levels fell slightly post-day three which is most likely due to the 
clearance  of  non-integrated  viral  genomes  and  RNA  which  had  not  been  reverse 
transcribed, but stabilised at a level within the unaffected range (Derek Burke, personal 
communication)  and  approximately  13  times  greater  than  that  of  untransduced  cells 101 
 
(Figure 3.5B). In order to confirm that the reduction in enzyme activity seen post-day 3 is 
due to clearance of unintegrated genomes, it would be necessary to perform a qPCR 
investigation to assess the number of genomes in the cell populations.    102 
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Figure 3.5 Glucocerebrosidase expression and viability over time in transduced 
cells.  
HEK293T cells were transduced with lentivirus carrying either eGFP or GBA at an MOI of 
50 and viability was assessed every day over a 14 day period for viability and GC activity. 
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A)  Viability  was  assessed using  trypan  blue  exclusion  dye.  No  significant  change  was 
found at any day in either condition and viability remained above 60% throughout. B) 
Levels of GC activity after transduction. Dashed lines indicate the unaffected range for 
fibroblasts. C) A representative western blot showing increase of protein between days 
one and four with a slight fall thereafter. All error bars show standard deviation.    104 
 
3.3.6  Integrated vector can restore enzyme activity in patient 
fibroblasts 
Fibroblasts derived from a type I patient who was a compound heterozygote with the 
genotype N370S/84GG and was reported to have 6% normal GC activity were purchased 
from the Coriell Institute (New Jersey, USA) to test the vector. Although fibroblasts are 
not  of  haematopoietic  lineage  and  are  not  the  primary  disease  cell  in  GD,  this  cell 
population was used as the only commercially available patient cell types are fibroblasts 
and B-lymphocytes. Of the two, fibroblasts express a higher level of GC and so are better 
suited to this project.  
The fibroblasts were transduced at an MOI of 50 to confirm that the vector delivered 
gene is capable of correcting the inherent metabolic defect which causes GD. One month 
post-transduction a western blot was performed on fibroblasts and the 4MUG assay was 
run to check for restoration of protein expression and activity respectively (Figure 3.6). 
The time period between transduction and harvesting cells for the assays was longer than 
would  be  expected  with  other  cell  lines  because  these  fibroblasts  were  very  slow 
growing.  Enzyme  activity  was  significantly  increased  to  a  value  which  exceeds  the 
unaffected range and which is 25 times greater than the baseline, untransduced activity 
levels. No increase in enzyme activity was seen when the same cells were transduced 
with  a  control  vector  expressing  a  fluorescent  protein  in  place  of  the  GBA  gene 
confirming that the increase in enzyme levels is a specific effect of the GBA vector and 
that viral transduction does not have an inherent effect on enzyme activity levels.    105 
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Figure 3.6 Expression and activity of glucocerebrosidase is restored in patient 
fibroblasts after transduction with LNT-GBA  
Fibroblasts derived from a type I GD patient were transduced with a lentiviral vector 
carrying either the GBA or eGFP gene and grown for one month to give enough cells to 
assay. A) Western blot on transduced cells showed increase in the amount of expressed 
GC protein. B) Enzyme activity assay on the same cells reveals restoration of healthy 
levels of GC activity (dashed lines) when transduced with the GBA vector but not with 
eGFP vectors. Error bars show standard deviation, n=7, significance was tested with one-
way ANOVA with Dunnett’s post-hoc test.    
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3.3.7  Chitotriosidase activity cannot be measured in fibroblasts in 
vitro 
Chitotriosidase (ChT) is an immune protein which is secreted into plasma and is elevated 
in both treated and untreated GD patients. It is an important biomarker for GD as ChT 
levels fall in response to treatment (179).  
Personal  communication  from  Dr  Filippo  Vairo  (Hospital  de  Clínicas  de  Porto  Alegre, 
Brazil) suggested that, although fibroblasts do not produce significant amounts of ChT, it 
is possible to observe changes in expression levels in vitro which could be a useful marker 
of correction in the patient-derived fibroblasts used in this study. 
Like  GC,  ChT  can  be  measured  using  a  non-fluorescent  substrate  which  emits  a 
fluorescent signal after cleavage by the enzyme. Because this assay is performed on the 
supernatant of cultured cells, it was first necessary to assess the culture medium for 
background fluorescence levels. The results, shown in Figure 3.7A, reveal that there is no 
significant  difference  in  fluorescence  levels  when  the  fluorescent  standard  4-
methylumbelliferone is diluted in water compared to the DMEM culture medium. This 
indicates that the medium neither autofluoresceces nor quenches the signal from the 
fluorescent product and so would not interfere with the study measurements. 
GD and unaffected fibroblasts were cultured in DMEM and samples were removed from 
the medium after 6 days to test for ChT activity (Figure 3.7B). The results showed that 
there was no significant difference in the enzyme activity levels after transduction with 
the GBA vector suggesting that ChT is unaffected in fibroblasts and therefore cannot be 
used as a surrogate measurement of correction in this work.  
This  result  was  not  entirely  unexpected  as  the  majority  of  ChT  is  expressed  from 
macrophages and other cells of the immune system whereas fibroblasts have no immune 107 
 
function. Although it appears that there may be a slight reduction in ChT in the patient 
condition compared to the unaffected cells, the difference is very slight compared to that 
seen in plasma where ChT levels of untreated patients are on average 600 times greater 
than those of unaffected individuals.    108 
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Figure 3.7 Chitotriosidase cannot be measured in cultured fibroblasts.  
A)  Diluting  4-methylumbelliferone  standard  in  DMEM  does  not  quench  or  increase 
fluorescence levels compared to diluting in water. B) Chitotriosidase activity measured in 
the  supernatant  of  control  and  Gaucher  fibroblast  cultures  reveals  no  significant 
difference  between  conditions.  Error  bars  show  large  standard  deviation  due  to 
variability of the assay but an unpaired t-test gave a p value of greater than 0.5 indicating 
no significant difference.    
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3.4  Summary 
In this chapter a lentiviral construct has been produced which contains a wild type copy 
of  the  glucocerebrosidase  gene  free  from  any  reporter  sequences.  Testing  of  this 
construct in HEK293T cells revealed that transduction with virus bearing this construct 
results in expression of protein of the correct molecular weight with enzymatic activity. 
Applying the virus to patient-derived fibroblasts corrects the enzymatic defect seen in 
these cells and restores enzyme activity levels to within the healthy range.  
A time course experiment to look at the changes in enzyme activity post-transduction 
showed that the levels of activity peak at around day three 3 and then fall slightly over 
the next four days but become stable at a level ten times greater than baseline. This is 
the expected pattern as when it is first introduced into the host cell the viral RNA genome 
will be expressed almost immediately producing a spike in protein levels. Not all copies of 
the viral genome will integrate and any copies which do not will be cleared from the cell 
and will not contribute to long term enzyme activity levels therefore, protein produced 
after the first few days is the result of integrated gene expression.  
One  of  the  problems  encountered  in  this  chapter  was  the  method  of  measuring  GC 
activity. The original assay used (FDGlu) was measured by flow cytometry and so was 
unable to give a quantifiable measurement of intracellular enzyme activity although it 
could indicate levels of transduction. It also gave incredibly variable results even when 
the same cell population was being assayed (Figure 3.3B). It was therefore decided to 
change to a different assay (4MUG) which was more reliable and gave readout in terms 
of exact enzyme activity. Both assays use similar substrates which release fluorescence 
when  cleaved  by  GC  but  the  method  of  fluorescence  detection  is  different  and 
performing the 4MUG assay on cell lysates makes it more useful to this work than the 
whole cell measurements generated by the FDGlu assay.  110 
 
In an attempt to develop another measure of cell correction, the use of the biomarker 
chitotriosidase  (ChT)  was  assessed  as  it  was  not  possible  to  use  substrate  storage 
reduction as a readout of cellular correction. This is because macrophages are the only 
cells to display accumulation of substrate and this work was performed using fibroblasts. 
ChT  was  chosen  because  it  is  well  established  as  a  biomarker  for  the  monitoring  of 
Gaucher disease in patients (151, 179) and personal communication from a GD specialist 
suggested  that  it  is  possible  to  measure  ChT  in  fibroblast  cultures.  However  this 
investigation showed that this is not the case as there was no significant difference in ChT 
levels between Gaucher disease and non-GD fibroblast populations and therefore it was 
only possible to use enzyme activity levels to indicate correction.    111 
 
4  Secreted glucocerebrosidase for the cross-correction of 
untransduced cells  
4.1  Aims 
  To add wild type and modified HIV-1 TAT protein transduction domains (PTD) to 
the GBA cDNA 
  To show that GBA is secreted from transduced cells 
  To compare uptake of GBA by untransduced cells using wild type and modified 
HIV-1 TAT protein transduction domains 
4.2  Introduction 
Although the primary cells to show a defect in GD are of the haematopoietic lineage, GBA 
is in fact a housekeeping gene and is expressed by almost all cell types at varying levels 
(378-380).  It  could  therefore  be  beneficial  to  patients  if  enzyme  expressed  from  the 
introduced gene could be used by non-haematopoietic cells within a tissue. This is of 
particular  relevance  in  the  bone  microenvironment  which  contains  osteoclasts,  of 
haematopoietic lineage as well as osteoblasts and osteocytes which are mesenchymal in 
origin (84). Targeting bone could be especially beneficial in treating GD as the skeletal 
aspects of the disease remain a significant burden, even to patients taking ERT (152, 153, 
156). However although it is known that the mannose receptor, used for uptake of GC by 
macrophages, is expressed during osteoclast development (387); it is not clear to what 
extent  the  receptor  is  capable  of  mediating  protein  uptake  in  situ  so  it  may  not  be 
possible to obtain this cross-correction through the mannose receptor.  
GC is an intracellular protein which is trafficked to the lysosome compartment by the 
receptor protein LIMP2 (23). Although it is not normally secreted, the GBA gene carries 112 
 
an endogenous secretion signal and the protein appears to be secreted by cells lacking 
LIMP2. It was therefore hypothesised that if the protein is expressed at supranormal 
levels due to viral vector transduction, the secretion signal could be used to prevent the 
accumulation of excess enzyme within cells. If this is the case then the secreted enzyme 
could serve as a natural reservoir of functional protein for other cells throughout the 
body. 
In correspondence with this hypothesis, it has previously been shown that GC is secreted 
from transduced cells and uptake of secreted protein can be mediated by endocytosis 
(388). However, this evidence is limited and the degree of uptake has been low.  
The enzyme preparation used for ERT has been engineered to have side chains which are 
mannose-terminated so that it will be taken up by the macrophage mannose receptor 
(MMR) and thereby directly target the macrophage. In order to achieve this targeting, the 
enzyme produced by Genzyme must be post-translationally modified to ensure that the 
terminal residues are recognised by the MMR (109). Other enzyme preparations have a 
high  proportion  of  mannose  terminated  side  chains  due  to  producer  cell  effects 
(taliglucerase  alfa)  (133)  or  culture  medium  additives  (velaglucerase  alfa)  (129,  130). 
However, mannose-termination is only of use when the macrophage is the target cell; 
when the aim is to get the enzyme into a wide range of cells a less specific strategy is 
required. 
One method used to achieve widespread delivery of therapeutic proteins is to fuse the 
protein to a generic protein transduction domain (PTD) which is capable of transducing 
protein  across  the  plasma  membrane  by  receptor-independent,  and  therefore  non-
specific,  means.  Fusion  of  GBA  to  a  PTD  could  produce  an  enzyme  variant  which,  if 
secreted, is able to enter other cells which may not have been directly corrected by the 
gene therapy. 113 
 
One of the best characterised PTDs is that of the HIV-1 transactivator of transcription 
(TAT) protein transduction domain. The PTD from the TAT protein has been shown to 
work by stimulating protein uptake by lipid raft-mediated endocytosis (346, 347) which is 
ideal for lysosomal proteins, such as GC as the protein is ultimately delivered to the 
lysosome (4, 13, 14).  
A previous study demonstrated that in an ERT setting, addition of the TAT PTD to the C-
terminus of GC results in a significant increase in the amount of protein taken up by 
fibroblasts in culture compared to imiglucerase and wild type GC but that fusion to the N-
terminus  of  the  protein  abolished  protein  expression  (315).  A  subsequent  study 
demonstrated the presence of two furin cleavage sites within the PTD which presents a 
possible explanation for the lack of expression from the N-terminal fusion (316). Furin is a 
ubiquitous endoprotease which recognises the sequence R-X-(K/R)-R and is responsible 
for the release of mature proteins from their precursor form. 
The  authors  who  identified  the  furin  cleavage  sites  within  the  TAT  PTD  produced  a 
modified version which lacked the furin recognition sites (mTAT). This version of the PTD 
was used in this study in addition to the WT version (WT TAT) to compare the effect of N- 
and C-terminal fusion. The sequences of the wild type and modified domains are shown 
in Figure 4.5A. The following chapter will document the work using the GC-PTD fusion 
products.    114 
 
4.3  Results 
4.3.1  Developing assay for secreted protein 
Neither of the GC assays used so far in this project are performed on supernatant but it 
was thought that the assay using the FDGlu substrate would be suitable for adaptation 
for  use  with  supernatant  samples  using  a  plate  reader  within  the  group  which  has 
suitable filters.  
There are two companies which produce the FDGlu substrate – Life Technologies (LT) and 
Marker Gene Technologies (MGT) – and substrate was purchased from both of them for 
testing. To begin with, levels of autofluorescence were measured when substrate was 
diluted in DMEM with or without foetal calf serum (FCS). FCS is added to culture medium 
because it contains a high concentration of growth factors and other components which 
aid in the propagation of cell lines. The substrate was tested in medium with and without 
FCS to ensure that there is no residual GC enzyme or other factor in the serum which may 
affect background fluorescence levels. Figure 4.1 shows that the substrate produced by 
MGT gave significantly higher levels of autofluorescence when added to medium and so it 
was decided to continue tests using the substrate from LT. 
To establish whether the high levels of autofluorescence seen with the LT substrate could 
be reduced, the assay was repeated using a range of media types, including PBS and 
water to resuspend the substrate. A GC inhibitor (conduritol-β-epoxide; CBE) was added 
to the media samples to control for any intrinsic enzyme activity within the media. These 
experiments revealed that the substrate produces a similar amount of autofluorescence 
in all media types with or without CBE (Figure 4.2).    115 
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Figure 4.1 Comparison of the levels of autofluorescence produced by different 
preparations of FDGlu substrate in medium 
To determine which of the two commercially available preparations of FDGlu substrate 
was  most  suitable  for  use  in  testing  for  GC  activity  in  transduced  cell  supernatant, 
substrate  produced  by  either  Life  Technologies  or  Marker  Gene  Technologies  was 
incubated for 45 minutes in DMEM with or without foetal calf serum and then assayed 
for fluorescence levels. No enzyme was added so any detected fluorescence is a result of 
substrate  autofluorescence.  The  substrate  from  Marker  Gene  Technologies  produced 
significantly higher levels of autofluorescence and so it was decided to proceed using the 
substrate  produced  by  Life  Technologies.  N=3,  error  bars  show  standard  deviation. 
Significance  was  tested  using  one-way  ANOVA  with  Bonferroni  post-hoc  test: 
***=p<0.0001.    116 
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Figure 4.2 Autofluorescence of fluorescein-β-D-glucopyranoside in media with 
and without conduritol-β-epoxide 
FDGlu substrate (LT) was incubated in a range of media types with or without the GC 
inhibitor CBE and fluorescence measured to determine the baseline signal from medium 
alone. No enzyme was added to the reactions so the detected fluorescence is caused by 
autofluorescence of the substrate as confirmed because levels of fluorescence do not 
decrease when the enzymatic inhibitor CBE is added. N=3, significance tested by one-way 
ANOVA with Dunnett’s post-hoc test, error bars show standard deviation ns = p>0.05.117 
 
Despite  high  levels  of  FDGlu  substrate  autofluorescence,  when  the  ERT  preparation 
velaglucerase alfa (Shire HGT) was diluted in water it was possible to detect enzyme 
levels of 10
-1 – 10
-2units/ml which is equivalent to protein concentrations of 2.5x10-3 – 
2.5x10-4mg/ml (Figure 4.3A). Comparatively, when the same enzyme dilutions were used 
in the 4MUG assay, detection limits extended from 10-2 – 10-5units/ml or 2.5x10-4 – 
2.5x10-6mg/ml which is a greater range and of more use in this project where it is likely 
that protein concentrations are going to be lower. For this reason it was decided that 
secreted protein levels would be assayed using the 4MUG assay only. 
Western blotting of the diluted velaglucerase alfa samples was much less sensitive than 
either  assay  and  could  barely  detect  enzyme  at  levels  below  0.625units/ml  (1.6x10-
2mg/ml) (Figure 4.3B).    118 
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Sample  [Protein] (µg)   Units  Relative density 
A  50.000  2.00E+00  1.000 
C  5.000  2.00E-01  0.345 
D  2.500  1.00E-01  0.148 
E  1.250  5.00E-02  0.052 
F  0.625  2.50E-02  0.017 
G  0.313  1.25E-02  0.003 
H  0.156  6.25E-03  0.005 
I  0.078  3.13E-03  0.001 
J  0.039  1.56E-03  Not detected 
 
Figure 4.3 Detection of velaglucerase alfa by enzymatic assay and western blot 
A) Velaglucerase alfa (VPRIV) was diluted in water and used to test the two fluorometric 
assays described previously. The 4MUG assay was found to be the more sensitive of the 
A  B  C  D  E  F  G  H  I  J 
62  GC 60kDa 
A) 
B) 
49 
kDa 119 
 
two as it was able to detect dilutions of 10
-5 units/ml whereas the FDGlu assay could only 
detect enzyme at a 100 times greater concentration. B) The sensitivity of the GC antibody 
used in this project was tested using dilutions of velaglucerase alfa and quantified using 
ImageJ software (table).    120 
 
4.3.2  Cloning vectors 
4.3.2.1  pHR-SFFV-GBA-mTAT and pHR-SFFV-mTAT-GBA 
Fusion of the HIV-1 TAT protein transduction domain (PTD) to GBA was achieved using a 
polymerase  chain  reaction  (PCR)  strategy  (Figure  4.4).  Primers  were  designed  which 
contained  part  of  the  PTD  and  part  of  the  GBA  sequence.  Overlapping  PCR  was 
performed using Pfu DNA polymerase to generate a full length GBA sequence with an in-
frame fusion of the modified TAT PTD on either the N- or C-terminus (Figure 4.5). The N-
terminal PTD sequence was placed after the endogenous GC secretion signal which is 
cleaved from the protein. 
The  full-length  fragment  was  purified  by  gel  electrophoresis.  The  fragment was  then 
subcloned into the TOPO-blunt vector to provide an easily amplified source of DNA for 
further cloning. The primers used contain restriction enzyme sites at either end of the 
gene so that it could be easily excised from the TOPO vector and cloned into the pHR 
lentiviral backbone. To perform this step the GBA fusion fragment was excised using the 
restriction enzymes EcoRV and XhoI. The plasmid backbone was digested with BamHI and 
blunted using DNA polymerase I Large Fragment (Klenow) to give a blunt end which is 
compatible  with  DNA  digested  by  EcoRV.  The  backbone  band  was  purified  from  the 
agarose  gel  following  electrophoresis  and  subsequently  digested  with  XhoI.  The  two 
fragments were then ligated using T4 DNA ligase and transformed into bacteria. The 
vectors produced are shown in Figure 4.5B. 
4.3.3  pHR-SFFV-GBA-WT TAT 
A  similar  strategy  to  the  one  detailed  above  was  employed  to  produce  a  construct 
carrying GBA fused to the wild type TAT PTD at the C-terminus (Figure  4.5B). An N-121 
 
terminal fusion of the WT TAT PTD to GBA was not produced because of the earlier work 
which showed that this fusion protein would not be expressed (315).    122 
 
 
Figure 4.4 Cloning strategies to generate fusion constructs 
A) N-terminal fusion of PTD to GBA. Two rounds of PCR are performed, the first using 
primers 1+2 or 3+4 and with the WT GBA cDNA as template produced two products, one 
which is the GBA leader sequence fused to a C-terminal PTD sequence and the second 
being  the  rest  of  the  GBA  gene  with  the  complementary  PTD  sequence  on  the  N-
terminus. Both products are purified and used as template in the second round of PCR 
which uses primers to the N- and C-terminus of GBA. The complementary PTD sequences 
A) 
B) 123 
 
present  on  the  round  one  products  anneal  during  synthesis  producing  a  complete 
template and allowing read through from primer 1 to 4. The resulting product of 1699bp 
in length is purified and cloned into pHR using EcoRV and XhoI restriction enzymes. B) 
Shows fusion of the TAT PTD sequence to the C-terminus of the GBA cDNA by a single 
round of PCR using a primer containing the full length PTD (primer 5). In both figures the 
blue line indicates the TAT sequence within the primer and the shaded bar corresponds 
to the TAT sequence within the PCR product.   124 
 
 
 
 
Figure 4.5 Schematic showing vectors produced 
Name  Amino acid sequence 
Wild type TAT (WT TAT)  YGRKKRRQRRR 
Modified TAT (mTAT)  YARKAARQARA 
 
A) 
B) 
1  2  3  4  5 
C) 125 
 
A) The sequences of the two versions of the TAT protein transduction domain used in this 
work.  mTAT  has  been  modified  to  remove  two  furin  cleavage  sites  (underlined).  B) 
Schematic of the produced pHR-GBA constructs. LTR: long terminal repeat; Ψ: packaging 
signal; cPPT: central polypurine tract; SFFV: spleen focus-forming virus promoter; WPRE: 
woodchuck hepatitis post-transcriptional regulatory element; ∆ LTR: self-inactivating LTR. 
C) Electrophoresis gel showing empty pHR backbone (1), pHR-GBA (2), pHR-mTAT-GBA 
(3), pHR-GBA-mTAT (4) and pHR-GBA-WT TAT (5) digested with the restriction enzyme 
HindIII. The lowest band in lanes 2-5 corresponds to 1.6kB which confirms the addition of 
the GBA gene. The electrophoresis gel used here was a 1% agarose gel meaning that the 
addition  of  the  TAT  domains  is  not  visible  and  therefore  had  to  be  confirmed  by 
sequencing. However had a higher percentage agarose gel been used, the addition of the 
PTD would have been detectable by electrophoresis. Sequencing would still have been 
required to ensure that the correct sequence had been added.   126 
 
4.3.4  The addition of the protein transduction domain does not 
affect expression or activity of GC 
Vectors were tested in GD-derived fibroblasts to ensure that the addition of the PTD does 
not have an adverse effect on protein expression or activity. Fibroblasts were transduced 
at an MOI of 50 and cultured for one month to provide enough material to perform 
western blots and GC assay in parallel. The results showed that cells transduced with the 
PTD  containing  vectors  yielded  a  protein  of  the  same  molecular  weight  as  the  WT 
construct (Figure 4.6A). Despite the addition of a transduction domain, an increase in 
protein size was not expected. This is because the PTD contains only 11 amino acids and 
an increase of this size is unlikely to be detectable by western blot.  
The  activity  of  the  protein  with  the  added  PTD  was  confirmed  when  transduced 
fibroblasts were harvested for use in the 4MUG assay. Transduction with all three of the 
vectors restored enzyme activity in the fibroblasts to within the range designated as 
healthy (Figure 4.6B). Transduction with a control vector expressing eGFP had no affect 
on enzyme activity levels confirming that the effect is vector specific. 
The western blot in Figure 4.6A seems to suggest that there is less GC protein being 
produced  from  the  mTAT-GBA  construct  compared  to  the  other  two  GC  plasmids. 
However this is most likely due to a loading error as the amount of GAPDH, an internal 
control protein is also reduced comapred to the other samples on the blot and this is 
supported by the data shown in Figure 4.6B which shows that cells transduced with all 
three GBA carrying vectors have equal levels of enzyme activity post-transduction.    127 
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Figure 4.6 Addition of the mTAT PTD does not affect GC expression or activity 
GD-derived fibroblasts were transduced with vectors carrying either GBA or eGFP and 
harvested one month post-transduction to assess GC expression and activity. A) Western 
blot of transduced cells shows production of a protein of similar molecular weight to WT 
GC from all constructs. B) 4MUG assay shows equal activity levels in WT and PTD fused 
forms of GC. Error bars show standard deviation, n=7 Significance was tested using one-
way  ANOVA  with  Dunnett’s  post-hoc  test.  The  dashed  lines  indicates  the  range 
designated as healthy levels of GC activity.   
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4.3.5  Transduced cells secrete GC protein via an endogenous 
secretion signal 
It is known that the GC protein contains an endogenous secretion signal however it is not 
commonly thought of as a secreted protein. It is likely that this is because GC is expressed 
at a relatively low level in all tissues and is therefore retained within the cell (378, 389). It 
was therefore hypothesised that cells which produce a very high level of GC as a result of 
transduction  by  GBA  carrying  lentivirus  would  secrete  excess  protein  into  the 
extracellular environment. 
After validation of the antibody used for western blots an experiment was performed to 
determine whether GC is secreted by transduced cells. HEK293T cells transduced at an 
MOI of 100 were seeded in a dish and after 72 hours the cell supernatant was harvested 
and western blots and 4MUG assays were performed (Figure 4.7). An MOI of 100 was 
used despite evidence above showing that an MOI of 50 is sufficient to produce healthy 
levels  of  GC  activity  because  it  was  though  that  GC  would  only  be  secreted  if  it  is 
expressed at supraphysiological levels. Figure 4.7 clearly shows that the GC protein is 
being secreted by transduced cells at high level with the highest level of secretion from 
cells  transduced  with  the  GBA-mTAT  vector  although  the  reason  for  this  is  unclear 
especially as intracellular protein levels are the same with all three constructs (Figure 
4.6). An expansion of this work would be to test lower levels of transduction and see at 
what point secretion can be observed. 
A time course run over 14 days on cells transduced with the WT GBA construct showed 
that enzymatic activity can be detected in supernatant from seven days post-transduction 
and continued to rise throughout the period of the study (Figure 4.8). Although GBA 
expression can be detected within the cell from day one post-transduction, it is likely that 
secretion cannot be detected from as early because the amount of protein within the cell 129 
 
has to accumulate to a point where secretion is required to reduce intracellular levels. 
This may also help to explain the decrease in intracellular protein levels post-day three as 
excess protein is removed.   130 
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Figure 4.7 Secretion of GC from transduced cells 
The supernatant of HEK293T cells 72 hours post-transduction was harvested and tested 
for the presence and activity of GC. A) Western blot showing GC can be detected in the 
supernatant of cells transduced with GBA vectors at high MOI. The lower panel shows 
BSA as a loading control. B) The 4MUG assay run on the same samples as in A, showing a 
significant  increase  in  the  enzymatic  activity  of  supernatant  from  transduced  cells 
compared to untransduced cell supernatant. Error bars show standard deviation, n=3. 
Significance tested with one-way ANOVA with Dunnett’s post-hoc test.    
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Figure 4.8 A 14-day time course showing GC activity within the supernatant of 
transduced cells revelas secretion of enzyme 
HEK293T cells were transduced with GBA virus at an MOI of 100 and cultured for 14 days 
with samples of supernatant harvested every day. A 4MUG assay run on the harvested 
samples  showed  that  secreted  protein  can  be  detected  from  around  day  6  post-
transduction  and  continues  to  accumulate  over  the  14  days  (n=3).  Error  bars  show 
standard deviation.   132 
 
4.3.6  Uptake of GC can be mediated by protein transduction 
domains 
Figure  4.9A  shows  the  experimental  protocol  followed  to  assess  cross-correction  of 
untransduced cells by secreted GC enzyme. HEK293T were transduced at MOI 100 and 
allowed to grow for 14 days so that they would be a point when enzyme secretion was at 
a high level. 10
5 cells were then seeded in a 12-well plate and left to adhere overnight. 
The next day a transwell insert with pore size 0.4μm was added to the top of the well 
which would allow the exchange of medium and low molecular weight proteins only 
between the two areas of the well. GD patient-derived LCLs were added to this insert 
after 2-4 hours and cultured without medium change for 72 hours. After this time period, 
cells were harvested, washed and assayed for enzyme uptake by western blot and 4MUG 
assay.  
Western blot was unable to detect GC enzyme, presumably because it was present only 
in small quantities but the assay detected a significant rise in enzyme activity within LCLs 
cultured with cells expressing the GBA-mTAT and GBA-WT TAT constructs (Figure 4.9B).    133 
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Figure 4.9 Cross-correction of GBA
-/- LCLs by protein secreted from transduced 
HEK293T cells 
A) Schematic showing the methodology involved in cross-correction experiments. B) Co-
culture with HEK293T cells transduced with  GBA-mTAT and GBA-WT TAT significantly 
increases the glucocerebrosidase activity in GD-derived LCLs. Other constructs do not 
have the same effect. Analysed with one-way ANOVA and Dunnett’s post-hoc test (n=3).    
A) 
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4.4  Summary 
In this chapter the work described in chapter 3 has been further developed by modifying 
the GBA cDNA to include a protein transduction domain derived from the HIV-1 TAT 
protein.  This  was  done  to  investigate  the  feasibility  of  using  transduced  cells  as  a 
reservoir  of  protein  which,  when  secreted,  could  be  taken  up  by  neighbouring, 
untransduced  cells  to  correct  the  metabolic  defect  throughout  the  body.  This  was 
investigated because GBA is a housekeeping gene and is expressed ubiquitously, albeit at 
low levels, and it could therefore be beneficial to correct multiple cell types. This is of 
particular  relevance  in  the  bone  microenvironment.  As  will  be  described  in  the  next 
chapter  it  is  thought  that  the  osteoclast,  a  cell  of  haematopoietic  origin,  is  a  major 
contributor to skeletal disease in GD but it is also possible that other cells such as the 
osteoblast  and  plasma  cell  may  also  be  implicated  in  the  development  of  skeletal 
complications (80, 89). As the osteoclast is haematopoietic in origin, it would be directly 
corrected by gene therapy; however, a reservoir of secreted GC could be of benefit to the 
other cells in the environment and thereby help alleviate symptoms. 
It has been shown here that fusion of the protein transduction domain is only successful 
in mediating uptake of GC when it is added to the C-terminus of the enzyme. Fusion of 
the PTD to the N-terminus does not mediate an increase in the enzymatic activity of co-
cultured cells. It is possible that this could be due to folding of the protein resulting in the 
PTD being internal to the protein and therefore not interacting with the untransduced 
cell  type.  However  this  requires  further  investigation  before  any  conclusions  can  be 
drawn.    135 
 
5  Investigating gene therapy as a potential treatment for 
the osteoclast 
5.1  Aims 
  To  show  that  gene  modified  haematopoietic  progenitor  cells  can  generate 
osteoclasts expressing an introduced gene. 
  To investigate the phenotype of osteoclasts derived from bone marrow cells from 
the GD type II mouse model. 
5.2  Introduction  
One of the most significant aspects of type I Gaucher disease (GD) in the post-ERT era is 
bone disease; 75-90% of patients still experience skeletal symptoms to some extent and 
in some people the condition can be severely debilitating (50, 77, 390). Although it has 
been shown that bone disease can respond to ERT, it can take several years to show any 
improvement (152, 153, 157) which is likely to be because the therapy is directed to 
target the macrophage rather than to treat the bone directly (109). A survey conducted 
as part of this project, and with the assistance of the Gauchers Association, supported 
this finding as 60% patients cited bone pain/skeletal symptoms as having a significant 
impact on their lives despite taking ERT (Figure 5.1). 
Another challenge to treating the skeletal aspect of type I GD is that the mechanism of 
the  disease  remains  unclear  although  recent  data  suggests  that  it  may  be  due  to 
increased differentiation and activity of the osteoclast (86). If this is the case then gene 
therapy  could  offer  a  method  of  preventing  bone  disease  and  potentially  directly 
correcting it. The osteoclast is a cell of hematopoietic origin (Figure 1.7) and so correction 
of HSCs by gene therapy would lead to the differentiation of GC positive osteoclasts in 136 
 
vivo. However very little work has been conducted to test the effect of gene therapy on 
osteoclasts and the differentiation of gene corrected HSCs to bone cells. 
One of the reasons that the molecular basis of skeletal pathology remains unclear is that 
over  the  years  there  has  been  a  shortage  of  animal  models  which  successfully 
recapitulate the symptoms of GD and none which mimic the skeletal problems seen in 
patients. A paper published in 2010 described a new mouse model which does show 
significant  osteonecrosis  and  osteopenia;  two  of  the  major  pathologies  found  in  GD. 
These  findings  were  attributed  to  defective  osteoblastogenesis  while  osteoclast 
differentiation appeared normal (89). It is therefore possible that this mouse model will 
not serve as an accurate representation of the cellular defect in human patients as there 
is emerging evidence for osteoclast involvement in the human disease (86). 
Recently  a  mouse  model  has  been  developed  by  Stefan  Karlsson  at  Lund  University, 
Sweden  which  is  a  conditional  knock-out  of  the  GBA  gene  and  displays  severe 
neuronopathic  GD  (184).  Although  this  mouse  is  not  a  perfect  model  for  the  work 
performed in this project, the strain was kindly made available to Simon Waddington 
(UCL Institute for Women’s Health) who has established a colony. Affected mice must be 
culled at the age of fourteen days as they develop continuous seizures and paralysis so 
they do not develop bone disease but, as cells do not produce GC, they could be a useful 
model for studying pathology in vitro.  137 
 
 
Figure 5.1 Surveyed type I patients find skeletal problems a significant aspect of 
living with Gaucher disease 
In a survey of a small group of type I GD patients, 60% reported bone pain and other 
skeletal symptoms as being the most difficult aspect of GD to cope with. Other reported 
difficulties include the frequency with which ERT must be administered and tiredness 
which  is  most  likely  associated  with  residual  anaemia.  No  respondents  reported 
neurological  symptoms  but  this  was  expected  as  type  I  disease  is  classically  ‘non-
neurological’.   138 
 
5.3  Results 
5.3.1  Comparison of osteoclast number in BL6 and CD1 mice  
Laboratory  mice  are  inbred  strains  which  have  been  engineered  to  have  certain 
characteristics. While many of these characteristics are well documented, the ability to 
produce  osteoclasts  is  not  usually  recorded.  Before  any  investigative  work  could  be 
performed it was necessary to assess the rates of osteoclastogenesis in the two mouse 
strains used in this study – BL6 and CD1. It is important to establish whether there is a 
difference in rate of osteoclast production for two reasons. Firstly, to know whether it 
would be feasible to compare work performed in different strains and second, because 
the disease may affect different strains to an unequal amount. The procedure used to 
differentiate osteoclasts from bone marrow is shown in Figure 5.2A, and the results from 
the two strains in Figure 5.2B. 
The results showed that the CD1 strain, which was used to breed the GBA
-/- mouse, is 
capable  of  producing  more  osteoclasts  in  vitro  although  this  result  is  not  entirely 
conclusive  as  only  one  mouse  was  used  in  each  condition.  However  a  high  rate  of 
osteoclastogenesis is beneficial to this study as it indicates that the CD1 background will 
be more sensitive to variation. This result indicates that it may be a suitable model for 
investigating differences in osteoclastogenesis between wild type and knock-out mice.   139 
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Figure 5.2 in vitro osteoclast differentiation differs in mice of different strains 
A) Bone marrow was harvested post-mortem from mice of the BL6 or CD1 strain and 
used to generate osteoclasts in vitro. After nine days the cultures were terminated and 
stained  for  tartrate  resistant  acid  phosphatase (TRAP)  activity  to  identify osteoclasts. 
Osteoclasts  were  defined  as  large,  TRAP  positive,  multinuclear  cells.  B)  Osteoclast 
numbers generated from bone marrow of two different mouse strains. One mouse was 
used in each condition and the error bars show the standard deviation of number of 
osteoclasts on culture discs (n=12). An unpaired t-test generated a p value of <0.001 
indicating a significant difference between strains.   
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5.3.2  Osteoclasts can be derived from transduced bone marrow  
There is limited evidence available that modified bone marrow can differentiate into 
osteoclasts when transplanted into a recipient and so it was necessary to confirm that 
genetic modification of HSCs did not impair their ability to generate osteoclasts. It is 
important to note that a cell can only be deemed a true osteoclast when it has been 
differentiated on a physiological substrate, such as animal bone. For this reason cells 
which have been differentiated on glass and identified by morphology are referred to in 
the text as ‘osteoclast-like cells’.   
Bone marrow was harvested from the long bones of mice that had been transplanted 
with HSCs transduced by a lentivirus carrying the gene for green fluorescent protein 
(eGFP).  Harvested  bone  marrow  was  differentiated  into  osteoclast-like  cells  in  vitro 
(Figure 5.3B) on glass coverslips and stained for nuclei and actin. An osteoclast-like cell 
was defined as a large, multinuclear cell with a defined actin ring.  
Differentiation  of  true  osteoclasts  from  the  harvested  marrow  was  confirmed  by 
performing the same protocol but culturing bone marrow on dentine discs to provide a 
substrate for resorption. Lysis of the cells after fixation revealed resorption pits made by 
active  osteoclasts  (Figure  5.3C)  suggesting  that  subjecting  bone  marrow  to  viral 
transduction does not limit the capacity for deriving functional osteoclasts. However, it 
was not possible to measure fluorescence of cells cultured on dentine so it is not possible 
to  conclude  that  the  resorption  pits  were  formed  by  osteoclasts  differentiated  from 
transduced cells, only that bone marrow which has been exposed to virus can retain its 
capacity to differentiate into osteoclasts.  
The bones which had been stripped of their marrow were macerated and the resulting 
cell suspension was plated on glass coverslips and stained for actin and nuclei to identify 
osteoclasts which had differentiated in vivo. Using this method it was possible to identify 141 
 
GFP positive osteoclasts from transplanted mice used which confirmed that transduced 
HSCs are able to differentiate into osteoclasts in vivo (Figure 5.4).   142 
 
             
Figure 5.3 Osteoclasts can be derived from a genetically modified, autologous 
bone marrow transplant 
A)  Schematic  showing  the  process  of  bone  marrow  modification,  transplant  and 
osteoclast  experiments.  This  procedure  up  to  and  including  culling  the  mice  was 
performed by Marlene Carmo and Maria Alonso-Ferrero (UCL Institute of Child Health). 
After culling the long bones were extracted and used for two experiments: (1) Bone 
marrow was harvested and differentiated into osteoclast or osteoclast-like cells in vitro 
C)  B) 
Flow cytometry for C51 
and GFP co-expression 
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and (2) the bones were macerated, plated on glass coverslips and stained to identify 
osteoclasts which had derived from transduced bone marrow in vitro (Figure 5.4). B) 
Confocal  image  of  an  osteoclast-like  cell  differentiated  in  vitro  from  harvested  bone 
marrow (1) on glass coverslips. The actin image shows the characteristic actin ring around 
the edge of the cell and DAPI staining reveals it to be multinucleated. The cell can be 
identified as having derived from transduced bone marrow as it is expressing eGFP C) 
Light  micrograph  of  dentine  disc  on  which  osteoclasts  were  cultured  showing  pits 
(arrows)  caused  by  the  bone  resorption  activity  of  functional  osteoclasts  (20x 
magnification).   144 
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Figure  5.4  in  vivo  osteoclasts  from  mice  transplanted  with  eGFP  transduced 
bone marrow. 
Bones of transplanted mice were removed, macerated (as shown in Figure 5.3A (1)) and 
the  cell  suspension  plated  on  glass  coverslips  to  identify  osteoclasts  which  had 
differentiated in vivo from transduced HSCs. Shown here are images of two cells stained 
for nuclei and actin.    
A) 
B) 145 
 
5.3.3  Osteoclast numbers in healthy vs GD mice 
It is known that Gaucher disease patients develop bone problems later in life (50) and 
there is some evidence to suggest that this may be due to osteoclast hyperactivity (86) 
which  may  result  in  increased  bone  resorption  accounting  for  the  osteonecrosis  and 
fractures common in patients.  
Data  published  recently  showed  increased  osteoclast  differentiation  and  activity  in 
peripheral  blood  mononuclear  cells  (PBMCs)  from  type  I  Gaucher  patients  in  vitro 
compared to healthy control (86) but this has been contradicted by in vitro data using 
bone marrow (BM) from a type I mouse (89). The development of mouse models may be 
of use in resolving this issue and the current study took advantage of a type II model 
(184) to investigate the osteoclast phenotype.  
BM from the knock-out mice was harvested when the mice were sacrificed at two weeks 
of age and was differentiated on glass coverslips to produce osteoclast-like cells in vitro. 
Differentiated  cells  were  treated  with  stains  for  the  nucleus  and  actin  to  identify 
osteoclasts (Figure 5.5A). True osteoclasts were also differentiated on dentine discs so 
that the activity of the cells could be assayed by comparing number of bone resorption 
pits produced by GD and control mice (Figure 5.5B). 
The results showed that while there is no difference in the potential for knock-out bone 
marrow  to  differentiate  into  osteoclast-like  cells,  the  GBA
-/-  osteoclasts  appear  to  be 
much more active. This can be seen as there is no significant difference in the number of 
osteoclast-like cells produced on glass coverslips between the conditions but there is a 
significantly higher number of resorption pits seen on the discs from knock-out cultures 
indicating  that  the  resorption  capacity  of  the  differentiated  GBA
-/-  osteoclasts  is 
significantly greater than their WT counterparts.    146 
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Figure 5.5 in vitro osteoclast generation in GBA
-/- mice and healthy controls 
Bone  marrow  was  harvested  from  GBA
-/-  mice  and  their  WT  siblings  at  the  time  of 
sacrifice and used to generate osteoclasts in vitro. The KO group had four mice and the 
control group contained eight. A) Osteoclast-like cells differentiated on glass coverslips 
were stained for TRAP activity and osteoclasts were defined as large, multinuclear cells 
with positive TRAP stain. There was no significant difference in the number of osteoclasts 
generated between the two conditions. B) Osteoclasts generated on dentine discs were 
lysed  and  the  discs  stained  with  toluidine  blue  to  reveal  resorption  pits.  Osteoclasts 
produced from KO bone marrow produced significantly more resorption pits indicating 
increased activity levels compared to the control cells. Significance was tested using an 
unpaired t test, ns=p>0.05.    
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5.3.4  Viral transduction of osteoclast cultures 
One  of  the  primary  reasons  for  investigating  the  potential  of  gene  therapy  as  a  GD 
treatment  is  because  the  current  therapy  does  not  have  a  significant  effect  on  the 
skeletal  complications  associated  with  the  disease.  It  is  hoped  that  gene  therapy  of 
patient  derived  HSCs  could  be  an  effective  method  of  treating  these  complications. 
Having demonstrated evidence of an overactive phenotype in osteoclasts generated from 
bone  marrow  of  the  GBA
-/-  mouse,  the  next  step  would  be  to  transduce  the 
differentiating osteoclasts with a GBA vector and assay for correction of the phenotype.  
First it was necessary to determine what point in the culture is optimal to perform the 
transduction. Bone marrow was harvested from a WT mouse and  osteoclast cultures 
were set up as for the GBA
-/- mice but with the cells grown on glass coverslips as opposed 
to dentine discs. Viral transductions were performed on days one, two and three of the 
culture using an MOI of 10. When the cultures were terminated, the number of GFP 
positive cells was determined as an indication of which transduction gave the highest 
efficiency.  
Transducing cells on day one (the day of harvest) gave a transduction efficiency of less 
than  38.5%  (standard  deviation:  11.96%).  Transduction  efficiency  this  low  is  not 
unexpected for this condition as the first day represents a selection step and therefore, 
not all of the cells transduced would be used in the final culture. Transducing the cells on 
day two or three of culture gave transduction efficiencies of 60.2% (standard deviation: 
20.99%) and 71.5% (standard deviation: 0.12%) respectively but the culture transduced 
on day two showed much greater variation and therefore it would probably be optimal to 
transduce osteoclast differentiation cultures on day three. Unfortunately time did not 
allow  the  development  of  this  work  but  it  is  an  aspect  which  warrants  further 
investigation.   148 
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Figure 5.6 in vitro transduction is most effective when performed at day 3 of 
osteoclastogenesis. 
Bone marrow was harvested from CD1 mice and differentiated into osteoclast-like cells in 
vitro. Transduction was performed with a vector carrying eGFP on each of the first three 
days in the protocol. After terminating differentiation and fixing the cells, the number of 
GFP positive cells in each culture was counted to assess the efficiency of transduction. 
The  results  showed  that  transduction  is  most  effective  when  performed  later  in  the 
protocol as the levels of GFP expression did not reach significance in cells transduced on 
the first day of differentiation. Error bars show standard deviation, n=3, significance was 
tested using one-way ANOVA with Tukey post-hoc test ns=p>0.05.   149 
 
5.3.5  CFU-assay in transduced bone marrow 
For the gene therapy strategy envisioned by this work to succeed it is vital to show that 
transducing GBA
-/- progenitors with a GC carrying vector will not result in toxicity to the 
stem cells as has been seen with the globoid cell leukodystrophy vector (391).  
To investigate this, lineage negative cells isolated from the bone marrow of GBA
-/- mice 
were transduced with vectors carrying either  GBA or eGFP at an MOI of 50.  Murine 
lineage  negative  cells  are  those  which  do  not  bear  any  markers  of  haematopoietic 
differentiation and can therefore be assumed to be a population of immature progenitor 
cells. These cells were isolated from whole bone marrow using the microbead lineage 
depletion kit from Miltenyi Biotec. The transduced cells were then cultured in a semi-
solid  medium  containing  the  necessary  cytokines  (stem  cell  factor,  interleukin-3, 
interleukin-6, and erythropoietin) to stimulate haematopoietic differentiation. After 10 
days of culture the number of colonies was assessed to determine if there was an effect 
on the viability or differentiation of cells transduced with the GBA vector (Figure 5.7). 
These data show that there is no significant difference between any of the conditions 
which suggests that the vector does not have a toxic effect on HSCs. However this work 
was performed on a relatively small number of mice and the inherent variability of such 
protocols, as indicated by the large error bars, combined with the fact that the results do 
show  a  downward  trend  after  transduction  with  the  GBA  vector  means  that  further 
investigation with a greater number of replicates is required before any firm conclusions 
can be drawn.   150 
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Figure 5.7 Colony forming assay with transduced GBA
-/- bone marrow 
Bone marrow harvested from three GBA
-/- mice and three of their WT siblings (control 
group) was cultured in semi-solid medium for 10 days to encourage the formation of 
haematopoietic colonies. The results suggest that there is no significant difference in the 
number  of  colonies  produced  by  GBA
-/-  mice  even  when  the  marrow  had  been 
transduced  with  either  GBA  or  eGFP  lentiviral  vectors.  Error  bars  show  standard 
deviation, significance was measured with 1-way ANOVA using Bonferroni’s post-hoc test 
and with p<0.05.    151 
 
5.4  Summary  
Bone  disease  is  the  main  feature  of  type  I  GD  that  remains  refractory  to  enzyme 
replacement therapy, and the results of our survey confirm that it is still a major aspect of 
the disease, but it is one that may be alleviated by gene therapy. 
The  data  in  this  chapter  has  confirmed  that  autologous  bone  marrow  progenitors 
modified by gene therapy are capable of differentiating into osteoclasts both in vitro and 
in  vivo.  This  is  important  as  there  have  been  very  few  other  demonstrations  of 
osteoclastogenesis  after  gene  therapy  in  the  literature.  One  paper  that  has  done  so 
transduced  CD34+  cells  from  patients  with  infantile  malignant  osteopetrosis  and 
differentiated them in vitro to produce osteoclasts with restored functionality. However 
they  were  unable  to  confirm  that  osteoclastogenesis  also  occurs  in  vivo  due  to  the 
species  specificity  of  M-CSF  (377).  In  this  project  we  have  been  able  to  show  the 
differentiation of osteoclasts from modified bone marrow both in vitro and in vivo.  
We have also demonstrated that a mouse model of type II GD has a previously unknown 
osteoclast phenotype. It has not been possible to observe this phenotype in the living 
mice because they die at the age of two weeks (183, 184) which is before the point at 
which  bone  disease  would  likely  develop.  However  by  harvesting  bone  marrow  and 
performing  the  differentiation  in  vitro  we  were  able  to  show  that,  while  the  same 
number of osteoclasts differentiate from the bone marrow, they are more active and 
there  is  an  increased  level  of  bone  resorption.  Currently  the  reason  for  the  skeletal 
disease  in  humans  is  unknown  although  it  if  thought  to  involve  a  disruption  of  the 
balance  between  osteoclast  and  osteoblast  action with  a  potential  role  for  both  cell 
types. Therefore it would be of interest to follow up this work with an investigation of 
osteoblasts from the model mouse to compare their activity to those of wild type mice. 
Such an experiment would help indicate whether treating the osteoclast in the manner 152 
 
suggested  here  would  be  likely  to  ameliorate  bone  disease  or  whether  it  would  be 
beneficial to attempt to develop an osteoblast directed therapy. 
This  work  has  shown  that,  despite  death  occurring  at  an  age  before  bone  disease 
develops, the type II GD mouse model can still serve as a useful model for the osteoclast 
phenotype found in GD and to demonstrate further evidence for the involvement of the 
osteoclast in GD bone pathology. It has also demonstrated that gene therapy can result in 
genetically marked osteoclasts which strengthens the hypothesis that gene therapy of GD 
would ameliorate the skeletal symptoms of the disorder in a way that is not possible with 
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6  Discussion 
Gaucher  disease  is  haematopoietic  in  origin  and  leaves  patients  unable  to  process 
glucocerebrosides causing their accumulation within the lysosomes of phagocytic cells (4, 
13, 14). Affected individuals experience hepatosplenomegaly, pancytopenia and skeletal 
complications  (53,  56,  74)  as  well  as  neurological  deterioration  in  the  most  severe 
subtypes  (51,  65).  Currently  the  majority  of  patients  are  treated  with  enzyme 
replacement  therapy  using  preparations  of  recombinant  or  gene-activated  enzyme 
however given the high cost of the treatment and the fact that it does not provide a 
permanent cure, there is room to consider other options. 
One such option may be gene therapy which was first hypothesised over 40 years ago 
(196) but which has experienced a number of stumbling blocks throughout its history. 
Nevertheless recent years have seen an ever increasing number of clinical trials showing 
significant therapeutic benefit in a wide range of conditions including haemophilia (392), 
Parkinson’s disease (393) and Leber congenital amaurosis, a form of inherited blindness 
(394). Most importantly in 2013 the first gene therapy was licensed for sale in the EU 
(395) for the treatment of lipoprotein lipase deficiency (396). 
Many early studies employed γ-retrovirus-based vectors because of their innate ability to 
integrate foreign DNA into the host chromosome, resulting in permanent correction of 
transduced cells (259, 260). However the publication of data linking integration of γ-
retroviral genomes close to proto-oncogenes with the development of leukaemia (234-
236) led to a shift in vector usage. 
Lentiviral vectors are derived from a family of the Retroviridae including HIV-1 and other 
immunodeficiency viruses. They retain the classic retroviral ability to integrate into the 154 
 
host  genome  but  appear  to  have  an  altered  integration  profile  (261)  which  greatly 
reduces the association with oncogenesis (397-399). 
Integration of the retroviral genome was believed to occur at random sites in the host 
chromosome  until  it  was  shown  that  different  virus  types  show  a  preference  for 
particular types of DNA sequence. The γ-retrovirus, such as murine leukaemia virus (MLV) 
shows a distinct preference for integrating at the start site of genes (262, 263). This helps 
explain the high rate of insertional mutagenesis after transduction with a  γ-retroviral 
vector  as  proximity  to  a  transcription  start  site  can  increase  the  effect  of  the  viral 
enhancers to upregulate the neighbouring gene. The integration profile of lentiviruses is 
different as they show a tendency to integrate within genes meaning that there is less 
opportunity for interactions with the regulatory regions of other, nearby genes (261-263). 
A crucial experiment performed in the tumour-prone Cdkn2a mouse strain used HSCs 
transduced  with  either  lentiviral  or  γ-retroviral  vectors  carrying  the  eGFP  gene  to 
compare the genotoxicity of the two vector types (398). The work showed that while 
there  was  no  difference  in  the  tumour-free  survival  rates  of  mice  in  the  different 
conditions, tumours in γ-retroviral treated mice had a much lower vector copy number 
than those of mice who received the lentivirus treated HSCs. Integration site analysis of 
the tumours revealed a significantly higher proportion of integration events within 10kb 
of the transcription start site in the γ-retroviral group but no such bias within lentiviral 
tumours  which  correlates  with  the  previous  in  vitro  findings  on  integration  site 
preference and oncogenesis. This study indicated that a γ-retroviral integration event has 
a greater chance of leading to oncogenesis than that of a lentiviral genome (398). 
It is not only the integration profile of lentiviruses which makes them more attractive 
than γ-retroviruses. The genome of γ-retroviruses is only able to integrate into the host 
chromosomes of cells during cell division as the genome is unable to cross the nuclear 155 
 
membrane (400, 401). This is not the case with lentiviral genomes which are able to 
integrate while the nuclear membrane is intact and therefore can efficiently transduce 
non-dividing cells such as those in post-mitotic tissues and stem cells which divide at a 
very slow rate (400, 402).  
Gene therapy is an attractive option for GD as lentiviral correction of the haematopoietic 
stem  cell  (HSC)  should  result  in  permanent  correction  of  the  haematopoietic  lineage 
removing the requirement for macrophage directed ERT.  
A  number  of  studies  have  been  performed  previous  to  this  project  which  have 
demonstrated the feasibility of using gene therapy to correct the enzymatic defect in GD 
(209, 363-366, 370, 371) but the majority of these used γ-retroviral vectors which are less 
relevant  than  those  derived  from  lentiviruses  due  to  the  low  rate  of  stem  cell 
transduction.  
A clinical trial in 1998 failed to show any efficacy of gene therapy when used to treat 
three  GD  patients  but  this  is  likely  to  be  because  the  protocol  did  not  include  a 
conditioning step (373). A significant number of gene therapy protocols to date have 
been intended to treat primary immunodeficiencies in which the corrected stem cells 
have  a  selective  advantage  over  the  untreated  HSCs  within  the  bone  marrow  and 
therefore  there  is  no  requirement  for  conditioning  to  destroy  the  existing  stem  cell 
component.  However,  this  is  not  the  case  in  GD  which  does  not  have  an 
immunodeficiency  associated  with  it  and  therefore  it  is  likely  that  a  successful  gene 
therapy treatment strategy will include myeloablative conditioning before the transfusion 
of corrected HSCs (Adrian Thrasher, personal communication).  
A  number  of  LSDs  and  similar,  metabolic  disorders  stand  to  benefit  from  the 
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enzyme  deficiencies  in  the  haematopoietic  compartment.  Notably,  gene  therapy  is 
currently  in  clinical  trials  for  the  treatment  of  adrenoleukodystrophy  (ALD)  and 
metachromatic  leukodystrophy  (MLD).  The  ALD  trial  treated  two  patients  who  were 
already showing the progressive demyelination of the CNS associated with the disease. 
Both patients were treated with autologous HSCs which had been transduced with a 
lentiviral vector carrying the ABCD1 gene and follow up has been reported for over three 
years. In common with patients who have undergone allogeneic HSCT, the gene therapy 
patients  showed  continuation  of  demyelination  followed  by  stabilisation  and  some 
reversion of the disease (397, 403). The period of continued demyelination occurs after 
HSCT because stabilisation of the condition relies on repopulation of the CNS by donor-
derived microglia and this can take up to 24 months (404) although studies in mice have 
shown that the process can be augmented by extensive conditioning which will fully 
ablate the haematopoietic cells of the CNS (405). The same strategy was used in a trial for 
MLD and showed stabilisation of disease up to 24 months post-gene therapy with treated 
patients  remaining  asymptomatic  with  arrested  demyelination  and  continued 
neurological development (406). 
Both of these studies have demonstrated the potential for gene therapy in metabolic 
disease and the promising results achieved with the CNS symptoms of both disorders 
allow for speculation that a gene therapy strategy could also be of benefit to type II and 
III GD patients. Both type II and III GD cause progressive neurological deterioration which 
is ultimately fatal. Despite being far from conclusive, data from type III HSCT recipients 
has  suggested  that the  procedure can  bring  about a  stabilisation  of  the  neurological 
disease (71, 101, 407) and so it is conceivable that these patients may also benefit from 
HSC-directed gene therapy.  157 
 
However the situation with type II GD is very different. CNS pathology likely develops in 
utero and is almost always in evidence at diagnosis (51, 408). Therefore it is unlikely that 
any intervention will be able to restore the damage which has already been done and so 
type II patients are not expected to benefit from the style of gene therapy used in this 
work (408, 409). 
This project produced lentiviral vectors which could be used for the gene therapy of 
Gaucher disease. The vectors carry a WT glucocerebrosidase gene which had been cloned 
from healthy tissue during previous work (Ahad Rahim, unpublished).  
Transduction of both HEK293T and GD patient-derived fibroblasts cell lines with the GBA 
vector resulted in a significant increase in both the expression and activity levels of the 
GC enzyme. The results of a time course study looking at expression levels in the first two 
weeks after transduction revealed a peak in activity after three days which then dropped 
but  remained  at  a  level  13-fold  greater  than  that  of  untreated  cells.  These  results 
confirmed  that  the  vector  produced  is  able  to  mediate  expression  of  functional  GC 
enzyme and can correct the defect in GD tissues. The reduction in activity three days 
post-transduction  is  not  unexpected  and  is  potentially  due  to  the  clearance  of  non-
integrated viral genomes from the cell. This clearance occurs as part of innate cellular 
defence mechanisms to remove any non-integrated linear DNA which may be of viral 
origin and thereby protect the cell from potential infections (410, 411).  
The vectors produced were under the control of a strong viral promoter (spleen focus-
forming virus: SFFV) which is not commonly used in clinical vectors as a high proportion 
of  viral  elements  may  allow  for  recombination  with  endogenous  retroviruses  and 
produce replication competent viral particles. In addition to this, viral DNA sequences are 
often recognised as foreign by the host cell and so are likely to undergo methylation and 
other forms of regulation which can lead to silencing of the transgene especially when a 158 
 
transduced stem or progenitor cell differentiates (340). The SFFV promoter was used in 
this study to provide reliable, high levels of protein expression which were required for 
this  proof-of-concept  work.  To  make  the  vectors  produced  in  this  project  clinically 
applicable  it  would  be  necessary  to  exchange  the  SFFV  promoter  for  a  promoter 
sequence such as elongation factor 1α (EF1α) or phosphoglycerate kinase (PGK). 
The  SFFV  promoter  was used  in  a  clinical  trial  for  the  treatment  of X-linked  chronic 
granulomatous disease (CGD) in which two patients received transduced autologous HSCs 
(320).  Both  patients  showed  clinical  resolution  of  disease  after  treatment  with  the 
clearance  of  pre-existing  infection  in  addition  to  correction  of  the  molecular  defect. 
Unfortunately,  both  patients  showed  clonal  expansions  of  transduced  cells  which 
ultimately led to the development of myelodysplastic syndrome and the death of one 
patient (412). However that study used a γ-retroviral vector and so is not comparable to 
the system being used here. In contrast a trial for the gene therapy of ADA-SCID using a 
lentiviral vector carrying the transgene under the control of the SFFV promoter has now 
treated 5 patients without the development of any monoclonal expansions suggesting 
that the promoter itself is not overtly oncogenic when used with a lentivirus (413, 414). 
Rather than using a viral promoter which may be subject to methylation or involved in 
the induction of mutagenesis, many researchers prefer to use a mammalian promoter 
element  and  two  of  the  most  popular  are  the  EF1α  and  PGK  elements.  EF1α  is  a 
housekeeping gene and the promoter has been shown to give high levels of protein 
expression which is maintained over a longer time period than viral promoters (415, 416). 
A further option when considering primer choice is to use a promoter which is restricted 
to the target cell or tissue which for GD is the macrophage. Levin et al. (2012) compared 
five macrophage specific promoters, three variations of the CD68 and two forms of a 
synthetic  promoter  (described  in  (417)),  with  the  SFFV  promoter  (418).  The  results 159 
 
showed that both promoters expressed the transgene at lower levels than SFFV and that 
although expression in non-macrophage cells was reduced with the non-viral promoters 
it was not completely abolished especially when the multiplicity of infection was high. For 
GD, restriction of transgene expression to the macrophage is not required as GC is a 
housekeeping gene (378-380) and therefore it is not necessary to prevent ubiquitous 
expression.  
However, something that may require further investigation is the effect of expressing GC 
at  high  levels  in  the  stem  cell.  Visigalli  et  al.  (2010)  showed  that  expression  of 
galactosylceramidase (GALC) in the HSC of Krabbe disease mice led to rapid death of the 
transduced cells due to the sudden increase of the pro-apoptotic molecule ceramide 
from digestion of the stored sphingolipid (419). To prevent this cell death the researchers 
found it necessary to fuse a target sequence for an HSC-specific miRNA to the transgene 
to prevent its transcription within the HSC. As glucocerebroside is also a sphingolipid 
whose metabolism results in the production of ceramide the same problem could occur 
in transduced GD HSCs.  
In Figure 5.7 of this project, bone marrow from a GD model mouse was transduced with 
the  vectors  and  cultured  in  semi-solid  medium  to  promote  the  differentiation  of 
haematopoietic  cells.  No  significant  differences  were  found  in  the  numbers  of 
differentiated colonies produced by transduced or untransduced cultures but there was a 
high degree of variation within the groups which suggests that, with further investigation, 
transduction may be found to affect survival and differentiation of HSCs. If this is shown 
to be the case the use of miRNA or a promoter which is not expressed within the HSC 
may be necessary to restrict GBA expression. 
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Although the main symptoms of GD are clearly associated with the phagocytic cells of the 
haematopoietic  system,  GBA  is  in  fact  a  housekeeping  gene  and  is  expressed 
ubiquitously, albeit at low levels (378-380, 389). There is no evidence to suggest that 
other cells  are  compromised  by  the  lack of  GBA expression,  but  it may  prove  to  be 
beneficial if it is possible to correct cells of other lineages in addition to haematopoietic 
cells. We therefore examined strategies that might allow for non-genetic correction of 
cells outside the haematopoietic system. 
It is known that the native GBA sequence contains a secretion signal although it is not 
considered to be a secreted protein as the enzyme is delivered directly to the lysosome 
from  the  endoplasmic  reticulum  by  association  with  lysosomal  integral  membrane 
protein 2 (LIMP2) (23, 24). However, it is possible that this secretion signal may be used 
when  the  protein  is  overexpressed  in  order  to  prevent  the  accumulation  of  enzyme 
within  a  cell.  Experiments  shown  here  have  confirmed  that  this  is  the  case;  when 
expressed  at  high  levels  within  a  cell,  excess  GC  is  secreted  into  the  extracellular 
environment. It is also shown that secreted protein retains its enzymatic activity. This 
work demonstrates that transduced cells which are overexpressing the transgene could 
act as reservoirs of protein with secreted enzyme potentially being available for use by 
untransduced cells. 
The secretion of GC after transduction by a GBA carrying virus has been demonstrated 
before from a number of cell types including GD fibroblasts (388) as well as both human 
and murine myoblasts (420). These studies were also able to show uptake of the secreted 
enzyme by untransduced GD fibroblasts (388) or WT murine macrophages (420). The 
uptake of GC by macrophages occurred at a much higher rate than uptake by either the 
fibroblasts in Liu et al. (2004) or the LCLs used in this study which perhaps reflects the 
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receptor  which  is  the  native  receptor  for  the  enzyme.  However  it  is  uptake  by  the 
fibroblast which is most relevant to this study; uptake by non-haematopoietic cells such 
as fibroblasts will be crucial for the success of the cross-correction strategy suggested 
here. The uptake by fibroblasts in the study by Liu et al. was only modest but as that work 
used the native enzyme, it is hoped that the addition of a PTD will improve levels of 
uptake. 
The protein used for ERT is deliberately targeted to macrophages by the exposure of 
mannose residues on the glycoprotein side chains allowing for uptake by the mannose 
receptor  (109).  However  this  is  a  macrophage  specific  receptor  and  therefore  an 
alternative strategy is required to target other cell types. 
The method we investigated for engineering uptake of secreted protein by neighbouring 
cells was to fuse a protein transduction domain (PTD) to the native protein sequence. We 
chose to use the PTD which has been isolated from the HIV-1 TAT protein because it has 
been shown to work independently of receptor and cell type (346, 347). Previous studies 
have  shown  that  the  TAT  PTD  can  vastly  improve  the  biodistribution  of  exogenous 
protein in an ERT style setting (421).  
Lee et al. (2005) fused the TAT PTD to GC in an attempt to improve uptake of the enzyme 
used for ERT (315). They found that fusion of the PTD to the C-terminus of the protein 
greatly increased the levels of enzyme taken up by GD fibroblast when compared to both 
imiglucerase and the native protein. However they also found that adding the PTD to the 
N-terminus  of  GC  abolished  protein  expression.  Further  investigation  of  the  PTD 
sequence by a group at King’s College London identified two potential furin endonuclease 
cleavage sites which could explain the absence of protein produced from the N-terminal 
fusion protein (316) if recognition of the cleavage sites leads to degradation of GC. The 
King’s  College  researchers  were  able  to  abolish  these  cleavage  sites  by  altering  the 162 
 
nucleotide sequence without affecting the transduction capability of the domain (mTAT) 
and with this modified TAT sequence we were able to produce an N-terminal fusion 
protein which expresses at comparable levels to the C-terminal constructs. This seems to 
support our hypothesis that in the study by Lee et al., the N-terminal fusion construct 
produced  is  expressed  but  that  recognition  of  the  furin  cleavage  sites  leads  to 
degradation  of  the  enzyme  and  that  this  effect  is  abolished  by  modifying  the  TAT 
sequence. 
In this study GC was fused to either the mTAT or the WT TAT version of the PTD and 
assayed for their effect on uptake of secreted enzyme by untransduced lymphoblastic 
cells. When they were co-cultured with fibroblasts expressing either version of the TAT 
domain fused to the C-terminus of the protein there was a seven-fold increase in GC 
enzyme activity within the untransduced cells compared to a modest doubling of enzyme 
activity in cells in the N-terminal fusion condition. The failure of the N-terminal construct 
to mediate high levels of protein transduction could be due to the way the protein folds 
during assembly. The transduction domain must be on the exterior of the protein after 
assembly in order to be accessible to the cell membrane; if it is obscured it may not be 
able to mediate transduction (346, 347).  
This work used transduced fibroblasts as the reservoir of protein and untransduced, GD 
patient-derived LCLs as the test cell line for uptake of secreted protein. In reality this is 
the reverse of the situation that would be seen in patients. The gene therapy strategy 
suggested by this work would transduce cells of the hematopoietic system and it would 
be these cells which secrete the protein allowing for the cross-correction of other tissues. 
Therefore, although this work demonstrates that cross-correction is a valid theory and 
that addition of a PTD can be used to enhance the effect, it does not accurately reflect 
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recapitulating  the  in  vivo  scenario  to  demonstrate  that  cross-correction  is  a  suitable 
strategy for use in GD.  
A number of previous studies have shown that the TAT PTD can be used to improve the 
biodistribution of exogenous proteins in whole animals. For example, Grubb et al. (2010) 
showed that fusion of the TAT PTD to β-glucuronidase (GUS), the enzyme deficient in 
mucopolysaccharidosis  (MPS)  VII,  resulted  in  an  enzymatic  preparation  which  greatly 
increased the degree of substrate clearance from the renal cells of MPS VII mice (317). 
The  authors  also  reported  seeing  clearance  of  stored  material  from  osteoclasts  and 
osteoblasts which is of great significance for this work as it suggests that the TAT PTD is 
capable of mediating protein transduction into osteological cells, something we aim to 
achieve with our treatment strategy.  
In addition to potentially transducing the osteoblast with the transprotein, it may be 
possible  to  target  neurological  symptoms  of  type  III  GD.  Farfel-Becker  et  al.  (2014) 
showed  that  accumulation  of  GlcCer  within  neurons  correlates  with  neurological 
deterioration in vivo (68). Another study by Pelled et al. (2000) showed that neuronal 
cultures which had been treated with a chemical inhibitor of GC could be prevented from 
undergoing apoptosis after culture with imiglucerase which may suggest that correction 
of  the  enzymatic  defect  may  be  able  to  mediate  prevention  or  stabilisation  of 
neurological disease (422). There has also been suggestion that fusion of the TAT PTD to a 
protein can allow the protein to cross the blood-brain barrier (357). If testing was to show 
that the TAT domain can stimulate or improve uptake of GC by neurons it may mean that 
the  therapy  suggested  here  could  be  extended  to  treatment  of  the  neurological 
component of type III GD.  
Although cross-correction of untransduced tissues may be of some benefit to patients, 
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against  the  protein.  An  immune  response  against the  transprotein  could  result  in  its 
clearance  from  the  extracellular  environment  and  therefore  prevent  cross-correction 
from occurring. Although there is evidence that long-term treatment with exogenous 
enzyme only produces an inhibitory immune response in a low number of GD patients, it 
is a significant problem in replacement therapy for other conditions including Pompe 
disease  (423,  424)  haemophilia  A  (425,  426)  and  Fabry  disease  (427,  428)  so  it  is 
therefore something which must be considered. 
 
With the introduction of ERT, many of the symptoms associated with GD  have been 
significantly reduced and patients are able to live relatively symptom-free lives. However 
the one aspect of type I GD which remains prevalent is bone disease. Treating the skeletal 
complications of GD is further complicated as the exact cause of the symptoms remains 
unclear. However, mounting evidence has recently been described which suggests the 
involvement of an osteoclast phenotype. It has been shown that a number of cytokines 
involved in osteoclastogenesis are found at elevated levels in the plasma of GD patients 
(85, 90, 93, 94) although the levels of each cytokine tend to vary between patients. It is 
also  worth  considering  that  the  majority  of  these  factors  are  produced  by  the 
macrophage  and  so  correction  of  the  HSC  should  normalise  levels  and  potentially 
alleviate the skeletal disease. More compelling evidence comes from Reed et al. (2013) 
who showed that, under the same culture conditions, precursor cells derived from GD 
patients are more likely than controls to differentiate into osteoclasts and that those 
osteoclasts are significantly more active than their counterparts which may help explain 
the bone pathology seen in patients (86).  
Based on this work we hypothesised that a similar phenotype may be observable in 
osteoclasts derived from the HSCs of the GBA
-/- mouse used in this project. It was found 165 
 
that  while  bone  marrow  harvested  from  knock-out  mice  did  not  undergo  increased 
osteoclastogenesis  as  was  the  case  with  human  cells,  they  did  show  the  same 
hyperactivity of generated osteoclasts. This is a significant finding as very few of the GD 
mouse models which have been developed to date have shown a skeletal phenotype and 
little work has been done to discover whether any of them show a defect in vitro. This 
work  therefore  presents  a  new  potential  tool  for  the  investigation  of  the  skeletal 
phenotype of GD.  
This finding is contrary to some previous findings including the skeletal phenotype found 
in the type I GD mouse model produced by Mistry et al. (2010). This work suggested that 
GBA deletion had no effect on the activity of osteoclasts but that the skeletal phenotype 
(including osteonecrosis and osteopenia) was due to impaired bone formation caused by 
reduced osteoblast formation (89). The work of Mucci et al. (2013) also supports the 
involvement of the osteoblast in the development of a skeletal phenotype as they found 
that  chemical  inhibition  of  GC  in  peritoneal  macrophages  led  to  reduced  collagen 
deposition and mineralisation in vitro (80). However they also showed an increase in 
osteoclast formation and activity in their chemical in vitro model. Given all of this work it 
seems most likely that a combination of osteoclast and osteoblast effects lead to the 
development of skeletal symptoms in patients.  
Gene therapy of the HSC should lead to direct correction of the GBA
-/- osteoclast and 
therefore alleviate any symptoms which are due to enzymatic defect in that cell but it 
may  also  be  possible  to  reduce  the  effect  of  GD  osteoblasts  if  the  cross-correction 
strategy  is  successful.  Mesenchymal  stem  cells  and  more  committed  osteoblast 
progenitors are found in the bone marrow (429, 430) and therefore will be exposed to GC 
secreted by the transduced HSCs which will also be in the bone marrow cavity. If the cells 166 
 
are able to take up that secreted enzyme this correction could be capable of ameliorating 
the disease phenotype from both sides of bone homeostasis. 
Knowing that a phenotype can be identified in in vitro derived, murine osteoclasts could 
be of substantial benefit to researchers working on gene therapy for GD. Transduction of 
precursor cells on day 2 or 3 of the differentiation protocol gives rise to a high number of 
transduced osteoclasts. This presents a measurable effect for future work investigating 
the principle of using gene therapy to correct the osteoclast defect.  
Hematopoietic gene therapy has traditionally been used to treat blood disorders and 
there has been very little research into correcting skeletal conditions using HSCs. Where 
gene therapy has been suggested for bone disorders, it has generally involved treating 
more committed precursor cells. 
However, a group in Sweden recently published a study which showed that it is possible 
to  treat  the  osteoclast  disorder  osteopetrosis  by  genetically  correcting  HSCs  using 
lentiviral vectors (377). We were also able to demonstrate that genetically modified HSCs 
are  capable  of  differentiating  into  osteoclasts  when  transplanted  into  irradiated 
recipients. HSCs were treated with a GFP expressing vector and transplanted into HLA-
identical recipient mice. Nine weeks post-transplant, mice were culled and it was found 
that GFP positive osteoclasts could be isolated from the macerated bones of recipient 
mice  demonstrating  not  only  that  the  transplanted  HSCs  could  differentiate  into 
osteoclasts, but also that the differentiated cells retained the ability to express the viral 
transgene. These two pieces of work taken together suggest that gene therapy of HSCs 
should be able to correct the skeletal phenotype associated with GD.  
Further work is required to comprehensively show the extent to which the osteoclast is 
responsible for the skeletal complications. The osteoblast is a cell of mesenchymal origin 167 
 
and therefore will not be directly affected by the gene therapy strategy suggested here. If 
the osteoblast is shown to be an important mediator in the development of skeletal 
complications another strategy may be required to target the skeletal symptoms of GD. 
 
The appeal of gene therapy as a treatment method for Gaucher disease was reduced 
after the introduction of ERT but recently the inefficient resolution of skeletal symptoms 
and the global shortage of enzyme preparation have led to a resurgence of interest.  
This project has shown that lentiviral transduction of patient cells can lead to correction 
of the metabolic defect in GD as well as producing a reservoir of protein which can be 
used to treat untransduced cells in a gene-independent fashion. The potential for treating 
the osteoclast in addition to cells of the haematopoietic system could be a significant 
bonus to gene therapy as compared to ERT but further work needs to be done to confirm 
the underlying defect and whether genetic correction could reverse the phenotype and 
the pre-existing damage.    168 
 
7  Appendix  
7.1  Papers presented 
Oral presentations 
1.  Lentiviral vectors for gene therapy of Gaucher disease – European Joint Lab 
Meeting, Rotterdam 2011 
2.  Developing lentiviral vectors for gene therapy of type I Gaucher disease – 
European Working Group on Gaucher Disease, Paris 2012 
3.  Gene therapy for metabolic disease – UCL Gene and Cell Therapy MSc course, 
2013 and 2014 
Poster presentations 
1.  Lentiviral vectors for gene therapy of type I Gaucher disease – European Society 
of Gene Therapy, Brighton 2011 
2.  Lentiviral vectors for gene therapy of type I Gaucher disease – British Society of 
Gene Therapy, London 2012 
3.  Lentiviral vectors for gene therapy of type I Gaucher disease – British Society of 
Gene Therapy, London 2013. Poster prize winner. 
4.  Lentiviral vectors for gene therapy of type I Gaucher disease – European Society 
of Gene Therapy, Madrid 2013 
Funding for travel was kindly provided by the following groups: 
1.  Jim Seakins Memorial Travel Fund, Institute of Child Health UCL 
2.  European Working Group on Gaucher Disease 
3.  Susan Lewis Memorial Award, UK Gaucher Association   169 
 
7.2  Sequence alignment of GBA including mTAT or WT TAT fusion 
            1                                                   50                                             
       GBA  ATGGAGTTTT CAAGTCCTTC CAGAGAGGAA TGTCCCAAGC CTTTGAGTAG GGTAAGCATC ATGGCTGGCA GCCTCACAGG ATTGCTTCTA 
  GBA-mTAT  ATGGAGTTTT CAAGTCCTTC CAGAGAGGAA TGTCCCAAGC CTTTGAGTAG GGTAAGCATC ATGGCTGGCA GCCTCACAGG ATTGCTTCTA 
GBA-WT_TAT  ATGGAGTTTT CAAGTCCTTC CAGAGAGGAA TGTCCCAAGC CTTTGAGTAG GGTAAGCATC ATGGCTGGCA GCCTCACAGG ATTGCTTCTA 
  mTAT-GBA  ATGGAGTTTT CAAGTCCTTC CAGAGAGGAA TGTCCCAAGC CTTTGAGTAG GGTAAGCATC ATGGCTGGCA GCCTCACAGG ATTGCTTCTA 
                     100                                                   150                                 
       GBA  CTTCAGGCAG TGTCGTGGGC ATCAGGT... .......... .......... .......... GCCCGCCCCT GCATCCCTAA AAGCTTCGGC 
  GBA-mTAT  CTTCAGGCAG TGTCGTGGGC ATCAGGT... .......... .......... .......... GCCCGCCCCT GCATCCCTAA AAGCTTCGGC 
GBA-WT_TAT  CTTCAGGCAG TGTCGTGGGC ATCAGGT... .......... .......... .......... GCCCGCCCCT GCATCCCTAA AAGCTTCGGC 
  mTAT-GBA  CTTCAGGCAG TGTCGTGGGC ATCAGGTTAC GCCAGAAAGG CCGCCAGGCA GGCCAGGGCA GCCCGCCCCT GCATCCCTAA AAGCTTCGGC 
                               200                                                    250                      
       GBA  TACAGCTCGG TGGTGTGTGT CTGCAATGCC ACATACTGTG ACTCCTTTGA CCCCCCGACC TTTCCTGCCC TTGGTACCTT CAGCCGCTAT 
  GBA-mTAT  TACAGCTCGG TGGTGTGTGT CTGCAATGCC ACATACTGTG ACTCCTTTGA CCCCCCGACC TTTCCTGCCC TTGGTACCTT CAGCCGCTAT 
GBA-WT_TAT  TACAGCTCGG TGGTGTGTGT CTGCAATGCC ACATACTGTG ACTCCTTTGA CCCCCCGACC TTTCCTGCCC TTGGTACCTT CAGCCGCTAT 
  mTAT-GBA  TACAGCTCGG TGGTGTGTGT CTGCAATGCC ACATACTGTG ACTCCTTTGA CCCCCCGACC TTTCCTGCCC TTGGTACCTT CAGCCGCTAT 
            251                           300                                                    350           
       GBA  GAGAGTACAC GCAGTGGGCG ACGGATGGAG CTGAGTATGG GGCCCATCCA GGCTAATCAC ACGGGCACAG GCCTGCTACT GACCCTGCAG 
  GBA-mTAT  GAGAGTACAC GCAGTGGGCG ACGGATGGAG CTGAGTATGG GGCCCATCCA GGCTAATCAC ACGGGCACAG GCCTGCTACT GACCCTGCAG 
GBA-WT_TAT  GAGAGTACAC GCAGTGGGCG ACGGATGGAG CTGAGTATGG GGCCCATCCA GGCTAATCAC ACGGGCACAG GCCTGCTACT GACCCTGCAG 
  mTAT-GBA  GAGAGTACAC GCAGTGGGCG ACGGATGGAG CTGAGTATGG GGCCCATCCA GGCTAATCAC ACGGGCACAG GCCTGCTACT GACCCTGCAG 
                                                     400                                                   450 
       GBA  CCAGAACAGA AGTTCCAGAA AGTGAAGGGA TTTGGAGGGG CCATGACAGA TGCTGCTGCT CTCAACATCC TTGCCCTGTC ACCCCCTGCC 
  GBA-mTAT  CCAGAACAGA AGTTCCAGAA AGTGAAGGGA TTTGGAGGGG CCATGACAGA TGCTGCTGCT CTCAACATCC TTGCCCTGTC ACCCCCTGCC 
GBA-WT_TAT  CCAGAACAGA AGTTCCAGAA AGTGAAGGGA TTTGGAGGGG CCATGACAGA TGCTGCTGCT CTCAACATCC TTGCCCTGTC ACCCCCTGCC 
  mTAT-GBA  CCAGAACAGA AGTTCCAGAA AGTGAAGGGA TTTGGAGGGG CCATGACAGA TGCTGCTGCT CTCAACATCC TTGCCCTGTC ACCCCCTGCC 
            451                                                500                                             
       GBA  CAAAATTTGC TACTTAAATC GTACTTCTCT GAAGAAGGAA TCGGATATAA CATCATCCGG GTACCCATGG CCAGCTGTGA CTTCTCCATC 
  GBA-mTAT  CAAAATTTGC TACTTAAATC GTACTTCTCT GAAGAAGGAA TCGGATATAA CATCATCCGG GTACCCATGG CCAGCTGTGA CTTCTCCATC 
GBA-WT_TAT  CAAAATTTGC TACTTAAATC GTACTTCTCT GAAGAAGGAA TCGGATATAA CATCATCCGG GTACCCATGG CCAGCTGTGA CTTCTCCATC 
  mTAT-GBA  CAAAATTTGC TACTTAAATC GTACTTCTCT GAAGAAGGAA TCGGATATAA CATCATCCGG GTACCCATGG CCAGCTGTGA CTTCTCCATC 
                    550                                                    600                                 
       GBA  CGCACCTACA CCTATGCAGA CACCCCTGAT GATTTCCAGT TGCACAACTT CAGCCTCCCA GAGGAAGATA CCAAGCTCAA GATACCCCTG 
  GBA-mTAT  CGCACCTACA CCTATGCAGA CACCCCTGAT GATTTCCAGT TGCACAACTT CAGCCTCCCA GAGGAAGATA CCAAGCTCAA GATACCCCTG 
GBA-WT_TAT  CGCACCTACA CCTATGCAGA CACCCCTGAT GATTTCCAGT TGCACAACTT CAGCCTCCCA GAGGAAGATA CCAAGCTCAA GATACCCCTG 
  mTAT-GBA  CGCACCTACA CCTATGCAGA CACCCCTGAT GATTTCCAGT TGCACAACTT CAGCCTCCCA GAGGAAGATA CCAAGCTCAA GATACCCCTG 
                               650                                                    700                      
       GBA  ATTCACCGAG CCCTGCAGTT GGCCCAGCGT CCCGTTTCAC TCCTTGCCAG CCCCTGGACA TCACCCACTT GGCTCAAGAC CAATGGAGCG 
  GBA-mTAT  ATTCACCGAG CCCTGCAGTT GGCCCAGCGT CCCGTTTCAC TCCTTGCCAG CCCCTGGACA TCACCCACTT GGCTCAAGAC CAATGGAGCG 
GBA-WT_TAT  ATTCACCGAG CCCTGCAGTT GGCCCAGCGT CCCGTTTCAC TCCTTGCCAG CCCCTGGACA TCACCCACTT GGCTCAAGAC CAATGGAGCG 
  mTAT-GBA  ATTCACCGAG CCCTGCAGTT GGCCCAGCGT CCCGTTTCAC TCCTTGCCAG CCCCTGGACA TCACCCACTT GGCTCAAGAC CAATGGAGCG 
                                          750                                                    800           
       GBA  GTGAATGGGA AGGGGTCACT CAAGGGACAG CCCGGAGACA TCTACCACCA GACCTGGGCC AGATACTTTG TGAAGTTCCT GGATGCCTAT 
  GBA-mTAT  GTGAATGGGA AGGGGTCACT CAAGGGACAG CCCGGAGACA TCTACCACCA GACCTGGGCC AGATACTTTG TGAAGTTCCT GGATGCCTAT 
GBA-WT_TAT  GTGAATGGGA AGGGGTCACT CAAGGGACAG CCCGGAGACA TCTACCACCA GACCTGGGCC AGATACTTTG TGAAGTTCCT GGATGCCTAT 
  mTAT-GBA  GTGAATGGGA AGGGGTCACT CAAGGGACAG CCCGGAGACA TCTACCACCA GACCTGGGCC AGATACTTTG TGAAGTTCCT GGATGCCTAT 
  mTAT-GBA  CCCGGAGACA TCTACCACCA GACCTGGGCC AGATACTTTG TGAAGTTCCT GACCTGGGCC AGATACTTTG TGAAGTTCCT GGATGCCTAT 
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                                                     850                                                   900 
       GBA  GCTGAGCACA AGTTACAGTT CTGGGCAGTG ACAGCTGAAA ATGAGCCTTC TGCTGGGCTG TTGAGTGGAT ACCCCTTCCA GTGCCTGGGC 
  GBA-mTAT  GCTGAGCACA AGTTACAGTT CTGGGCAGTG ACAGCTGAAA ATGAGCCTTC TGCTGGGCTG TTGAGTGGAT ACCCCTTCCA GTGCCTGGGC 
GBA-WT_TAT  GCTGAGCACA AGTTACAGTT CTGGGCAGTG ACAGCTGAAA ATGAGCCTTC TGCTGGGCTG TTGAGTGGAT ACCCCTTCCA GTGCCTGGGC 
  mTAT-GBA  GCTGAGCACA AGTTACAGTT CTGGGCAGTG ACAGCTGAAA ATGAGCCTTC TGCTGGGCTG TTGAGTGGAT ACCCCTTCCA GTGCCTGGGC 
                                                                950                                            
       GBA  TTCACCCCTG AACATCAGCG AGACTTCATT GCCCGTGACC TAGGTCCTAC CCTCGCCAAC AGTACTCACC ACAATGTCCG CCTACTCATG 
  GBA-mTAT  TTCACCCCTG AACATCAGCG AGACTTCATT GCCCGTGACC TAGGTCCTAC CCTCGCCAAC AGTACTCACC ACAATGTCCG CCTACTCATG 
GBA-WT_TAT  TTCACCCCTG AACATCAGCG AGACTTCATT GCCCGTGACC TAGGTCCTAC CCTCGCCAAC AGTACTCACC ACAATGTCCG CCTACTCATG 
  mTAT-GBA  TTCACCCCTG AACATCAGCG AGACTTCATT GCCCGTGACC TAGGTCCTAC CCTCGCCAAC AGTACTCACC ACAATGTCCG CCTACTCATG 
                    1000                                                  1050                                 
       GBA  CTGGATGACC AACGCTTGCT GCTGCCCCAC TGGGCAAAGG TGGTACTGAC AGACCCAGAA GCAGCTAAAT ATGTTCATGG CATTGCTGTA 
  GBA-mTAT  CTGGATGACC AACGCTTGCT GCTGCCCCAC TGGGCAAAGG TGGTACTGAC AGACCCAGAA GCAGCTAAAT ATGTTCATGG CATTGCTGTA 
GBA-WT_TAT  CTGGATGACC AACGCTTGCT GCTGCCCCAC TGGGCAAAGG TGGTACTGAC AGACCCAGAA GCAGCTAAAT ATGTTCATGG CATTGCTGTA 
  mTAT-GBA  CTGGATGACC AACGCTTGCT GCTGCCCCAC TGGGCAAAGG TGGTACTGAC AGACCCAGAA GCAGCTAAAT ATGTTCATGG CATTGCTGTA 
                              1100                                                    1150                     
       GBA  CATTGGTACC TGGACTTTCT GGCTCCAGCC AAAGCCACCC TAGGGGAGAC ACACCGCCTG TTCCCCAACA CCATGCTCTT TGCCTCAGAG 
  GBA-mTAT  CATTGGTACC TGGACTTTCT GGCTCCAGCC AAAGCCACCC TAGGGGAGAC ACACCGCCTG TTCCCCAACA CCATGCTCTT TGCCTCAGAG 
GBA-WT_TAT  CATTGGTACC TGGACTTTCT GGCTCCAGCC AAAGCCACCC TAGGGGAGAC ACACCGCCTG TTCCCCAACA CCATGCTCTT TGCCTCAGAG 
  mTAT-GBA  CATTGGTACC TGGACTTTCT GGCTCCAGCC AAAGCCACCC TAGGGGAGAC ACACCGCCTG TTCCCCAACA CCATGCTCTT TGCCTCAGAG 
                                          1200                                                   1250          
       GBA  GCCTGTGTGG GCTCCAAGTT CTGGGAGCAG AGTGTGCGGC TAGGCTCCTG GGATCGAGGG ATGCAGTACA GCCACAGCAT CATCACGAAC 
  GBA-mTAT  GCCTGTGTGG GCTCCAAGTT CTGGGAGCAG AGTGTGCGGC TAGGCTCCTG GGATCGAGGG ATGCAGTACA GCCACAGCAT CATCACGAAC 
GBA-WT_TAT  GCCTGTGTGG GCTCCAAGTT CTGGGAGCAG AGTGTGCGGC TAGGCTCCTG GGATCGAGGG ATGCAGTACA GCCACAGCAT CATCACGAAC 
  mTAT-GBA  GCCTGTGTGG GCTCCAAGTT CTGGGAGCAG AGTGTGCGGC TAGGCTCCTG GGATCGAGGG ATGCAGTACA GCCACAGCAT CATCACGAAC 
                                                    1300                                                  1350 
       GBA  CTCCTGTACC ATGTGGTCGG CTGGACCGAC TGGAACCTTG CCCTGAACCC CGAAGGAGGA CCCAATTGGG TGCGTAACTT TGTCGACAGT 
  GBA-mTAT  CTCCTGTACC ATGTGGTCGG CTGGACCGAC TGGAACCTTG CCCTGAACCC CGAAGGAGGA CCCAATTGGG TGCGTAACTT TGTCGACAGT 
GBA-WT_TAT  CTCCTGTACC ATGTGGTCGG CTGGACCGAC TGGAACCTTG CCCTGAACCC CGAAGGAGGA CCCAATTGGG TGCGTAACTT TGTCGACAGT 
  mTAT-GBA  CTCCTGTACC ATGTGGTCGG CTGGACCGAC TGGAACCTTG CCCTGAACCC CGAAGGAGGA CCCAATTGGG TGCGTAACTT TGTCGACAGT 
            1351                                              1400                                             
       GBA  CCCATCATTG TAGACATCAC CAAGGACACG TTTTACAAAC AGCCCATGTT CTACCACCTT GGCCACTTCA GCAAGTTCAT TCCTGAGGGC 
  GBA-mTAT  CCCATCATTG TAGACATCAC CAAGGACACG TTTTACAAAC AGCCCATGTT CTACCACCTT GGCCACTTCA GCAAGTTCAT TCCTGAGGGC 
GBA-WT_TAT  CCCATCATTG TAGACATCAC CAAGGACACG TTTTACAAAC AGCCCATGTT CTACCACCTT GGCCACTTCA GCAAGTTCAT TCCTGAGGGC 
  mTAT-GBA  CCCATCATTG TAGACATCAC CAAGGACACG TTTTACAAAC AGCCCATGTT CTACCACCTT GGCCACTTCA GCAAGTTCAT TCCTGAGGGC 
                   1450                                                   1500                                 
       GBA  TCCCAGAGAG TGGGGCTGGT TGCCAGTCAG AAGAACGACC TGGACGCAGT GGCACTGATG CATCCCGATG GCTCTGCTGT TGTGGTCGTG 
  GBA-mTAT  TCCCAGAGAG TGGGGCTGGT TGCCAGTCAG AAGAACGACC TGGACGCAGT GGCACTGATG CATCCCGATG GCTCTGCTGT TGTGGTCGTG 
GBA-WT_TAT  TCCCAGAGAG TGGGGCTGGT TGCCAGTCAG AAGAACGACC TGGACGCAGT GGCACTGATG CATCCCGATG GCTCTGCTGT TGTGGTCGTG 
  mTAT-GBA  TCCCAGAGAG TGGGGCTGGT TGCCAGTCAG AAGAACGACC TGGACGCAGT GGCACTGATG CATCCCGATG GCTCTGCTGT TGTGGTCGTG 
                              1550                                                    1600                     
       GBA  CTAAACCGCT CCTCTAAGGA TGTGCCTCTT ACCATCAAGG ATCCTGCTGT GGGCTTCCTG GAGACAATCT CACCTGGCTA CTCCATTCAC 
  GBA-mTAT  CTAAACCGCT CCTCTAAGGA TGTGCCTCTT ACCATCAAGG ATCCTGCTGT GGGCTTCCTG GAGACAATCT CACCTGGCTA CTCCATTCAC 
GBA-WT_TAT  CTAAACCGCT CCTCTAAGGA TGTGCCTCTT ACCATCAAGG ATCCTGCTGT GGGCTTCCTG GAGACAATCT CACCTGGCTA CTCCATTCAC 
  mTAT-GBA  CTAAACCGCT CCTCTAAGGA TGTGCCTCTT ACCATCAAGG ATCCTGCTGT GGGCTTCCTG GAGACAATCT CACCTGGCTA CTCCATTCAC 
                                          1650                           1677                                  
       GBA  ACCTACCTGT GGCGTCGCCA GTGA...... .......... .......... ....... 
  GBA-mTAT  ACCTACCTGT GGCGTCGCCA GTACGCCAGA AAGGCCGCCA GGCAGGCCAG GGCATGA 
GBA-WT_TAT  ACCTACCTGT GGCGTCGCCA GTACGGCCGC AAGAAACGCC GCCAGCGCCG CCGCTGA 
  mTAT-GBA  ACCTACCTGT GGCGTCGCCA GTGA...... .......... .......... .......  
Sequence alignments of the GBA constructs used in this project.  171 
 
The wild type or modified TAT sequences are shown in red, leader sequence (including 
secretion signal) is highlighted in green and initiator codons are underlined.    172 
 
7.3  Gene therapy factsheet sent to Gaucher patients 
Gene Therapy: what is it and why is it worth talking about? 
My name is Kathy and I’m a PhD student working at University College London (UCL). My 
project is looking at possible methods of developing gene therapy for type I Gaucher 
disease and so I am writing to you to ask for your perspective on the concept of gene 
therapy and whether it is something you as a patient would be interested in. 
This article has been written to introduce you to the concept of gene therapy and how it 
can be applied to Gaucher disease.  
  Gaucher  disease  is  a  genetic  disorder  in  which  patients  have  two  non-
functional copies of the glucocerebrosidase (GBA) gene.  
  Gene therapy aims to correct this by inserting an additional, working copy of 
the GBA gene into the patient’s own cells. 
Therefore gene therapy has been suggested as a new method of treating Gaucher disease 
as the introduced gene could be able to compensate for the two non-functional copies 
the patient has. 
What is it? 
Gene  therapy  describes  a  treatment  option  where  a  genetic  defect  is  corrected  by 
addition of a healthy copy of the gene to a patient’s cells. 
How is it done? 
We have chosen to use a lentivirus to correct the patient’s own bone marrow stem cells 
in order to treat Gaucher disease.  
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  Lentivirus is a term that refers to a family of viruses which includes HIV. We use 
safe,  disabled  versions  of  these  viruses  for  gene  therapy  because  they  have 
evolved over thousands of years to be very efficient at getting genes into cells.  
  The virus we will use has had all of the genes used for replication and disease 
removed so that it is simply a harmless tool, like a case for delivering genes.  
  Bone marrow stem cells are the foundation of the whole blood system; over the 
course of your life they divide and then differentiate to produce every type of 
blood cell in the body. This includes the macrophage which is the major cause of 
illness in Gaucher disease. 
By using lentivirus which can effectively target stem cells and integrate the gene into the  
patient’s chromosomes, we are able to get correction of the whole system as the gene 
will be passed on to both new cells when they divide. In this way it is possible that the 
blood could be permanently corrected with no need for enzyme replacement therapy 
(ERT). 
Why would this work for Gaucher disease? 
  Gaucher disease is a caused by a mutation in a single, well-understood gene that 
makes the enzyme – glucocerebrosidase – which we have been able to insert into 
a virus. 
  Bone marrow transplant from a healthy, matched donor has been shown in the 
past to cure type I Gaucher patients, which demonstrates that correcting the 
bone marrow can alleviate illness. 
Initially this is being presented as a potential treatment option for type I Gaucher disease 
however there is also some evidence that after bone marrow transplant some of the 
stem cells differentiate into microglia; macrophage-like cells in the brain. If this is the 
case  then  it  is  possible  that  this  treatment  could  lessen  some  of  the  neurological 
symptoms experienced by type III patients. 174 
 
What would the procedure involve? 
The procedure is very similar to bone marrow transplant but there is no need to find a 
matched donor as the patient’s own bone marrow is used. 
  To begin with bone marrow stem cells are harvested either from the bones, or 
from the blood (leukapheresis). 
  To  harvest  bone  marrow  from  the  bones,  the  patient  is  put  under  general 
anaesthetic  and  a  needle  is  used  to  remove  cells  from  the  pelvic  bone.  The 
procedure takes around one hour. 
  For leukapheresis the patient is given a drug called G-CSF (granulocyte colony 
stimulating factor) over 5 days to encourage the stem cells to enter the blood 
stream. Blood is taken and used to isolate the stem cells. 
  The cells are then grown in the laboratory for up to one week and a lentivirus is 
used to insert a functioning copy of the glucocerebrosidase gene. Some cells will 
be frozen for use in the unlikely event that the patient’s bone marrow fails to 
recover after gene therapy. 
  During this time the patient will undergo a course of chemotherapy to destroy 
any remaining stem cells in the bone marrow and allow the modified cells to be 
the dominant population after transplant. Without this ‘conditioning’ it is likely 
that  the  transplanted  cells  will  struggle  to  survive  as  the  existing  cells  will 
compete  with  them  in  the  bone  marrow  space.  This  is  usually  the  same 
treatment a patient receives before bone marrow transplant. 
  The modified stem cells are then transplanted back into the patient in the form 
of  an  intravenous  transfusion  which  will  take  around  30-45  minutes  and  the 
introduced cells should go on to form a complete, healthy blood system. 
  The  patient  would  have  to  remain  in  hospital  while  the  immune  system 
regenerates which is likely to be a period of one month to six weeks. 175 
 
What are the potential benefits? 
  It is a one-off procedure; targeting the stem cell and integration of the gene into 
the chromosomes could give permanent correction of the blood system removing 
the need for further treatment.  
  Because this treatment uses the patient’s own bone marrow there is much lower 
risk of rejection than with a conventional bone marrow transplant. 
  This method should also correct an important bone cell – the osteoclast – and so 
may be able to reduce or prevent the bone pain and other skeletal symptoms 
associated with type I Gaucher disease. 
  The protocol performs all the genetic manipulation outside of the body so it is 
very unlikely that the gene would be inserted into any other cells in the body.  
What are the drawbacks? 
  The virus inserts the gene into the patient’s DNA at a random site so there is a 
very low risk of a phenomenon known as insertional mutagenesis. This occurs 
when the gene integrates close to, and affects the function of, another gene. In a 
small number of cases where gene therapy using an early version of another virus 
was successful in treating an immune disorder, insertional mutagenesis led to 
some patients developing a form of leukaemia. However, this is rare and has 
never been seen with the kind of virus we are proposing for treating Gaucher 
disease. 
  The chemotherapy used can cause a number of side effects including nausea and 
temporary hair loss. In particular it used to destroy the immune system and so 
leaves the patient at increased risk of contracting infections until the immune 
system  has  been  restored  by  the  transplanted  cells.  There  is  also  a  risk  of 
chemotherapy leading to infertility. 176 
 
  This  treatment  is  experimental  and  may  not  work,  but  if  gene  therapy  is 
unsuccessful the patient would be able to resume enzyme replacement therapy. 
Has it been done before? 
Yes! Gene therapy has been successfully used to treat a range of disorders. 
Problems with the immune system such as: 
  X-linked severe combined immunodeficiency  
  Adenosine deaminase deficiency 
  Chronic granulomatous disease   
  Wiskott-Aldrich Syndrome 
Other diseases including: 
  Adrenoleukodystrophy; a disorder which affects the brain and featured in the 
film Lorenzo’s Oil 
  A form of blindness called Leber congenital amaurosis (LCA) 
  Haemophilia B; a blood clotting disorder 
Gene therapy has been suggested as a treatment option for Gaucher disease before and 
a clinical trial involving three patients was run in 1998. However this trial did not produce 
a  prolonged  improvement  in  any  of  the  treated  patients,  probably  because  the 
transplanted cells failed to establish themselves in the bone marrow. This trial also used a 
different type of virus to the one we are using in our current work. It did however show 
that the procedure used is safe as the patients didn’t experience any adverse events and 
treated patients were able to resume ERT at the same dose they had previously taken.    177 
 
7.4  Results of survey to Gaucher patients 
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7.5  Free text answers to Q5 
Q5: If you or your child were given the opportunity to participate in a gene therapy trial 
(knowing that ERT would always be available as a back-up) would you be interested in 
doing so?  
  Yes - To eradicate the disease totally. Advancement in gene therapy is the long 
term answer to a disease that is very debilitating and enzyme treatment does not 
always prevent the disease from becoming more difficult 
  Not sure - I would be willing to participate but would worry about the side effects 
or the possibility of things going wrong 
  Not sure - Would have to think very hard about it given the intrusive nature of 
the trial, requirement for chemo, long period in hospital etc. 
  No - am happy with enzyme replacement, it works and has limited side effects. 
(as  type  1  patient  I’m  happy  with  enzyme  replacement,  I’m  sure  that  gene 
therapy would have further benefits for type 3 patients if it was found to help the 
neurological aspect of condition.) 
  Not sure - I have been on a medical trial before which me very unwell. (Q6. 
Offered fully licensed treatment would you take it? No.) 
  Yes - I am in my mid 60s have had a family - lost most of my hair anyway and - if I 
became a GMO and was banned from Safeway - 'it wouldn't bother me' :-). Have 
been  on  ERT  since  1996  and  provided  risk  assessment  seemed  acceptable  I 
believe contributing to such progress/research would help others in the future. 
  Yes  -  The  thought  of  curing  Gaucher  (Quite  scary  reading  but  sure  further 
questions would help) 182 
 
  No - I was aware of gene therapy in very vague terms before reading your paper. 
Now I have read it, I feel both very positive about it (in the sense that it offers the 
possibility for a wonderful new cure for a disease which was previous thought of 
as being incurable) and very negative (in the sense that the process itself sounds 
extremely traumatic for the patient. In fact it has provoked an emotional reaction 
in  me  which  I  was  surprised  to  experience!).  I  feel  it  would  be  suitable  for 
someone who was suffering very much from Gaucher Disease, perhaps a Type 3 
patient or a newly diagnosed Type 1 patient, but not for someone like me whose 
disease is relatively controlled and who is a seasoned veteran of ERT and doesn't 
find it that bad. I should add that I have answered question 6 (fully licensed 
treatment – said no) below from that perspective but I would perhaps answer 
differently if I had been newly diagnosed and was faced with the prospect of a 
lifetime of ERT.   183 
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